
<html lang="en"     class="pb-page"  data-request-id="fdd982b6-a350-400b-8208-fe981c66fe69"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;article:article:10.1021/acs.jmedchem.9b00161;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2020.63.issue-5"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Design and Discovery of N-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the Clinic" /></meta><meta name="dc.Creator" content="Savithri  Ramurthy" /></meta><meta name="dc.Creator" content="Benjamin R.  Taft" /></meta><meta name="dc.Creator" content="Robert J.  Aversa" /></meta><meta name="dc.Creator" content="Paul A.  Barsanti" /></meta><meta name="dc.Creator" content="Matthew T.  Burger" /></meta><meta name="dc.Creator" content="Yan  Lou" /></meta><meta name="dc.Creator" content="Gisele A.  Nishiguchi" /></meta><meta name="dc.Creator" content="Alice  Rico" /></meta><meta name="dc.Creator" content="Lina  Setti" /></meta><meta name="dc.Creator" content="Aaron  Smith" /></meta><meta name="dc.Creator" content="Sharadha  Subramanian" /></meta><meta name="dc.Creator" content="Victoriano  Tamez" /></meta><meta name="dc.Creator" content="Huw  Tanner" /></meta><meta name="dc.Creator" content="Lifeng  Wan" /></meta><meta name="dc.Creator" content="Cheng  Hu" /></meta><meta name="dc.Creator" content="Brent A.  Appleton" /></meta><meta name="dc.Creator" content="Mulugeta  Mamo" /></meta><meta name="dc.Creator" content="Laura  Tandeske" /></meta><meta name="dc.Creator" content="John E.  Tellew" /></meta><meta name="dc.Creator" content="Shenlin  Huang" /></meta><meta name="dc.Creator" content="Qin  Yue" /></meta><meta name="dc.Creator" content="Apurva  Chaudhary" /></meta><meta name="dc.Creator" content="Hung  Tian" /></meta><meta name="dc.Creator" content="Raman  Iyer" /></meta><meta name="dc.Creator" content="A. Quamrul  Hassan" /></meta><meta name="dc.Creator" content="Lesley A.  Mathews Griner" /></meta><meta name="dc.Creator" content="Laura R.  La Bonte" /></meta><meta name="dc.Creator" content="Vesselina G.  Cooke" /></meta><meta name="dc.Creator" content="Anne  Van Abbema" /></meta><meta name="dc.Creator" content="Hanne  Merritt" /></meta><meta name="dc.Creator" content="Kalyani  Gampa" /></meta><meta name="dc.Creator" content="Fei  Feng" /></meta><meta name="dc.Creator" content="Jing  Yuan" /></meta><meta name="dc.Creator" content="Yuji  Mishina" /></meta><meta name="dc.Creator" content="Yingyun  Wang" /></meta><meta name="dc.Creator" content="Jacob R.  Haling" /></meta><meta name="dc.Creator" content="Sepideh  Vaziri" /></meta><meta name="dc.Creator" content="Mohammad  Hekmat-Nejad" /></meta><meta name="dc.Creator" content="Valery  Polyakov" /></meta><meta name="dc.Creator" content="Richard  Zang" /></meta><meta name="dc.Creator" content="Vijay  Sethuraman" /></meta><meta name="dc.Creator" content="Payman  Amiri" /></meta><meta name="dc.Creator" content="Mallika  Singh" /></meta><meta name="dc.Creator" content="William R.  Sellers" /></meta><meta name="dc.Creator" content="Emma  Lees" /></meta><meta name="dc.Creator" content="Wenlin  Shao" /></meta><meta name="dc.Creator" content="Michael P.  Dillon" /></meta><meta name="dc.Creator" content="Darrin D.  Stuart" /></meta><meta name="dc.Description" content="Direct pharmacological inhibition of RAS has remained elusive, and efforts to target CRAF have been challenging due to the complex nature of RAF signaling, downstream of activated RAS, and the poor..." /></meta><meta name="Description" content="Direct pharmacological inhibition of RAS has remained elusive, and efforts to target CRAF have been challenging due to the complex nature of RAF signaling, downstream of activated RAS, and the poor..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="May 6, 2019" /></meta><meta name="dc.Type" content="news" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b00161" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2019 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00161" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b00161" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00161" /></link>
        
    
    

<title>Design and Discovery of N-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the Clinic | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b00161" /></meta><meta property="og:title" content="Design and Discovery of N-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the Clinic" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/large/jm-2019-00161v_0017.jpeg" /></meta><meta property="og:description" content="Direct pharmacological inhibition of RAS has remained elusive, and efforts to target CRAF have been challenging due to the complex nature of RAF signaling, downstream of activated RAS, and the poor overall kinase selectivity of putative RAF inhibitors. Herein, we describe 15 (LXH254, Aversa, R.; et al. Int. Patent WO2014151616A1, 2014), a selective B/C RAF inhibitor, which was developed by focusing on drug-like properties and selectivity. Our previous tool compound, 3 (RAF709; Nishiguchi, G. A.; et al. J. Med. Chem. 2017, 60, 4969), was potent, selective, efficacious, and well tolerated in preclinical models, but the high human intrinsic clearance precluded further development and prompted further investigation of close analogues. A structure-based approach led to a pyridine series with an alcohol side chain that could interact with the DFG loop and significantly improved cell potency. Further mitigation of human intrinsic clearance and time-dependent inhibition led to the discovery of 15. Due to its excellent properties, it was progressed through toxicology studies and is being tested in phase 1 clinical trials." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b00161"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b00161">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b00161&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b00161&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b00161&amp;href=/doi/10.1021/acs.jmedchem.9b00161" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 5</span><span class="cit-fg-pageRange">, 2013-2027</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/5" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b02014" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Drug Annotation</span><a href="/doi/10.1021/acs.jmedchem.9b01546" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Design and Discovery of <i>N</i>-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the Clinic</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Savithri Ramurthy</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Savithri Ramurthy</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Institutes for BioMedical Research, 5300 Chiron Way, Emeryville, California 94608, United States</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#e99a889f809d819b80c79b88849c9b9d8190a98e84888085c78a8684"><span class="__cf_email__" data-cfemail="1d6e7c6b7469756f74336f7c70686f6975645d7a707c7471337e7270">[email protected]</span></a>. Telephone: 925-324-3692.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Savithri++Ramurthy">Savithri Ramurthy</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2444-5309" title="Orcid link">http://orcid.org/0000-0002-2444-5309</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Benjamin R. Taft</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Benjamin R. Taft</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Institutes for BioMedical Research, 5300 Chiron Way, Emeryville, California 94608, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Benjamin+R.++Taft">Benjamin R. Taft</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Robert J. Aversa</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Robert J. Aversa</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Robert+J.++Aversa">Robert J. Aversa</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9873-4381" title="Orcid link">http://orcid.org/0000-0002-9873-4381</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Paul A. Barsanti</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Paul A. Barsanti</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Institutes for BioMedical Research, 5300 Chiron Way, Emeryville, California 94608, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Paul+A.++Barsanti">Paul A. Barsanti</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Matthew T. Burger</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Matthew T. Burger</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Matthew+T.++Burger">Matthew T. Burger</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yan Lou</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yan Lou</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Institutes for BioMedical Research, 5300 Chiron Way, Emeryville, California 94608, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yan++Lou">Yan Lou</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Gisele A. Nishiguchi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gisele A. Nishiguchi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gisele+A.++Nishiguchi">Gisele A. Nishiguchi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Alice Rico</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Alice Rico</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Institutes for BioMedical Research, 5300 Chiron Way, Emeryville, California 94608, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Alice++Rico">Alice Rico</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lina Setti</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lina Setti</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Institutes for BioMedical Research, 5300 Chiron Way, Emeryville, California 94608, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lina++Setti">Lina Setti</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Aaron Smith</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Aaron Smith</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Institutes for BioMedical Research, 5300 Chiron Way, Emeryville, California 94608, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Aaron++Smith">Aaron Smith</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sharadha Subramanian</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sharadha Subramanian</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Institutes for BioMedical Research, 5300 Chiron Way, Emeryville, California 94608, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sharadha++Subramanian">Sharadha Subramanian</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Victoriano Tamez</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Victoriano Tamez</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Victoriano++Tamez">Victoriano Tamez</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Huw Tanner</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Huw Tanner</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Institutes for BioMedical Research, 5300 Chiron Way, Emeryville, California 94608, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Huw++Tanner">Huw Tanner</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lifeng Wan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lifeng Wan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Institutes for BioMedical Research, 5300 Chiron Way, Emeryville, California 94608, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lifeng++Wan">Lifeng Wan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Cheng Hu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Cheng Hu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Institutes for BioMedical Research, 5300 Chiron Way, Emeryville, California 94608, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Cheng++Hu">Cheng Hu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Brent A. Appleton</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Brent A. Appleton</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Institutes for BioMedical Research, 5300 Chiron Way, Emeryville, California 94608, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Brent+A.++Appleton">Brent A. Appleton</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mulugeta Mamo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mulugeta Mamo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Institutes for BioMedical Research, 5300 Chiron Way, Emeryville, California 94608, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mulugeta++Mamo">Mulugeta Mamo</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Laura Tandeske</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Laura Tandeske</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology, Novartis Institutes for BioMedical Research, 5300 Chiron Way, Emeryville, California 94608, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Laura++Tandeske">Laura Tandeske</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">John E. Tellew</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">John E. Tellew</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=John+E.++Tellew">John E. Tellew</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Shenlin Huang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shenlin Huang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shenlin++Huang">Shenlin Huang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Qin Yue</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Qin Yue</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Institutes for BioMedical Research, 5300 Chiron Way, Emeryville, California 94608, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Qin++Yue">Qin Yue</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Apurva Chaudhary</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Apurva Chaudhary</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Process Research and Development, Chemical and Analytical Development, Novartis Institute for Biomedical Research, One Health Plaza, East Hanover, New Jersey 07936, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Apurva++Chaudhary">Apurva Chaudhary</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hung Tian</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hung Tian</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Technical Research & Development, Global Drug Development, Novartis Pharmaceuticals Corp., One Health Plaza, East Hanover, New Jersey 07936, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hung++Tian">Hung Tian</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Raman Iyer</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Raman Iyer</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Technical Research & Development, Global Drug Development, Novartis Pharmaceuticals Corp., One Health Plaza, East Hanover, New Jersey 07936, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Raman++Iyer">Raman Iyer</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">A. Quamrul Hassan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">A. Quamrul Hassan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=A.+Quamrul++Hassan">A. Quamrul Hassan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lesley A. Mathews Griner</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lesley A. Mathews Griner</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lesley+A.++Mathews+Griner">Lesley A. Mathews Griner</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Laura R. La Bonte</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Laura R. La Bonte</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Laura+R.++La+Bonte">Laura R. La Bonte</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Vesselina G. Cooke</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Vesselina G. Cooke</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Vesselina+G.++Cooke">Vesselina G. Cooke</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Anne Van Abbema</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Anne Van Abbema</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology, Novartis Institutes for BioMedical Research, 5300 Chiron Way, Emeryville, California 94608, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Anne++Van+Abbema">Anne Van Abbema</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hanne Merritt</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hanne Merritt</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology, Novartis Institutes for BioMedical Research, 5300 Chiron Way, Emeryville, California 94608, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hanne++Merritt">Hanne Merritt</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kalyani Gampa</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kalyani Gampa</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kalyani++Gampa">Kalyani Gampa</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Fei Feng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Fei Feng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Fei++Feng">Fei Feng</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jing Yuan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jing Yuan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jing++Yuan">Jing Yuan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yuji Mishina</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yuji Mishina</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yuji++Mishina">Yuji Mishina</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yingyun Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yingyun Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology, Novartis Institutes for BioMedical Research, 5300 Chiron Way, Emeryville, California 94608, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yingyun++Wang">Yingyun Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jacob R. Haling</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jacob R. Haling</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jacob+R.++Haling">Jacob R. Haling</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sepideh Vaziri</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sepideh Vaziri</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sepideh++Vaziri">Sepideh Vaziri</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mohammad Hekmat-Nejad</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mohammad Hekmat-Nejad</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology, Novartis Institutes for BioMedical Research, 5300 Chiron Way, Emeryville, California 94608, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mohammad++Hekmat-Nejad">Mohammad Hekmat-Nejad</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Valery Polyakov</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Valery Polyakov</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Institutes for BioMedical Research, 5300 Chiron Way, Emeryville, California 94608, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Valery++Polyakov">Valery Polyakov</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Richard Zang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Richard Zang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Institutes for BioMedical Research, 5300 Chiron Way, Emeryville, California 94608, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Richard++Zang">Richard Zang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Vijay Sethuraman</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Vijay Sethuraman</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology, Novartis Institutes for BioMedical Research, 5300 Chiron Way, Emeryville, California 94608, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Vijay++Sethuraman">Vijay Sethuraman</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Payman Amiri</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Payman Amiri</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology, Novartis Institutes for BioMedical Research, 5300 Chiron Way, Emeryville, California 94608, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Payman++Amiri">Payman Amiri</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mallika Singh</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mallika Singh</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology, Novartis Institutes for BioMedical Research, 5300 Chiron Way, Emeryville, California 94608, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mallika++Singh">Mallika Singh</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">William R. Sellers</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">William R. Sellers</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=William+R.++Sellers">William R. Sellers</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Emma Lees</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Emma Lees</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Emma++Lees">Emma Lees</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Wenlin Shao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wenlin Shao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wenlin++Shao">Wenlin Shao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Michael P. Dillon</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michael P. Dillon</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Global Discovery Chemistry, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michael+P.++Dillon">Michael P. Dillon</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Darrin D. Stuart</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Darrin D. Stuart</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Darrin+D.++Stuart">Darrin D. Stuart</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00161&amp;href=/doi/10.1021%2Facs.jmedchem.9b00161" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 5</span><span class="cit-pageRange">, 2013–2027</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">May 6, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>26 January 2019</li><li><span class="item_label"><b>Published</b> online</span>6 May 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 12 March 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b00161" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00161</a></div><div class="article_header-article-copyright"><strong>Copyright © 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D2013%26pageCount%3D15%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DSavithri%2BRamurthy%252C%2BBenjamin%2BR.%2BTaft%252C%2BRobert%2BJ.%2BAversa%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D5%26contentID%3Dacs.jmedchem.9b00161%26title%3DDesign%2Band%2BDiscovery%2Bof%2BN-%25283-%25282-%25282-Hydroxyethoxy%2529-6-morpholinopyridin-4-yl%2529-4-methylphenyl%2529-2-%2528trifluoromethyl%2529isonicotinamide%252C%2Ba%2BSelective%252C%2BEfficacious%252C%2Band%2BWell-Tolerated%2BRAF%2BInhibitor%2BTargeting%2BRAS%2BMutant%2BCancers%253A%2BThe%2BPath%2Bto%2Bthe%2BClinic%26numPages%3D15%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D2027%26publicationDate%3DMarch%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b00161"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">10393</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">10</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b00161" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Design and Discovery of N-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the Clinic&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Savithri&quot;,&quot;last_name&quot;:&quot;Ramurthy&quot;},{&quot;first_name&quot;:&quot;Benjamin&quot;,&quot;last_name&quot;:&quot;R. Taft&quot;},{&quot;first_name&quot;:&quot;Robert&quot;,&quot;last_name&quot;:&quot;J. Aversa&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;A. Barsanti&quot;},{&quot;first_name&quot;:&quot;Matthew&quot;,&quot;last_name&quot;:&quot;T. Burger&quot;},{&quot;first_name&quot;:&quot;Yan&quot;,&quot;last_name&quot;:&quot;Lou&quot;},{&quot;first_name&quot;:&quot;Gisele&quot;,&quot;last_name&quot;:&quot;A. Nishiguchi&quot;},{&quot;first_name&quot;:&quot;Alice&quot;,&quot;last_name&quot;:&quot;Rico&quot;},{&quot;first_name&quot;:&quot;Lina&quot;,&quot;last_name&quot;:&quot;Setti&quot;},{&quot;first_name&quot;:&quot;Aaron&quot;,&quot;last_name&quot;:&quot;Smith&quot;},{&quot;first_name&quot;:&quot;Sharadha&quot;,&quot;last_name&quot;:&quot;Subramanian&quot;},{&quot;first_name&quot;:&quot;Victoriano&quot;,&quot;last_name&quot;:&quot;Tamez&quot;},{&quot;first_name&quot;:&quot;Huw&quot;,&quot;last_name&quot;:&quot;Tanner&quot;},{&quot;first_name&quot;:&quot;Lifeng&quot;,&quot;last_name&quot;:&quot;Wan&quot;},{&quot;first_name&quot;:&quot;Cheng&quot;,&quot;last_name&quot;:&quot;Hu&quot;},{&quot;first_name&quot;:&quot;Brent&quot;,&quot;last_name&quot;:&quot;A. Appleton&quot;},{&quot;first_name&quot;:&quot;Mulugeta&quot;,&quot;last_name&quot;:&quot;Mamo&quot;},{&quot;first_name&quot;:&quot;Laura&quot;,&quot;last_name&quot;:&quot;Tandeske&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;E. Tellew&quot;},{&quot;first_name&quot;:&quot;Shenlin&quot;,&quot;last_name&quot;:&quot;Huang&quot;},{&quot;first_name&quot;:&quot;Qin&quot;,&quot;last_name&quot;:&quot;Yue&quot;},{&quot;first_name&quot;:&quot;Apurva&quot;,&quot;last_name&quot;:&quot;Chaudhary&quot;},{&quot;first_name&quot;:&quot;Hung&quot;,&quot;last_name&quot;:&quot;Tian&quot;},{&quot;first_name&quot;:&quot;Raman&quot;,&quot;last_name&quot;:&quot;Iyer&quot;},{&quot;first_name&quot;:&quot;A.&quot;,&quot;last_name&quot;:&quot;Quamrul Hassan&quot;},{&quot;first_name&quot;:&quot;Lesley&quot;,&quot;last_name&quot;:&quot;A. Mathews Griner&quot;},{&quot;first_name&quot;:&quot;Laura&quot;,&quot;last_name&quot;:&quot;R. La Bonte&quot;},{&quot;first_name&quot;:&quot;Vesselina&quot;,&quot;last_name&quot;:&quot;G. Cooke&quot;},{&quot;first_name&quot;:&quot;Anne&quot;,&quot;last_name&quot;:&quot;Van Abbema&quot;},{&quot;first_name&quot;:&quot;Hanne&quot;,&quot;last_name&quot;:&quot;Merritt&quot;},{&quot;first_name&quot;:&quot;Kalyani&quot;,&quot;last_name&quot;:&quot;Gampa&quot;},{&quot;first_name&quot;:&quot;Fei&quot;,&quot;last_name&quot;:&quot;Feng&quot;},{&quot;first_name&quot;:&quot;Jing&quot;,&quot;last_name&quot;:&quot;Yuan&quot;},{&quot;first_name&quot;:&quot;Yuji&quot;,&quot;last_name&quot;:&quot;Mishina&quot;},{&quot;first_name&quot;:&quot;Yingyun&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Jacob&quot;,&quot;last_name&quot;:&quot;R. Haling&quot;},{&quot;first_name&quot;:&quot;Sepideh&quot;,&quot;last_name&quot;:&quot;Vaziri&quot;},{&quot;first_name&quot;:&quot;Mohammad&quot;,&quot;last_name&quot;:&quot;Hekmat-Nejad&quot;},{&quot;first_name&quot;:&quot;Valery&quot;,&quot;last_name&quot;:&quot;Polyakov&quot;},{&quot;first_name&quot;:&quot;Richard&quot;,&quot;last_name&quot;:&quot;Zang&quot;},{&quot;first_name&quot;:&quot;Vijay&quot;,&quot;last_name&quot;:&quot;Sethuraman&quot;},{&quot;first_name&quot;:&quot;Payman&quot;,&quot;last_name&quot;:&quot;Amiri&quot;},{&quot;first_name&quot;:&quot;Mallika&quot;,&quot;last_name&quot;:&quot;Singh&quot;},{&quot;first_name&quot;:&quot;William&quot;,&quot;last_name&quot;:&quot;R. Sellers&quot;},{&quot;first_name&quot;:&quot;Emma&quot;,&quot;last_name&quot;:&quot;Lees&quot;},{&quot;first_name&quot;:&quot;Wenlin&quot;,&quot;last_name&quot;:&quot;Shao&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;P. Dillon&quot;},{&quot;first_name&quot;:&quot;Darrin&quot;,&quot;last_name&quot;:&quot;D. Stuart&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;05&quot;,&quot;day&quot;:&quot;06&quot;,&quot;issue&quot;:&quot;5&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;2013-2027&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b00161&quot;},&quot;abstract&quot;:&quot;Direct pharmacological inhibition of RAS has remained elusive, and efforts to target CRAF have been challenging due to the complex nature of RAF signaling, downstream of activated RAS, and the poor overall kinase selectivity of putative RAF inhibitors. Herein, we describe 15 (LXH254, Aversa, R.; et al. Int. Patent WO2014151616A1, 2014), a selective B/C RAF inhibitor, which was developed by focusing on drug-like properties and selectivity. Our previous tool compound, 3 (RAF709; Nishiguchi, G. A.; et al. J. Med. Chem. 2017, 60, 4969), was potent, selective, efficacious, and well tolerated in preclinical models, but the high human intrinsic clearance precluded further development and prompted further investigation of close analogues. A structure-based approach led to a pyridine series with an alcohol side chain that could interact with the DFG loop and significantly improved cell potency. Further mitigation of human intrinsic clearance and time-dependent inhibition led to the discovery of 15. Due to its excellen&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00161&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00161" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00161&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00161" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00161&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00161" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00161&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00161&amp;href=/doi/10.1021/acs.jmedchem.9b00161" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b00161" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b00161" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (7 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00161&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b00161%26sid%3Dliteratum%253Aachs%26pmid%3D31059256%26genre%3Darticle%26aulast%3DRamurthy%26date%3D2020%26atitle%3DDesign%2Band%2BDiscovery%2Bof%2BN-%25283-%25282-%25282-Hydroxyethoxy%2529-6-morpholinopyridin-4-yl%2529-4-methylphenyl%2529-2-%2528trifluoromethyl%2529isonicotinamide%252C%2Ba%2BSelective%252C%2BEfficacious%252C%2Band%2BWell-Tolerated%2BRAF%2BInhibitor%2BTargeting%2BRAS%2BMutant%2BCancers%253A%2BThe%2BPath%2Bto%2Bthe%2BClinic%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D5%26spage%3D2013%26epage%3D2027%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/5" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/jmcmar.2020.63.issue-5/20200312/jmcmar.2020.63.issue-5.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/medium/jm-2019-00161v_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/large/jm-2019-00161v_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00161&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Direct pharmacological inhibition of RAS has remained elusive, and efforts to target CRAF have been challenging due to the complex nature of RAF signaling, downstream of activated RAS, and the poor overall kinase selectivity of putative RAF inhibitors. Herein, we describe <b>15</b> (LXH254, Aversa, R.; et al. Int. Patent WO2014151616A1, 2014), a selective B/C RAF inhibitor, which was developed by focusing on drug-like properties and selectivity. Our previous tool compound, <b>3</b> (RAF709; Nishiguchi, G. A.; et al. <i>J. Med. Chem.</i><a href="/doi/abs/10.1021/acs.jmedchem.6b01862" class="ext-link"><b>2017</b>, <i>60</i>, 4969</a>), was potent, selective, efficacious, and well tolerated in preclinical models, but the high human intrinsic clearance precluded further development and prompted further investigation of close analogues. A structure-based approach led to a pyridine series with an alcohol side chain that could interact with the DFG loop and significantly improved cell potency. Further mitigation of human intrinsic clearance and time-dependent inhibition led to the discovery of <b>15</b>. Due to its excellent properties, it was progressed through toxicology studies and is being tested in phase 1 clinical trials.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="specialIssueNotice" class="extra-info-sec articleNote"><h4>SPECIAL ISSUE</h4><p class="last">This article is part of the <a href="/toc/jmcmar/63/5"><issue-title>Women in Medicinal Chemistry</issue-title></a> special issue.</p></div><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64032" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64032" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The RAS-RAF-MEK-ERK or MAPK pathway plays a prominent role in transmitting signals from the cell membrane to the nucleus. Extracellular growth factors bind and activate cell surface receptor tyrosine kinases, resulting in turnover of RAS-GDP (H-, N-, KRAS) to RAS-GTP, in turn resulting in the engagement and activation of RAF kinases (A-, B-, CRAF), thus initiating the MAPK cascade. Just as this pathway is critical for growth, differentiation, and homeostasis of normal tissues, it also plays a central role in the uncontrolled growth and invasiveness of human cancer. The RAS genes and BRAF are mutationally activated in approximately one-third of human tumors, and genetic inactivation of CRAF prevents the development of KRAS mutant tumors in genetically engineered mice. This dependence on signaling downstream of mutant RAS has provided therapeutic opportunities for targeting the RAF, MEK, and ERK kinases which are eminently more druggable than RAS, with the possible exception of KRAS G12C, for which covalent inhibitor approaches have been undertaken.<a onclick="showRef(event, 'ref3 ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref3 ref4 ref5">(1−3)</a></div><div class="NLM_p">Clinical proof-of-concept for targeting RAF has been demonstrated with drugs like dabrafenib (<b>1</b>, <a class="ref internalNav" href="#cht1" aria-label="Chart 1">Chart 1</a>) which potently inhibit BRAF<sup>V600E</sup> and provide significant tumor regression and increased survival in melanoma patients. However, the therapeutic potential of these drugs is restricted to tumors with BRAF<sup>V600</sup> mutations because in this context BRAF functions as a constitutively active monomer, while in the RAS mutant setting, BRAF and CRAF function as dimers which are resistant to inhibition by these drugs.<a onclick="showRef(event, 'ref6 ref7 ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref6 ref7 ref8 ref9">(4−7)</a> Therefore, testing the therapeutic potential of targeting RAF downstream of mutant RAS will require compounds optimized to inhibit RAF dimers.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(8)</a> Furthermore, robust evaluation of this therapeutic hypothesis will require inhibitors with highly selective profiles so that the pharmacology is not compromised by off-target toxicity. For example, LY3009120 (<b>2</b>, <a class="ref internalNav" href="#cht1" aria-label="Chart 1">Chart 1</a>), a pan-RAF inhibitor that effectively inhibits active RAF homo- and heterodimers, has demonstrated preclinical activity in tumors with RAS mutations. However, <b>2</b> inhibits several other kinases, including those that have important roles in cancer, such as Ephrin receptors, JNK, and SRC family members, which could also lead to off-target toxicities.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(9)</a> Such a profile could preclude dose escalation to achieve potent RAF suppression in tumors and ultimately compromise the therapeutic utility of such a compound. Therefore, a highly selective RAF inhibitor will be invaluable in assessing the therapeutic utility in RAS mutant and atypical BRAF mutant tumors.</div><figure id="cht1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Chart 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/medium/jm-2019-00161v_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/large/jm-2019-00161v_0001.jpeg" id="gr4" class="inline-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/large/jm-2019-00161v_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00161&amp;id=cht1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22335" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22335" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Our previous disclosure<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(10)</a> detailed the medicinal chemistry efforts to identify highly selective RAF inhibitors that potently suppress the RAF-MEK-ERK pathway in RAS/RAF mutant tumor cells without causing paradoxical activation. This led to the discovery of a key compound, <b>3</b>, which enabled numerous early pharmacology studies in RAS/RAF mutant xenograft models and validated the hypothesis that a wild-type B/C RAF inhibitor could prevent tumorigenesis in a RAS mutant setting with minimal paradoxical activation.</div><div class="NLM_p">A key concern with <b>3</b> was the observed high clearance in human microsomes (Cl<sub>int</sub> = 94 μL/min/mg), limiting the projected human exposure and preventing the compound from progressing as a clinical candidate. For this reason, we set out to understand the clearance mechanism and design analogues that could mitigate the high intrinsic human clearance. A cross species metabolism study was performed for <b>3</b> in rat, dog, and human hepatocytes, where a number of metabolites were identified by LC/MS/MS (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). The major metabolites observed were an O-dealkylation product (M3) and tetrahydro-pyranyl ring oxidation (M4, M5) in all species. In addition, the amide hydrolysis product (M1, M2) was found to be relatively abundant in rat hepatocytes compared to other species. No human unique metabolites were identified (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).</div><figure id="fig1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/medium/jm-2019-00161v_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/large/jm-2019-00161v_0002.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of metabolites of <b>3</b> in rat (R), dog (D), and human (H) hepatocyte (quantification based on UV response).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/large/jm-2019-00161v_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00161&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">With this knowledge, a focused set of THP analogues, in addition to the metabolite <b>4</b>, were synthesized, and human microsomal clearance was determined (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Not surprisingly, metabolite <b>4</b> showed 10-fold lower human Cl<sub>int</sub> (9.4 vs 94), although when tested in a Calu-6 cellular proliferation (CP) assay, the compound was 4-fold less potent (EC<sub>50</sub> = 3.9 μM vs 0.95 μM). This might be attributed to the significant increase in polarity and negative impact on cellular permeability as measured in the Caco-2 assay (AB/BA:0.3/43). The fluoro-tetrahydropyranyl analogue <b>5</b> retained good cellular potency and permeability, but this substitution had only a modest impact on the human Cl<sub>int</sub> (65.5 vs 94). The methoxy-tetrahydropyranyl and deuterio analogues (<b>6</b>, <b>7</b>) both showed good cellular potency, but neither had improved human Cl<sub>int</sub>, and in fact, <b>6</b> had the highest measured Cl<sub>int</sub> of all the analogues tested.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Potency, ADME, and Solubility Data for Tetrahydropyranyl Analogues</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/medium/jm-2019-00161v_0013.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/medium/jm-2019-00161v_0014.gif" alt="" id="GRAPHIC-d7e868-autogenerated" /></img><div></div></div><div class="NLM_p">Given the limited success in lowering human microsomal clearance by fine-tuning <b>3</b>, we hypothesized that increasing the polarity of the molecules might help mitigate oxidative metabolism. Analogues were synthesized, and a representative set is shown in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>. Though polar analogues <b>8</b> and <b>9</b> had significantly lower human microsomal Cl<sub>int</sub> compared to <b>3</b> and an acceptable <i>in vitro</i> potency profile, these compounds had poor <i>in vivo</i> efficacy and a poor tolerability profile, limiting their further progression.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Potency, ADME, and Solubility Data for CORE Analogues</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/medium/jm-2019-00161v_0015.gif" alt="" id="fx2" /></img><div></div></div><div class="NLM_p">We next re-evaluated the original pyrimidine hit scaffold,<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(10)</a> as this series had lower intrinsic clearance (43 μL/min/mg) while maintaining potent inhibition of pMEK and proliferation in Calu-6 cells. During this time, we considered many strategic options, one of which was to further optimize the cellular antiproliferative effect and pMEK EC<sub>50</sub>. Although the protein–ligand interactions of our lead compounds were highly optimized, we re-examined early X-ray co-crystal structures to identify opportunities for growing into new vectors and gaining positive interactions with the protein. Careful examination of the crystal structure of <b>10</b> (IC<sub>50</sub> = 0.04 μM) with BRAF (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>a) revealed no hinge binding, unlike typical type 2 B/C RAF kinase inhibitors which rely on interaction with the hinge. We attributed the potency to a very weak H-bonding interaction (N···O distance is slightly more than 3 Å) with the backbone carbonyl of F595, which could impact binding (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>a) and is unique, to the best of our knowledge, for type 2 B/C RAF inhibitors. This prompted the team to search for compounds that are capable of interacting both with the hinge and with F595. Docking studies allowed us to hypothesize that compounds from our lead series could interact with F595 by extending an H-bond donor from the second carbon atom of the pyrimidine analogue, as with <b>11</b> (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). This strategy led to the synthesis of many new analogues, as represented in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>, and we found that interaction with F595 led to compounds with significant improvement in cellular potency, although we do not have a clear mechanistic understanding for this observation. The F595 H-bonding interaction was best exemplified by <b>12</b>, which included an amino-ethanol side chain at the second carbon of the pyrimidine ring and is a “matched-pair” with <b>11</b>. As can be seen in the docking model of <b>12</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>b), the side chain extends directly toward the F595 carbonyl without disrupting the conformation or other primary interactions. The oxygen atom of the side chain is 2.9 Å away from the carbonyl of F595 and has an approach angle of 118°, strongly suggesting an H-bond with the protein. Compound <b>12</b> showed a 33-fold improvement in cell activity compared to <b>11</b> (CP Calu-6 EC<sub>50</sub> = 0.16 vs 5.28 μM), despite having slightly lower permeability (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>).</div><figure id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/medium/jm-2019-00161v_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/large/jm-2019-00161v_0003.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) X-ray structure of <b>10</b> in BRAF (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6N0Q">6N0Q</a>)<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(11)</a> (B) Docking models of <b>11</b> and <b>12</b> showing H-bond interaction with F595.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/large/jm-2019-00161v_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00161&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Potency, ADME, and TDI for Pyridine/Pyrimidine Analogues</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/medium/jm-2019-00161v_0016.gif" alt="" id="fx3" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Forward and reverse flux were measured via transit across 21-day cultured Caco-2 monolayers at pH 7.4 with quantification via LC/MS/MS.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">Solubility (shake–flask assay) was measured with Cl-free PBS at pH 6.8.</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last">cLogP was calculated using Biobyte software.</p></div><div class="footnote" id="t3fn4"><sup><sup>d</sup></sup><p class="last">Time-dependent inhibition (TDI; <i>k</i><sub>obs</sub>) measured as described by Zimmerlin et al.,<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Time-dependent CYP3A4 inactivation screening assay (<i>k</i><sub>obs</sub>): Test compound at 10 μM is incubated with 0.5 mg/mL human liver microsome in phosphate buffer containing 1 mM NADPH at 37 °C for 0, 5, 15, and 30 min. The incubation mixture is then diluted 20 times and incubated with CYP3A4 substrate midazolam (20 μM) at 37 °C for 6 min to determine residual CYP3A4 enzyme activity. The enzyme activity vs incubation time is plotted to obtain the initial rate of decline which is defined as <i>k</i><sub>obs</sub> value.</p></div></div><div></div></div><div class="NLM_p">Despite the improved cellular antiproliferative effect of <b>12</b>, the compound had low solubility, high lipophilicity, and sub-optimal Cl<sub>int</sub> (HLM). With this in mind, analogues with greater polarity in the aryl-rings were investigated, exemplified here by <b>13</b> and <b>14</b> (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). When comparing <b>12</b>, <b>13</b>, and <b>14</b>, there was a clear trend that Cl<sub>int</sub> (HLM) could be mitigated and solubility could be improved by increasing polarity albeit at the cost of reduced permeability and decreased cellular potency. In addition, during extended safety profiling of this chemical series, we observed a Cyp3A4 TDI signal which did not correlate with lipophilicity. It appeared that all pyridine analogues <b>13</b> and <b>14</b> bearing an amino-ethanol side chain had a high risk for TDI (<i>k</i><sub>obs</sub> > 0.03), and this led us to hypothesize that the issue was associated with the electron-rich bis-amino pyridine functionality embedded in each compound. In an effort to make the rings electron deficient, the amino-ethanol side chain was changed to an ethylene glycol side chain (replacing nitrogen with oxygen). This strategy led to the discovery of <b>15</b> (LXH254),<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(12)</a> which maintained the critical F595 H-bond but exhibited low risk for Cyp3A4 TDI (<i>k</i><sub>obs</sub> = 0.01) with the best balance of ADME properties and good cellular potency.</div><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> X-ray Structure of <b>15</b></h3><div class="NLM_p">The X-ray co-crystal structure of <b>15</b> in BRAF, as illustrated in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, showed a binding mode similar to <b>3</b>.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(10)</a> As with <b>3</b>, the central toluyl tightly occupies a narrow hydrophobic pocket formed by a number of the side chains including K483 and the gatekeeper residue T529. The CF<sub>3</sub> pyridyl moiety occupies the hydrophobic pocket formed by rotation of the DFG group, i.e., DFG-out, similar to the structure of compound <b>3</b> and other type 2 kinase inhibitors.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> The biggest difference with previously known structures was that the hydroxyl of the glycolic moiety of <b>15</b> formed a strong hydrogen bond to the carbonyl of F595 manifested by 2.6 Å distance between the oxygen atoms and an approach angle of 120°. All other hydrogen bonds seemed to be retained in the co-crystal, which might explain the strong potency of the compound.</div><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/medium/jm-2019-00161v_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/large/jm-2019-00161v_0004.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. X-ray structure of <b>15</b> in BRAF (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6N0P">6N0P</a>).<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(11)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/large/jm-2019-00161v_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00161&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> <i>In Vitro</i> Profiling of <b>15</b><a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a></h3><div class="NLM_p">The biochemical activity of <b>15</b> was further characterized against purified full-length BRAF, where the IC<sub>50</sub> was 0.0004 μM, consistent with the potency against CRAF. Off-rate can be an important attribute of potency, affecting both the cellular activity in the face of feedback and the pharmacokinetic/pharmacodynamic (PK/PD) relationship <i>in vivo</i>. The dissociation rate constant for <b>15</b> was measured using the rapid dilution method and full-length CRAF (with activating mutations Y340E/Y341E) kinase assay. The compound has a slow dissociation rate constant (<i>T</i><sub>1/2</sub> > 6.5 h), as there was little recovery of enzyme activity after 6 h of incubation in the kinase assay.</div><div class="NLM_p">In cellular assays, the dose–response of <b>15</b> was measured using a pMEK assay in Calu-6 cells with an EC<sub>50</sub> = 0.05 μM, minimal paradoxical activation (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>), and inhibition of proliferation with EC<sub>50</sub> = 0.28 μM. These data are clearly distinct from Compound <b>1</b> which demonstrated clear paradoxical activation in the pMEK assay (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>) with maximum activity at 3 μM and no resultant inhibition up to the highest concentration tested (24 μM).</div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/medium/jm-2019-00161v_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/large/jm-2019-00161v_0005.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. pMEK activity in Calu-6 cells of <b>15</b> vs <b>1</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/large/jm-2019-00161v_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00161&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The ability of <b>15</b> to stabilize RAF dimerization was measured using the CRAF:BRAF NanoBiT luciferase complementation assay (Promega). Consistent with most other RAF inhibitors<a onclick="showRef(event, 'ref11 ref16'); return false;" href="javascript:void(0);" class="ref ref11 ref16">(9,16)</a><b>15</b> stabilized BRAF-CRAF dimers with an EC<sub>50</sub> = 0.16 μM (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>), while <b>1</b> yielded no significant effect on RAF dimerization, as reported previously. Additional supporting data were revealed in the X-ray crystal structure of <b>15</b> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>), where each BRAF protomer in the dimer structure is occupied with compound. This also demonstrated that (at least under the conditions of crystallization) binding of <b>15</b> to one protomer did not preclude binding to the other protomer in the dimer structure. Altogether, these data demonstrate that <b>15</b> stabilizes RAF dimers but is relatively equipotent at inhibiting both protomers since it induces minimal paradoxical activation but effectively suppresses signaling.</div><figure id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/medium/jm-2019-00161v_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/large/jm-2019-00161v_0006.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Effect of <b>1</b> and <b>15</b> on the RAF dimerization in HCT116 cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/large/jm-2019-00161v_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00161&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Kinase Selectivity of <b>15</b></h3><div class="NLM_p">Consistent with our early <i>in vivo</i> tool compound,<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(10)</a><b>15</b> was found to be highly selective when evaluated using the KINOME<i>scan</i> screening platform. Of the 456 kinases tested, <b>15</b> showed a high level of selectivity (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>), demonstrating greater than 98% on-target binding to BRAF, BRAF<sup>V600E</sup>, and CRAF at 1 μM and very few off-targets, with DDR1 (>99%), DDR2 (84%), and PDGFRb (>99%) the only kinases with binding >80% at 1 μM. The <i>K</i><sub>d</sub> values for these kinases were determined and were consistent with <b>15</b> being a potent inhibitor of BRAF (<i>K</i><sub>d</sub> = 1.3 nM) and CRAF (<i>K</i><sub>d</sub> = 3.6 nM), with similar potency against DDR1 (<i>K</i><sub>d</sub> = 1.8 nM) and less against DDR2 (<i>K</i><sub>d</sub> = 10 nM) and PDGFRb (<i>K</i><sub>d</sub> = 14 nM). To the best of our knowledge, this compound along with our earlier series exhibit an extremely high level of kinase selectivity relative to other type 2 RAF inhibitors with a selectivity score of S(35) = 0.025.<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17,18)</a></div><figure id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/medium/jm-2019-00161v_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/large/jm-2019-00161v_0007.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. KINOME<i>scan</i> profile of <b>15</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/large/jm-2019-00161v_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00161&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Pharmacokinetics of <b>15</b></h3><div class="NLM_p">In pre-clinical pharmacokinetics (PK) experiments (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>), <b>15</b> had low to moderate clearance in mouse (19 mL/min/kg), rat (31 mL/min/kg), and dog (3.5 mL/min/kg). <i>C</i><sub>max</sub> in mouse (1.6 μM), rat (0.5 μM), and dog (0.4 μM) reached pharmacologically active concentrations, and acceptable oral availability was observed in mouse (65%), rat (38%), and dog (79%).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. PK Profile of <b>15</b> across Species</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="/" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">species</th><th class="colsep0 rowsep0" align="center" char="/">dose (i.v./p.o, mg/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>max</sub> (p.o., μM)</th><th class="colsep0 rowsep0" align="center" char=".">AUC<sub>inf</sub><a class="ref internalNav" href="#t4fn1" aria-label="a">a</a> (p.o., μM·h)</th><th class="colsep0 rowsep0" align="center" char=".">Cl (mL/min/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>V</i><sub>ss</sub> (L/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>F</i> (p.o.) (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mouse</td><td class="colsep0 rowsep0" align="char" char="/">2/4</td><td class="colsep0 rowsep0" align="char" char=".">1.6</td><td class="colsep0 rowsep0" align="char" char=".">4.3</td><td class="colsep0 rowsep0" align="char" char=".">19</td><td class="colsep0 rowsep0" align="char" char=".">2.1</td><td class="colsep0 rowsep0" align="char" char=".">65</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="char" char="/">2/4</td><td class="colsep0 rowsep0" align="char" char=".">0.5</td><td class="colsep0 rowsep0" align="char" char=".">1.8</td><td class="colsep0 rowsep0" align="char" char=".">31</td><td class="colsep0 rowsep0" align="char" char=".">5.4</td><td class="colsep0 rowsep0" align="char" char=".">38</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="char" char="/">0.2/0.4</td><td class="colsep0 rowsep0" align="char" char=".">0.4</td><td class="colsep0 rowsep0" align="char" char=".">3.1</td><td class="colsep0 rowsep0" align="char" char=".">3.5</td><td class="colsep0 rowsep0" align="char" char=".">1.7</td><td class="colsep0 rowsep0" align="char" char=".">79</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Formulation (i.v./p.o): 25% PEG300 + 5% Solutol.</p></div></div></div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> PK/PD of <b>15</b></h3><div class="NLM_p">The PK/PD/efficacy relationship of <b>15</b> was examined in nude rats bearing Calu-6 (KRAS<sup>Q61K</sup>) human NSCLC xenograft tumors. The plasma exposure and pMEK levels in tumor tissue were determined following a single oral administration of <b>15</b> across a dose range of 15, 35, 75, or 150 mg/kg. For each treatment group, tumor and blood samples were collected at 1, 4, 7, 24, and 48 h post-dose. The effect of <b>15</b> on pMEK levels in the tumor was determined using an MSD immunoassay. The free plasma exposures of <b>15</b> were shown to be dose-proportional, corresponding with dose-dependent reductions in pMEK levels in tumors (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). At the higher dose level of 150 mg/kg, free plasma concentrations of <b>15</b> were maintained above the <i>in vitro</i> cellular pMEK IC<sub>50</sub> value in Calu-6 for at least 24 h, correlating with a sustained <i>in vivo</i> pMEK target inhibition of ∼70% for the same duration.</div><figure id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/medium/jm-2019-00161v_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/large/jm-2019-00161v_0008.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. PK/PD analysis of <b>15</b> in the human Calu-6 NSCLC xenograft in rats. Percent pMEK levels (left axis) and free exposure (right axis) following a single dose of <b>15</b>, at time points indicated, in Calu-6 tumor-bearing rats.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/large/jm-2019-00161v_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00161&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Efficacy and Tolerability of <b>15</b> in the Calu-6 Xenograft Model</h3><div class="NLM_p">The anti-tumor efficacy and tolerability of <b>15</b> were determined in the Calu-6 xenograft nude rat model. Rats were treated with vehicle or <b>15</b> at 15, 35, 75, or 150 mg/kg p.o. daily beginning 13 days after tumor implantation and continuing until day 31. The anti-tumor activity was determined by assessing %T/C or %regression on day 31 post-implant (18 days of treatment). Treatment with <b>15</b> resulted in dose-dependent anti-tumor activity, with 15 mg/kg achieving 29% T/C. Treatment with 35 mg/kg resulted in tumor stasis (%T/C = 9%), and both 75 and 150 mg/kg resulted in mean tumor regression of 21% and 56%, respectively (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A). All doses were well tolerated, with no significant body weight loss and no signs of toxicity or mortality (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>B). Following the last dose of <b>15</b> in the efficacy study, plasma was collected, the concentration of <b>15</b> measured, and the area under the curve (AUC) calculated for each dose (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). <b>15</b> showed dose-proportional plasma exposures, and total plasma concentration giving AUC<sub>0–24</sub> = 104 510 nM·h at steady state was associated with the lowest dose achieving tumor regression.</div><figure id="fig8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/medium/jm-2019-00161v_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/large/jm-2019-00161v_0009.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Efficacy of <b>15</b> in Calu-6 xenograft in rats. Tumor volumes (A) or percent body weight change from initial (B) treatment groups vs vehicle control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/large/jm-2019-00161v_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00161&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Mean Plasma PK Parameters of <b>15</b> at Different Doses on Day 31</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">15 mg/kg</th><th class="colsep0 rowsep0" align="center">35 mg/kg</th><th class="colsep0 rowsep0" align="center">75 mg/kg</th><th class="colsep0 rowsep0" align="center">150 mg/kg</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC (nM·h)</td><td class="colsep0 rowsep0" align="left">7913</td><td class="colsep0 rowsep0" align="left">25210</td><td class="colsep0 rowsep0" align="left">104510</td><td class="colsep0 rowsep0" align="left">216680</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (nM)</td><td class="colsep0 rowsep0" align="left">878</td><td class="colsep0 rowsep0" align="left">2347</td><td class="colsep0 rowsep0" align="left">8680</td><td class="colsep0 rowsep0" align="left">12671</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>max</sub> (h)</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">5.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>last</sub> (h)</td><td class="colsep0 rowsep0" align="left">24</td><td class="colsep0 rowsep0" align="left">24</td><td class="colsep0 rowsep0" align="left">24</td><td class="colsep0 rowsep0" align="left">24</td></tr></tbody></table></div></div><div class="NLM_p">With these encouraging rodent pharmacology activities and PK properties across species, <b>15</b> was profiled further with respect to developability and drug-like properties. The melting point of <b>15</b> as a free base is 192 °C. Free form <b>15</b> has a log <i>P</i> > 3, log <i>D</i> > 4 (at pH 6.5), and p<i>K</i><sub>a</sub> = 3.86. Its crystalline form solubility is 2 μg/mL. To increase the oral bioavailability, an amorphous solid dispersion formulation was developed. The solid dispersion was formed by combining drug and a stabilizing polymer in a suitable ratio along with other adjuvants under high thermomechanical stress, followed by cooling and milling. The permeability (A–B) of <b>15</b> is medium to high, at 9 × 10<sup>–6</sup> cm/s. The stability in human plasma is high, with >90% intact after a 3 h incubation, and the human plasma protein binding is 98%. In a manual patch clamp hERG assay, the compound exhibited a >10 μM IC<sub>50</sub>.</div><div class="NLM_p last">On the basis of favorable cellular potency, kinase selectivity, preclinical pharmacology, and physical properties, <b>15</b> was advanced into human clinical trials.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41674" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41674" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Compounds <b>3</b>–<b>9</b> were synthesized according to <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. In order to enable last-step diversification and obtain the final compounds exemplified in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, intermediate <b>18</b> was synthesized from commercially available <b>16</b> via bis-alkylation with O(CH<sub>2</sub>CH<sub>2</sub>Br)<sub>2</sub>. Subsequent Suzuki–Miyaura coupling reaction between <b>18</b> and <i>N</i>-(6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-3-(trifluoromethyl)benzamide<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(10)</a> yielded a fluoro-pyridine intermediate which was penultimate to the desired analogues. Treatment of this intermediate with the desired pre-formed alkoxide in dioxane or dimethylformamide allowed for isolation of final products <b>3</b>–<b>7</b> upon HPLC purification (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). The pyridazine analogue <b>8</b> was prepared in a similar fashion starting from commercial trichloride <b>17</b>. Compound <b>4</b> was prepared as reported in our previous paper.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(10)</a> Compound <b>9</b> was prepared starting from amino-pyridazine <b>20</b> via hydrolysis of the corresponding diazonium species and subsequent <i>N</i>-methylation to give <b>21</b>. S<sub>N</sub>2 addition of morpholine, followed by Suzuki–Miyaura coupling of 4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline, provided intermediate <b>22</b>, which was transformed to final compound <b>9</b> via typical amide coupling conditions. The scheme and synthesis of compound <b>10</b> have been reported,<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(10)</a> and the synthesis and experimental procedure for compound <b>10</b> are reported in the <a href="/doi/suppl/10.1021/acs.jmedchem.9b00161/suppl_file/jm9b00161_si_001.pdf" class="ext-link">Supporting Information</a>.</div><figure id="sch1" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/medium/jm-2019-00161v_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/large/jm-2019-00161v_0010.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Analogues <b>3</b>–<b>9</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/large/jm-2019-00161v_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00161&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) O(CH<sub>2</sub>CH<sub>2</sub>Br)<sub>2</sub>, NaH, DMF, 0 °C to RT; (b) morpholine, EtOH, RT; (c) <i>N</i>-(6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-3-(trifluoromethyl)benzamide, PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub>, DME, 2 M Na<sub>2</sub>CO<sub>3</sub>, 120 °C; (d) R-OH, NaH, dioxane or DMF, 90 °C; (e) NaNO<sub>2</sub>, H<sub>2</sub>SO<sub>4</sub>, acetic acid, 0–25 °C, then water, 25 °C; (f) Cs<sub>2</sub>CO<sub>3</sub>, MeI, DMF; (g) morpholine, DMF, DIEA, 120 °C; (h) 4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline, PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub>, DME, 2 M Na<sub>2</sub>CO<sub>3</sub>, 120 °C; (i) aryl-CO<sub>2</sub>H, HATU, DIEA, DMF.</p></p></figure><div class="NLM_p">The synthesis of analogues <b>12</b>–<b>15</b> is outlined in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. Compound <b>12</b> was synthesized starting from dichloropyrimidine <b>23</b>, which was first subjected to S<sub>N</sub>2 reaction with morpholine, followed by Suzuki–Miyaura coupling with <i>N</i>-(4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3-(trifluoromethyl)benzamide, and then oxidation via mCPBA to yield intermediate <b>24</b>. Compound <b>24</b> was converted to analogue <b>12</b> via S<sub>N</sub>2 reaction with 2-aminoethanol.</div><figure id="sch2" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/medium/jm-2019-00161v_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/large/jm-2019-00161v_0011.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Analogues <b>12</b>–<b>15</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/large/jm-2019-00161v_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00161&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) morpholine, DIPEA, EtOH, RT or 55 °C; (b) <i>N</i>-(4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3-(trifluoromethyl)benzamide, PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub>, DME, 2 M Na<sub>2</sub>CO<sub>3</sub>, 120 °C; (c) mCPBA, DCM, RT; (d) R-OH, NaH, dioxane, NMP, 150 °C or R-NH<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, DMSO, 55 °C; (e) (2,6-difluoropyridin-4-yl)boronic acid, PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub>, DME, 2 M Na<sub>2</sub>CO<sub>3</sub>, 60 °C; (f) H<sub>2</sub>, 10% Pd/C, EtOH; (g) aryl-CO<sub>2</sub>H, HATU, DIPEA, DMF.</p></p></figure><div class="NLM_p">Compounds <b>13</b>–<b>15</b> were prepared from commercial aryl- and pyridyl-nitro compounds <b>25</b> and <b>26</b>. Intermediates <b>29</b> and <b>30</b> were synthesized via Suzuki–Miyaura coupling reaction with (2,6-difluoropyridin-4-yl)boronic acid followed by S<sub>N</sub>2 reaction with morpholine. Hydrogenation then yielded intermediates <b>31</b> and <b>32</b>. Introduction of the side-chain groups at the 2-position of pyridine was performed through S<sub>N</sub>Ar reaction, and subsequent coupling of the anilines with carboxylic acids yielded <b>13</b>–<b>15</b> upon HPLC purification.</div><div class="NLM_p">An optimized synthetic route for <b>15</b>, used to supply larger quantities of material for <i>in vivo</i> studies, is outlined in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>. A direct Suzuki–Miyaura coupling of 3-bromo-4-methylaniline <b>33</b> with the previously used boronic ester was possible using the Pd-XPhos precatalyst. Installation of the morpholine and ethylyene glycol moieties was accomplished by successive S<sub>N</sub>Ar reactions, providing aniline <b>35</b>. Coupling of the aniline with the 2-(trifluoromethyl)-isonicotinic acid was followed by <i>in situ</i> acidic deprotection of the glycolic THP protecting group to afford <b>15</b> in high yield.</div><figure id="sch3" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/medium/jm-2019-00161v_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/large/jm-2019-00161v_0012.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Optimized Synthesis of <b>15</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/large/jm-2019-00161v_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00161&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (2,6-difluoropyridin-4-yl)boronic acid, Pd-XPhos precatalyst, 0.5 M K<sub>3</sub>PO<sub>4</sub>, THF, 35–60 °C, 64% yield; (b) morpholine, K<sub>2</sub>CO<sub>3</sub>, DMSO, 40 °C, quantitative yield; (c) 2-((tetrahydro-2<i>H</i>-pyran-2-yl)oxy)ethanol, NaH, dioxane, 60–70 °C, 72% yield; (d) 2-(trifluoromethyl)-isonicotinic acid, EDC·HCl, HOAT, DIPEA, DMF, RT, then 2 M aqueous HCl, RT, 94% yield.</p></p></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64403" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64403" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Despite the clinical efficacy of RAF and MEK inhibitors in BRAF<sup>V600</sup> mutant melanoma,<a onclick="showRef(event, 'ref19 ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref19 ref20 ref21">(19−21)</a> they are ineffective in RAS mutant tumors, leaving a significant unmet medical need. This class of RAF inhibitors, approved for the treatment of BRAF<sup>V600mut</sup> melanoma, including <b>2</b>, can induce paradoxical activation in BRAF wild-type cells and growth of RAS<sup>mut</sup> tumors. However, given the central role of CRAF in driving mutant KRAS-driven tumorigenesis, there remains a significant interest in developing RAF inhibitors that will be efficacious in RAS mutant tumors. Our work demonstrates that type 2 RAF inhibitors have the potential to be effective in RAS mutant tumors because they induce minimal paradoxical activation compared to RAF inhibitors with other binding modes (i.e., type 1 or type 1.5).<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> A previously disclosed <i>in vivo</i> tool, <b>3</b>,<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(10)</a> gave the first evidence supporting this hypothesis but could not be progressed further due to high intrinsic clearance in human microsomes. Due to limitations with the <i>in vivo</i> profile, we focused our efforts toward balancing physicochemical properties such as solubility and Cl<sup>int</sup> HLM with cellular potency by tweaking the electronics of the ring system. This approach led to the identification of <b>15</b>, a compound shown to be highly kinase-selective and cellularly potent in a RAS mutant cell line (Calu-6) with minimal paradoxical activation. We believe this profile will enable the clinical development of the compound as a single agent or in combination therapy. With the combination of potent <i>in vitro</i> activity and low to moderate Cl, <b>15</b> demonstrates <i>in vivo</i> target modulation (pMEK), single-agent anti-tumor activity in the Calu-6 rat xenograft model, and drug-like properties suitable for development. <b>15</b> was advanced into human studies and is currently being assessed in phase I trials.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50210" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50210" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> General Methods</h3><div class="NLM_p">The compounds and/or intermediates were characterized by high-performance liquid chromatography (HPLC) using a Waters Millennium chromatography system with a 2695 separation module (Milford, MA). The analytical columns were Alltima C-18 reverse-phase, 4.6 mm × 50 mm, flow 2.5 mL/min, from Alltech (Deerfield, IL). A gradient elution was used, typically starting with 5% acetonitrile/95% water and progressing to 100% acetonitrile over a period of 10 min. All solvents contained 0.1% trifluoroacetic acid (TFA). Compounds were detected by ultraviolet (UV) light absorption at either 220 or 254 nm. HPLC solvents were from Burdick and Jackson (Muskegan, MI) or Fisher Scientific (Pittsburgh, PA). Mass spectrometric analysis was performed on an LCMS instrument with a Waters system (Alliance HT HPLC and a Micromass ZQ mass spectrometer, Eclipse XDB-C18, 2.1 mm × 50 mm; solvent system, 5–95% acetonitrile in water with 0.1% TFA; flow rate 0.8 mL/min; molecular weight range 200–800; cone voltage 20 V; column temperature 40 °C). All masses were reported as those of the protonated parent ions. <sup>1</sup>H nuclear magnetic resonance (NMR) analyses described herein were performed on some of the compounds with a Varian 400-MR MHz NMR (Palo Alto, CA) spectrometer operating at a frequency of 399.89 MHz for <sup>1</sup>H or Bruker DRX-500 NMR spectrometer operating at a frequency of 500.13 MHz for <sup>1</sup>H. The spectral reference was either TMS or the known chemical shift of the solvent. The spectra were recorded at a temperature of 298 K. Preparative separations were carried out using a Teledyne ISCO chromatography system, or by HPLC using a Waters 2767 sample manager, C-18 reverse-phase column, 30 × 50 mm, flow 75 mL/min. Typical solvents employed for the Teledyne ISCO chromatography system were dichloromethane, methanol, ethyl acetate, and heptane. Typical solvents employed for the reverse-phase HPLC were varying concentrations of acetonitrile and water with 0.1% trifluoroacetic acid. The purity of all compounds screened in the biological assays was examined by LC-MS analysis and found to be ≥95%. Experimental details for the synthesis and characterization of compounds <b>3</b>, <b>4</b>, and <b>11</b> were reported earlier.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(10)</a></div><div id="sec5_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> General Procedure for S<sub>N</sub>Ar</h4><div class="NLM_p last">To a mixture of sodium hydride and 60% in mineral oil (3–4 mmol) in dioxane or DMF at ambient temperature was added the appropriate alcohol (1.6 mmol). To that mixture was added <i>N</i>-(6′-fluoro-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide,<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(10)</a> and the mixture was stirred for 2 h at 90 °C. The cooled reaction mixture was poured into water and extracted twice with EtOAc). The combined organics were washed with brine, dried over sodium sulfate, filtered, and concentrated. The mixture was purified by reverse-phase HPLC to give the desired product.</div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> General Procedure for the Amide Formation Reaction</h4><div class="NLM_p last">To the appropriate aniline (0.050 mmol) in DMF (0.75 mL volume) at RT were added HATU (0.050 mmol) and Huenig’s base (0.137 mmol), and the mixture was stirred overnight. The reaction was filtered, dissolved in DMSO, and then purified via reverse-phase HPLC to give the desired product.</div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> General Procedure for the Suzuki–Miyaura Reaction</h4><div class="NLM_p">To the appropriate heteroaryl halide (0.10 mmol) and the appropriate boronic ester (0.12 mmol) in DME (1 mL) were added PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> adduct (0.010 mmol) and 2 M aqueous sodium carbonate (0.50 mmol). The reaction mixture was irradiated at 120 °C in a Biotage Initiator microwave for 10–12 min. The cooled reaction mixture was diluted with 2:1 DCM:MeOH (15 mL) and filtered. The filtrate was concentrated and purified by reverse-phase HPLC to give the desired product as its TFA salt.</div><div id="sec5_1_3_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i25" class="anchor-spacer"></div><h5 class="article-section__title" id="_i25"> <i>N</i>-(6′-(((3<i>R</i>,4<i>S</i>)-3-Fluorotetrahydro-2<i>H</i>-pyran-4-yl)oxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (<b>5</b>)</h5><div class="NLM_p">To a stirred solution of 3-fluorodihydro-3-fluorodihydro-2<i>H</i>-pyran-4(3<i>H</i>)-one (100 mg, 0.847 mmol) in THF (5 mL) at −78 °C was added L-Selectride (1 M in THF, 0.847 mL, 0.847 mmol), and the mixture was warmed to RT and stirred until no bubbling was observed. 4-(5-Bromo-2-fluoropyridin-3-yl)morpholine (221 mg, 0.847 mmol) was added, and the reaction mixture was refluxed for 2 h. The mixture was concentrated and purified by preparatory HPLC to give 4-(5-bromo-2-(((3<i>R</i>,4<i>S</i>)-3-fluorotetrahydro-2<i>H</i>-pyran-4-yl)oxy)pyridin-3-yl)morpholine (54 mg, 17.6% yield). LCMS <i>m</i>/<i>z</i> [M+H] = 361/363, <i>t</i><sub>R</sub> = 0.88 min.</div><div class="NLM_p">A mixture of 4-(5-bromo-2-(((3<i>R</i>,4<i>S</i>)-3-fluorotetrahydro-2<i>H</i>-pyran-4-yl)oxy)pyridin-3-yl)morpholine (54 mg, 0.15 mmol), <i>N</i>-(6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-3-(trifluoromethyl)benzamide(60.7 mg, 0.149 mmol), 2 M sodium carbonate solution (0.224 mL, 0.448 mmol), and PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> adduct (6 mg, 0.0007 mmol) in DME (2 mL) was stirred at RT overnight. The reaction mixture was concentrated and purified by preparatory HPLC. The racemic mixture obtained was purified by chiral HPLC to give <i>N</i>-(6′-(((3<i>R</i>,4<i>S</i>)-3-fluorotetrahydro-2<i>H</i>-pyran-4-yl)oxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (9.9 mg, 11.6% yield). LCMS <i>m</i>/<i>z</i> [M+H] = 561.2, <i>t</i><sub>R</sub> = 0.78 min. HRMS <i>m</i>/<i>z</i> (M<sup>+</sup>+1) calcd 561.2119, obsd 561.2115.</div><div class="NLM_p last"><i>The following compounds were prepared by the above method starting from the appropriate heteroaryl halide and the appropriate alcohol.</i></div></div><div id="sec5_1_3_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i26" class="anchor-spacer"></div><h5 class="article-section__title" id="_i26"> <i>N</i>-(6′-(((3<i>S</i>,4<i>S</i>)-3-Methoxytetrahydro-2<i>H</i>-pyran-4-yl)oxy)-2-methyl-5′-morpholino-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (<b>6</b>)</h5><div class="NLM_p last">Obtained in 2% yield. LCMS <i>m</i>/<i>z</i> [M+H<sup>+</sup>] = 573.1, <i>t</i><sub>R</sub> = 0.76 min. HRMS <i>m</i>/<i>z</i> (M<sup>+</sup>+1) calcd 573.2319, obsd 573.2312.</div></div><div id="sec5_1_3_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i27" class="anchor-spacer"></div><h5 class="article-section__title" id="_i27"> <i>N</i>-(2-Methyl-5′-morpholino-6′-((tetrahydro-2<i>H</i>-pyran-4-yl)oxy)-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (<b>7</b>)</h5><div class="NLM_p last">Obtained in 6% yield. LCMS <i>m</i>/<i>z</i> [M+H<sup>+</sup>] = 544.1, <i>t</i><sub>R</sub> = 0.8 min. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.72 (ddd, <i>J</i> = 12.8, 8.3, 4.0 Hz, 2H), 2.05 (dt, <i>J</i> = 9.1, 4.0 Hz, 2H), 3.11 (t, <i>J</i> = 4.5 Hz, 3H), 3.58 (ddd, <i>J</i> = 11.6, 8.2, 3.2 Hz, 2H), 3.77 (t, <i>J</i> = 4.5 Hz, 4H), 3.85 (dt, <i>J</i> = 10.9, 4.9 Hz, 2H), 7.29 (d, <i>J</i> = 2.1 Hz, 1H), 7.90–7.77 (m, 2H), 8.03 (d, <i>J</i> = 7.8 Hz, 1H), 8.26 (s, 1H), 8.31 (d, <i>J</i> = 7.9 Hz, 1H), 8.35 (s, 1H), 9.03 (d, <i>J</i> = 2.3 Hz, 1H), 10.93 (s, 1H). HRMS <i>m</i>/<i>z</i> (M<sup>+</sup>+1) calcd 544.2276, obsd 544.2271.</div></div><div id="sec5_1_3_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i28" class="anchor-spacer"></div><h5 class="article-section__title" id="_i28"> <i>N</i>-(6-Methyl-5-(5-morpholino-6-((tetrahydro-2<i>H</i>-pyran-4-yl)oxy)pyridazin-3-yl)pyridin-3-yl)-3-(trifluoromethyl)benzamide (<b>8</b>)</h5><div class="NLM_p last">Obtained in 43% yield. LCMS (<i>m</i>/<i>z</i>) (M+H) = 544.2, <i>t</i><sub>R</sub> = 0.75 min. LCMS (<i>m</i>/<i>z</i>) (M+H) = 472.3, <i>t</i><sub>R</sub> = 0.88 min. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.03 (t, <i>J</i> = 7.04 Hz, 1H), 1.76 (dtd, <i>J</i> = 12.62, 8.36, 8.36, 3.91 Hz, 2H), 2.05–2.17 (m, 2H), 3.32–3.38 (m, 4H), 3.57 (ddd, <i>J</i> = 11.44, 8.51, 3.13 Hz, 2H), 3.69–3.77 (m, 4H), 3.79–3.88 (m, 2H), 5.51 (tt, <i>J</i> = 8.02, 3.91 Hz, 1H), 7.06 (s, 1H), 7.79 (t, <i>J</i> = 7.83 Hz, 1H), 7.98 (d, <i>J</i> = 7.83 Hz, 1H), 8.20 (d, <i>J</i> = 2.35 Hz, 1H), 8.28 (d, <i>J</i> = 7.83 Hz, 1H), 8.32 (s, 1H), 8.88 (d, <i>J</i> = 2.74 Hz, 1H), 10.68 (s, 1H). HRMS <i>m</i>/<i>z</i> (M<sup>+</sup>+1) calcd 544.2166, obsd 544.216.</div></div><div id="sec5_1_3_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i29" class="anchor-spacer"></div><h5 class="article-section__title" id="_i29"> 2-(2-Cyanopropan-2-yl)-<i>N</i>-(4-methyl-3-(1-methyl-5-morpholino-6-oxo-1,6-dihydropyridazin-3-yl)phenyl)isonicotinamide (<b>9</b>)</h5><div class="NLM_p">To a cooled solution (0–5 °C) of sodium nitrite (1.350 g, 19.57 mmol) in concentrated H<sub>2</sub>SO<sub>4</sub> (10.1 mL, 189 mmol) was added 4-bromo-6-chloropyridazin-3-amine (1.7 g, 8.16 mmol) in acetic acid (33 mL). The reaction mixture was then stirred at 0 °C for 30 min before warming to RT. It was stirred for 1 h, followed by the addition of water (51 mL), and stirred at RT for a further 4 h. The reaction mixture was then extracted with EtOAc, and the organic layer was dried over MgSO<sub>4</sub>, filtered, and concentrated <i>in vacuo</i> to yield a brown oil which was further purified by flash column chromatography over silica gel, eluting with 100% heptanes to 80% EtOAc:heptanes to yield 4-bromo-6-chloropyridazin-3(2<i>H</i>)-one (1.42 g, 6.78 mmol) in 83% yield. LCMS <i>m</i>/<i>z</i> [M+H] = 210.9/212.9, <i>t</i><sub>R</sub> = 0.42 min. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.08–8.32 (m, 1H), 13.25–13.71 (m, 1H).</div><div class="NLM_p">To a solution of 4-bromo-6-chloropyridazin-3(2<i>H</i>)-one (500 mg, 2.387 mmol) and Cs<sub>2</sub>CO<sub>3</sub> (933 mg, 2.86 mmol) in DMF (33 mL) was added MeI (0.224 mL, 3.58 mmol) dropwise over 20 min. The resulting mixture was stirred for 3 h. The reaction mixture was then diluted with saturated aqueous NH<sub>4</sub>Cl and then extracted twice with EtOAc. The combined organics were dried over MgSO<sub>4</sub>, filtered, and concentrated <i>in vacuo</i> to yield a brown solid. The oil was further purified by flash column chromatography over silica gel, eluting with 100% heptanes to 80% EtOAc:heptanes to give 4-bromo-6-chloro-2-methylpyridazin-3(2<i>H</i>)-one as an off white solid (423 mg, 1.9 mmol) in 79% yield.</div><div class="NLM_p">To a solution of 4-bromo-6-chloro-2-methylpyridazin-3(2<i>H</i>)-one (300 mg, 1.343 mmol) in DMF (4.5 mL) were added DIPEA (0.234 mL, 1.343 mmol) and morpholine (0.117 mL, 1.343 mmol) at RT. The resulting mixture was heated to 120 °C for 5 h. The reaction mixture was then diluted with water and extracted twice with EtOAc. The combined organics were dried over MgSO<sub>4</sub>, filtered, and concentrated <i>in vacuo</i> to give 6-chloro-2-methyl-4-morpholinopyridazin-3(2<i>H</i>)-one (300 mg, 1.3 mmol) in 97% yield. LCMS <i>m</i>/<i>z</i> [M+H] = 230/232, <i>t</i><sub>R</sub> = 0.64 min. The solid was utilized without further purification.</div><div class="NLM_p last">A solution of 6-chloro-2-methyl-4-morpholinopyridazin-3(2<i>H</i>)-one (100 mg, 0.435 mmol), Na<sub>2</sub>CO<sub>3</sub> (302 mg, 2.85 mmol), 4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (112 mg, 0.479 mmol), and PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> adduct (178 mg, 0.5 mmol) in DME (1.45 mL) and water (0.726 mL) was heated under microwave irradiation for 40 min at 120 °C. The reaction mixture was then diluted with EtOAc and water, and the aqueous layer was then separated and extracted twice with EtOAc. The combined organics were dried over MgSO<sub>4</sub>, filtered, and concentrated <i>in vacuo</i>. The residue was purified by reverse-phase HPLC to afford <b>9</b> as a brown solid in 24% yield. LCMS (<i>m</i>/<i>z</i>) (M+H) = 473.4, <i>t</i><sub>R</sub> = 0.84 min. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 1.75 (s, 6H), 2.29 (s, 3H), 3.36–3.51 (m, 4H), 3.57–3.76 (m, 7H), 6.59 (s, 1H), 7.30 (d, <i>J</i> = 8.22 Hz, 1H), 7.65–7.78 (m, 2H), 7.85 (d, <i>J</i> = 3.91 Hz, 1H), 7.94–8.06 (m, 1H), 8.79 (d, <i>J</i> = 5.09 Hz, 1H), 10.56 (s, 1H). HRMS <i>m</i>/<i>z</i> (M<sup>+</sup>+1) calcd 473.2296, obsd 473.2291.</div></div><div id="sec5_1_3_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i30" class="anchor-spacer"></div><h5 class="article-section__title" id="_i30"> <i>N</i>-(4-Methyl-3-(1-methyl-2-oxo-2,3-dihydro-1<i>H</i>-benzo[<i>d</i>]imidazol-5-yl)phenyl)-3-(trifluoromethyl)benzamide (<b>10</b>)</h5><div class="NLM_p">NaH (60% in mineral oil, 1.64 g, 41.0 mmol) was added portionwise to a stirred solution of 1<i>H</i>-benzo[<i>d</i>]imidazol-2(3<i>H</i>)-one (5 g, 37.3 mmol) in dry DMF (100 mL) at RT that was maintained under an atmosphere of argon. After 75 min, a solution of di-<i>tert</i>-butyl dicarbonate (8.14 g, 37.3 mmol) in dry DMF (20 mL) was added dropwise, and the mixture was stirred at RT for 22 h. The solvent was removed <i>in vacuo</i>, and the residue was diluted with saturated NH<sub>4</sub>Cl solution and extracted twice with EtOAc. The combined organics were dried over MgSO<sub>4</sub>, filtered, and concentrated <i>in vacuo</i>. The residue was purified by flash column chromatography over silica gel using a mixture of hexane and EtOAc (7:3) as eluent to furnish <i>tert</i>-butyl 2-oxo-2,3-dihydro-1<i>H</i>-benzo[<i>d</i>]imidazole-1-carboxylate (6.92 g, 29.5 mmol, 79% yield) as a white solid. LCMS (<i>m</i>/<i>z</i>) (M+H) = 235.1, <i>t</i><sub>R</sub> = 0.76 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.70 (s, 9H), 7.05–7.21 (m, 3H), 7.67–7.84 (m, 1H), 9.16–9.30 (m, 1H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ ppm 28.13 (s, 1C), 76.70 (s, 1C), 77.01 (s, 1C), 77.33 (s, 1C), 85.04 (s, 1C), 109.90 (s, 1C), 114.51 (s, 1C), 122.12 (s, 1C), 124.18 (s, 1C), 126.91 (s, 1C), 127.67 (s, 1C), 148.61 (s, 1C), 153.27 (s, 1C).</div><div class="NLM_p">Bromine (0.263 mL, 5.12 mmol) was added dropwise to a stirred solution of <i>tert</i>-butyl 2-oxo-2,3-dihydro-1<i>H</i>-benzo[<i>d</i>]imidazole-1-carboxylate (1 g, 4.27 mmol) and sodium acetate (0.366 g, 5.55 mmol) in acetic acid (13 mL) at RT. After 10 min, a precipitate formed, and the mixture was continually stirred at RT for 2 h. The mixture was diluted with ice/water, and the yellow solid was filtered off and dried in air to give <i>tert</i>-butyl 6-bromo-2-oxo-2,3-dihydro-1<i>H</i>-benzo[<i>d</i>]imidazole-1-carboxylate (1.2937 g, 4.13 mmol, 97% yield) as a white solid. LCMS (<i>m</i>/<i>z</i>) (M+H) = 334.9/336.9, <i>t</i><sub>R</sub> = 0.93 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.69 (s, 10H), 6.92–6.96 (m, 1H), 7.28–7.33 (m, 1H), 7.92–8.00 (m, 1H), 9.03–9.15 (m, 1H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ ppm 28.13 (s, 1C), 76.70 (s, 1C), 77.01 (s, 1C), 77.33 (s, 1C), 85.04 (s, 1C), 109.90 (s, 1C), 114.51 (s, 1C), 122.12 (s, 1C), 124.18 (s, 1C), 126.91 (s, 1C), 127.67 (s, 1C), 148.61 (s, 1C), 153.27 (s, 1C).</div><div class="NLM_p">A mixture of <i>tert</i>-butyl 6-bromo-2-oxo-2,3-dihydro-1<i>H</i>-benzo[<i>d</i>]imidazole-1-carboxylate (300 mg, 0.958 mmol), MeI (0.090 mL, 1.437 mmol), and potassium carbonate (212 mg, 1.533 mmol) in acetonitrile (5 mL) was stirred at RT under argon for 16 h. As the reaction was incomplete by LCMS after this time, another 212 mg of potassium carbonate and 0.090 mL of methyl iodide were added into this mixture. It was stirred under argon at RT for another 5 h. Upon completion of the reaction, EtOAc was added, and the organic layer was washed with water, dried over sodium sulfate, filtered, and concentrated. The crude residue was purified by flash column chromatography over silica gel, eluting with 50–100% ethyl acetate in hexanes, to give <i>tert</i>-butyl 6-bromo-3-methyl-2-oxo-2,3-dihydro-1<i>H</i>-benzo[<i>d</i>]imidazole-1-carboxylate (120.6 mg, 0.369 mmol, 38.5% yield). LCMS (<i>m</i>/<i>z</i>) (M+H) = 228.9/230.9.</div><div class="NLM_p"><i>tert</i>-Butyl 6-bromo-3-methyl-2-oxo-2,3-dihydro-1<i>H</i>-benzo[<i>d</i>]imidazole-1-carboxylate (120.6 mg, 0.369 mmol) was dissolved in 2 mL of 1:1 TFA/DCM. The reaction mixture was stirred at RT for 30 min under argon. The solution was concentrated to remove most of the solvent and TFA and then basified to neutral with saturated aqueous sodium carbonate solution. The solution was extracted with ethyl acetate, and the organic layer was separated, dried over sodium sulfate, filtered, and concentrated. The crude residue was purified by flash column chromatography over silica gel to yield 5-bromo-1-methyl-1<i>H</i>-benzo[<i>d</i>]imidazol-2(3<i>H</i>)-one in quantitative yield.</div><div class="NLM_p">A mixture of 5-bromo-1-methyl-1<i>H</i>-benzo[<i>d</i>]imidazol-2(3<i>H</i>)-one (70 mg, 0.308 mmol), 4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (216 mg, 0.925 mmol), and cesium carbonate (100 mg, 0.308 mmol) in dioxane (6 mL) and water (1.5 mL) was purged under argon for 3 min. Pd(PPh<sub>3</sub>)<sub>4</sub> (35.6 mg, 0.031 mmol) was added into the mixture, which was then heated in a microwave oven at 100 °C for 20 min. The reaction mixture was partitioned between ethyl acetate and water, and the organic layer was separated, washed with water and brine, dried over sodium sulfate, filtered, and concentrated. It was purified by flash column chromatography over silica gel eluting with 20% ethyl acetate in heptane to yield 5-(5-amino-2-methylphenyl)-1-methyl-1<i>H</i>-benzo[<i>d</i>]imidazol-2(3<i>H</i>)-one (60 mg, 0.237 mmol, 77%). LCMS (<i>m</i>/<i>z</i>) (M+H) = 254.1/230.9, <i>t</i><sub>R</sub> = 0.45 min.</div><div class="NLM_p last">To a mixture of 5-(5-amino-2-methylphenyl)-1-methyl-1<i>H</i>-benzo[<i>d</i>]imidazol-2(3<i>H</i>)-one (60 mg, 0.237 mmol) in ethyl acetate (2 mL) at RT were added DIPEA (0.084 mL, 0.474 mmol) and 3-(trifluoromethyl)benzoyl chloride (0.039 mL, 0.261 mmol) dropwise. The mixture was stirred at RT for 30 min. The reaction mixture was quenched with water and then was partitioned between ethyl acetate and water. The organic layer was separated, washed with water and brine, dried over sodium sulfate, filtered, and concentrated. The residue was purified by flash column chromatography over silica gel, eluting with 20% ethyl acetate in heptane, to yield <i>N</i>-(4-methyl-3-(1-methyl-2-oxo-2,3-dihydro-1<i>H</i>-benzo[<i>d</i>]imidazol-5-yl)phenyl)-3-(trifluoromethyl)benzamide (43.9 mg, 0.103 mmol, 43.6% yield). LCMS (<i>m</i>/<i>z</i>) (M+H) = 425.6 <i>t</i><sub>R</sub> = 0.95 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 2.19 (s, 3H), 3.29 (s, 3H), 6.89 (d, <i>J</i> = 1.2 Hz, 1H), 6.95–7.01 (m, 1H), 7.12 (d, <i>J</i> = 7.8 Hz, 1H), 7.24 (d, <i>J</i> = 8.2 Hz, 1H), 7.62 (s, 2H), 7.71–7.79 (m, 1H), 7.88–7.99 (m, 1H), 8.16–8.33 (m, 2H), 10.39 (s, 1H), 10.81–10.93 (m, 1H). HRMS <i>m</i>/<i>z</i> (M<sup>+</sup>+1) calcd 426.1424, obsd 426.1418.</div></div><div id="sec5_1_3_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i31" class="anchor-spacer"></div><h5 class="article-section__title" id="_i31"> <i>N</i>-(3-(2-((2-Hydroxyethyl)amino)-6-morpholinopyrimidin-4-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (<b>12</b>)</h5><div class="NLM_p">To a solution of triethylamine (0.057 mL, 0.410 mmol) and 4,6-dichloro-2-(methylthio)pyrimidine (100 mg, 0.513 mmol) in ethanol (2.56 mL) at RT was added morpholine (0.046 mL, 0.513 mmol) in one portion. The resulting mixture was stirred at RT for 6 h. The precipitate formed was filtered and washed with ethanol to give 4-(6-chloro-2-(methylthio)pyrimidin-4-yl)morpholine (83 mg, 66%). LCMS (<i>m</i>/<i>z</i>) (M+H) = 246/247.9, <i>t</i><sub>R</sub> = 0.74 min.</div><div class="NLM_p">The general procedure for the Suzuki–Miyaura reaction was followed for the next step utilizing the modified workup: the reaction mixture was partitioned between water and EtOAc. The aqueous was further washed with EtOAc (2 × 100 mL). The combined organics were dried over MgSO<sub>4</sub>, filtered, and concentrated. The residue was purified by flash column chromatography over silica gel, eluting with 0–60% EtOAc in heptanes, to provide <i>N</i>-(4-methyl-3-(2-(methylthio)-6-morpholinopyrimidin-4-yl)phenyl)-3-(trifluoromethyl)benzamide. Obtained in 60.4% yield. LCMS (<i>m</i>/<i>z</i>) (M+H) = 489.3, <i>t</i><sub>R</sub> = 0.8 min.</div><div class="NLM_p">To a solution of <i>N</i>-(4-methyl-3-(2-(methylthio)-6-morpholinopyrimidin-4-yl)phenyl)-3-(trifluoromethyl)benzamide (1.20 g, 2.456 mmol) in DCM (33.0 mL) was added mCPBA (1.211 g, 5.40 mmol) portionwise. The reaction mixture was stirred at RT for 4 h and then diluted with DCM (150 mL) and washed with 0.5 M Na<sub>2</sub>CO<sub>3</sub>. The resulting emulsion was filtered through a pad of Celite, and the cake was washed with DCM. The organic layer was dried over MgSO<sub>4</sub>, filtered, and concentrated. The solid was triturated in DCM/heptanes, and the product was filtered and dried to yield a light yellow solid, identified as <i>N</i>-(4-methyl-3-(2-(methylsulfonyl)-6-morpholinopyrimidin-4-yl)phenyl)-3-(trifluoromethyl)benzamide. LCMS (<i>m</i>/<i>z</i>) (M+H) = 521.2, <i>t</i><sub>R</sub> = 0.97 min.</div><div class="NLM_p last">To a solution of <i>N</i>-(4-methyl-3-(2-(methylsulfonyl)-6-morpholinopyrimidin-4-yl)phenyl)-3-(trifluoromethyl)benzamide (50 mg, 0.09 mmol) in THF (1 mL) were added 2-aminoethanol (11 mg, 0.19 mmol) and TEA (48.6 mg, 0.48 mmol), and the reaction mixture was heated to 120 °C in a microwave vial. The reaction mixture was concentrated, dissolved in DMSO, and purified by preparatory HPLC to give <i>N</i>-(3-(2-((2-hydroxyethyl)amino)-6-morpholinopyrimidin-4-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide (11.2 mg, 0.017 mmol) in 18% yield. LCMS (<i>m</i>/<i>z</i>) (M+H) = 502.3, <i>t</i><sub>R</sub> = 0.76 min. <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) δ ppm 2.02–2.26 (m, 2H), 2.38 (s, 3H), 3.62–3.85 (m, 9H), 4.04 (br s, 2H), 4.56 (br s, 1H), 6.52 (s, 1H), 7.41 (d, <i>J</i> = 8.22 Hz, 1H), 7.66 (dd, <i>J</i> = 8.22, 2.35 Hz, 1H), 7.72–7.78 (m, 1H), 7.92 (d, <i>J</i> = 7.83 Hz, 1H), 7.94 (d, <i>J</i> = 1.96 Hz, 1H), 8.21 (d, <i>J</i> = 7.83 Hz, 1H), 8.26 (s, 1H). HRMS <i>m</i>/<i>z</i> (M<sup>+</sup>+1) calcd 502.2061, obsd 502.2055.</div></div><div id="sec5_1_3_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i32" class="anchor-spacer"></div><h5 class="article-section__title" id="_i32"> <i>N</i>-(3-(2-((2-Hydroxyethyl)amino)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide (<b>13</b>)</h5><div class="NLM_p">To a mixture of 2-bromo-1-methyl-4-nitrobenzene (7 g, 32.5 mmol) and (2,6-difluoropyridin-4-yl)boronic acid (6.7 g, 42.1 mmol) were added DME (72 mL), 2 M aqueous sodium carbonate solution (36 mL), and PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> adduct (1.02 g, 1.62 mmol), and the mixture was heated overnight at 60 °C. The reaction mixture was partitioned between water and ethyl acetate, and the organic phase was dried with sodium sulfate, filtered, and concentrated. The crude material was purified by flash column chromatography over silica gel, eluting with 0–100% ethyl acetate in heptanes, to provide 2,6-difluoro-4-(2-methyl-5-nitrophenyl)pyridine (4.24 g, 16.95 mmol, 52.3% yield) as white crystalline solid. LCMS (<i>m</i>/<i>z</i>) (M+H) = 251, <i>t</i><sub>R</sub> = 0.94 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 2.40 (s, 3H), 6.82 (s, 2H), 7.51 (d, <i>J</i> = 8.22 Hz, 1H), 8.11 (d, <i>J</i> = 2.35 Hz, 1H), 8.22 (dd, <i>J</i> = 8.61, 2.35 Hz, 1H).</div><div class="NLM_p">To a solution of Huenig’s base (0.817 mL, 4.68 mmol) and 2,6-difluoro-4-(2-methyl-5-nitrophenyl)pyridine (390 mg, 1.559 mmol) in ethanol (5.2 mL) at RT was added morpholine (0.407 mL, 4.68 mmol) in one portion. The resulting mixture was then heated at 55 °C for 18 h. Water was then added, and the resulting precipitate was filtered off to yield 4-(6-fluoro-4-(2-methyl-5-nitrophenyl)pyridin-2-yl)morpholine (500 mg, 1.5 mmol, 100% yield). LCMS (<i>m</i>/<i>z</i>) (M+H) = 318.1, <i>t</i><sub>R</sub> = 1.04 min.</div><div class="NLM_p">To a solution of 4-(6-fluoro-4-(2-methyl-5-nitrophenyl)pyridin-2-yl)morpholine (495 mg, 1.56 mmol) in ethanol (5.6 mL) was added 10% palladium-on-carbon, and the mixture was vacuum-degassed three times with hydrogen and stirred overnight under an atmosphere of hydrogen. The solution was filtered through Celite and concentrated to yield 3-(2-fluoro-6-morpholinopyridin-4-yl)-4-methylaniline (440 mg, 1.531 mmol, 98% yield). LCMS (<i>m</i>/<i>z</i>) (M+H) = 288, <i>t</i><sub>R</sub> = 0.63 min.</div><div class="NLM_p">To a round-bottomed flask was added sodium hydride (69.6 mg, 1.740 mmol) and ethylene glycol (485 μL, 8.70 mmol) in dioxane (7.25 mL) and NMP (3.625 mL), and the mixture was stirred at RT for 20 min. At this time, a solution of 3-(2-fluoro-6-morpholinopyridin-4-yl)-4-methylaniline (250 mg, 0.870 mmol) in dioxane (1.0 mL) was added, and the mixture was heated at 90 °C for 18 h, at which time LCMS showed ∼40% conversion. The reaction mixture was further heated to 150 °C in the microwave for 30 min, The reaction mixture was quenched with saturated into NaHCO<sub>3</sub> solution and extracted twice with EtOAc. The combined organics were dried over MgSO<sub>4</sub>, filtered, concentrated. The residue was purified by flash column chromatography over silica gel, eluting with 0–10% MeOH/DCM, to yield 2-((4-(5-amino-2-methylphenyl)-6-morpholinopyridin-2-yl)oxy)ethanol (279 mg, 0.847 mmol, 97% yield). LCMS (<i>m</i>/<i>z</i>) (M+H) = 330.1, <i>t</i><sub>R</sub> = 0.53 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 2.26 (d, <i>J</i> = 4.9 Hz, 3H), 3.51 (q, <i>J</i> = 4.8 Hz, 4H), 3.79 (ddd, <i>J</i> = 6.7, 4.0, 1.8 Hz, 4H), 3.91–3.84 (m, 1H), 4.41–4.33 (m, 1H), 4.76–4.59 (m, 2H), 6.32–6.24 (m, 1H), 6.13 (dd, <i>J</i> = 28.4, 0.9 Hz, 1H), 7.33–7.25 (m, 1H), 7.68–7.56 (m, 2H), 8.14–8.07 (m, 1H), 8.31–8.26 (m, 1H), 8.93–8.86 (m, 1H).</div><div class="NLM_p">Following the general procedure for the amide formation, <b>13</b> was obtained in 30% yield. LCMS (<i>m</i>/<i>z</i>) (M+H) = 502.1, <i>t</i><sub>R</sub> = 0.73 min. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 2.32 (s, 3H), 3.52 (q, <i>J</i> = 4.43 Hz, 6H), 3.72–3.95 (m, 6H), 6.21 (d, <i>J</i> = 10.96 Hz, 1H), 7.35 (d, <i>J</i> = 8.22 Hz, 1H), 7.60 (dd, <i>J</i> = 8.22, 1.96 Hz, 1H), 7.77 (s, 1H), 8.12 (d, <i>J</i> = 4.70 Hz, 1H), 8.29 (s, 1H), 8.92 (d, <i>J</i> = 5.09 Hz, 1H). HRMS <i>m</i>/<i>z</i> (M<sup>+</sup>+1) calcd 502.2061, obsd 502.2055.</div><div class="NLM_p last"><i>The following compounds were synthesized following procedures similar to that described for compound <b>13</b> above.</i></div></div><div id="sec5_1_3_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i33" class="anchor-spacer"></div><h5 class="article-section__title" id="_i33"> 2-(1,1-Difluoroethyl)-<i>N</i>-(2′-((2-hydroxyethyl)amino)-2-methyl-6′-morpholino-[3,4′-bipyridin]-5-yl)isonicotinamide (<b>14</b>)</h5><div class="NLM_p last">Obtained in 63.2% yield. LCMS (<i>m</i>/<i>z</i>) (M+H) = 499.2, <i>t</i><sub>R</sub> = 0.53 min. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ ppm 2.07 (t, <i>J</i> = 18.76 Hz, 3H), 2.64 (s, 3H), 3.52–3.59 (m, 6H), 3.80–3.88 (m, 6H), 6.20–6.28 (m, 1H), 8.03 (d, <i>J</i> = 5.04 Hz, 1H), 8.25 (s, 1H), 8.43 (d, <i>J</i> = 2.52 Hz, 1H), 8.88 (d, <i>J</i> = 4.73 Hz, 1H), 9.09 (d, <i>J</i> = 1.58 Hz, 1H). HRMS <i>m</i>/<i>z</i> (M<sup>+</sup>+1) calcd 499.2264, obsd 499.2256.</div></div><div id="sec5_1_3_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i34" class="anchor-spacer"></div><h5 class="article-section__title" id="_i34"> <i>N</i>-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide (<b>15</b>)</h5><div class="NLM_p last">Obtained in 36% yield. LCMS (<i>m</i>/<i>z</i>) (M+H) = 503.1, <i>t</i><sub>R</sub> = 0.89 min. <sup>1</sup>H NMR (500 MHz, methanol-<i>d</i><sub>4</sub>) δ ppm 2.26 (d, <i>J</i> = 4.9 Hz, 3H), 3.51 (q, <i>J</i> = 4.8 Hz, 4H), 3.79 (ddd, <i>J</i> = 6.7, 4.0, 1.8 Hz, 4H), 3.91–3.84 (m, 1H), 4.41–4.33 (m, 1H), 4.76–4.59 (m, 2H), 6.13 (dd, <i>J</i> = 28.4, 0.9 Hz, 1H), 6.32–6.24 (m, 1H), 7.33–7.25 (m, 1H), 7.68–7.56 (m, 2H), 8.14–8.07 (m, 1H), 8.31–8.26 (m, 1H), 8.93–8.86 (m, 1H). HRMS <i>m</i>/<i>z</i> (M<sup>+</sup>+1) calcd 503.1906, obsd 503.1902.</div></div><div id="sec5_1_3_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i35" class="anchor-spacer"></div><h5 class="article-section__title" id="_i35"> Optimized Synthesis of <i>N</i>-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide (<b>15</b>)</h5><div class="NLM_p">3-Bromo-4-methylaniline (8.03 g, 43.1 mmol), (2,6-difluoropyridin-4-yl)boronic acid (10 g, 41.5 mmol), and Pd-XPhos precatalyst (0.163 g, 0.207 mmol) were stirred in a solution of THF (83 mL) under nitrogen. Next, 0.5 M potassium phosphate solution (166 mL) was added, and the mixture was heated overnight at 35 °C. More Pd-Xphos precatalyst (0.163 g, 0.207 mmol) was added, and the mixture was warmed to 60 °C for 18 h. The mixture was carefully poured into water and extracted three times with ethyl acetate. The combined organics were washed with water, dried over magnesium sulfate, filtered, and concentrated. The crude material was purified by flash column chromatography over silica gel, eluting with 0–100% ethyl acetate in heptane, to give 3-(2,6-difluoropyridin-4-yl)-4-methylaniline (5.87 g, 26.7 mmol, 64% yield). LCMS (<i>m</i>/<i>z</i>) (M+H) = 220.9, <i>t</i><sub>R</sub> = 0.54 min.</div><div class="NLM_p">To a solution of 3-(2,6-difluoropyridin-4-yl)-4-methylaniline (5.87 g, 26.7 mmol) in DMSO (26.7 mL) was added morpholine (6.92 mL, 80 mmol) and potassium carbonate (7.37 g, 53.3 mmol). The mixture was heated at 40 °C for 3 h. Upon cooling to RT, it was diluted with water and sodium bicarbonate and extracted three times with ethyl acetate. The combined organics were dried over MgSO<sub>4</sub>, filtered, and concentrated to give 3-(2-fluoro-6-morpholinopyridin-4-yl)-4-methylaniline (7.66 g, 26.7 mmol, quantitative yield). LCMS (<i>m</i>/<i>z</i>) (M+H) = 288.0, <i>t</i><sub>R</sub> = 0.60 min.</div><div class="NLM_p">To a solution of 3-(2-fluoro-6-morpholinopyridin-4-yl)-4-methylaniline (7.66 g, 26.7 mmol) in dioxane (132 mL) was added 2-((tetrahydro-2<i>H</i>-pyran-2-yl)oxy)ethanol (7.18 mL, 52.9 mmol). Sodium hydride (60% dispersion, 2.116 g, 52.9 mmol) was added carefully, and the reaction was stirred at RT for 30 min, then warmed to 60 °C for 2 h. At this point, about 75% conversion to product was observed by LCMS, so the mixture was heated to 70 °C for an additional 1 h. The reaction was cooled to RT, quenched with aqueous sodium bicarbonate, and extracted three times ethyl acetate. The combined organics were dried over magnesium sulfate, filtered, and concentrated. The crude material was purified by flash column chromatography over silica gel, eluting with 0–5% methanol in DCM and then 0–100% ethyl acetate in heptanes, to give 4-methyl-3-(2-morpholino-6-(2-((tetrahydro-2<i>H</i>-pyran-2-yl)oxy)ethoxy)pyridin-4-yl)aniline (8.8 g, 19.15 mmol, 72% yield). LCMS (<i>m</i>/<i>z</i>) (M+H) = 414.1, <i>t</i><sub>R</sub> = 0.73 min.</div><div class="NLM_p last">A solution of 4-methyl-3-(2-morpholino-6-(2-((tetrahydro-2<i>H</i>-pyran-2-yl)oxy)ethoxy)pyridin-4-yl)aniline (6.39 g, 13.91 mmol), 2-(trifluoromethyl)isonicotinic acid (3.19 g, 16.69 mmol), <i>N</i>1-((ethylimino)methylene)-<i>N</i>3,<i>N</i>3-dimethylpropane-1,3-diamine hydrochloride (3.20 g, 16.69 mmol), 3<i>H</i>-[1,2,3]triazolo[4,5-<i>b</i>]pyridin-3-ol hydrate (2.57 g, 16.69 mmol), and Huenig’s base (2.70 g, 20.86 mmol) in DMF (100 mL) was stirred at RT overnight. HCl (2.0 M aqueous solution, 34.75 mL, 69.5 mmol) was then added, and the reaction was stirred for 90 min, at which point LC/MS indicated about 90% conversion to product. Additional HCl (34.75 mL, 69.5 mmol) was added, and the mixture was stirred for 30 min at RT. The solution was diluted with water, and solid sodium bicarbonate was carefully added until pH = 5 was reached. The solution was extracted three times with ethyl acetate, and the combined organics were dried over magnesium sulfate, filtered, and concentrated. The crude material was purified by flash column chromatography over silica gel, eluting with 0–100% ethyl acetate in heptanes, to give <i>N</i>-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide (6.64 g, 13.08 mmol, 94% yield).</div></div></div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> Biochemical Kinase Specificity Profile of <b>15</b></h3><div class="NLM_p last">The kinase specificity profile for compound <b>15</b> reported in <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a> was determined as previously described.<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17,18)</a> Compound <b>15</b> was assessed in the DiscoverX KINOME<i>scan</i> binding assay at 1 μM with activity presented as % of control = [(test compound signal – positive control signal)/(negative control signal – positive control signal]] × 100. Data for the 457 kinase KINOME<i>scan</i> are in <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> <i>In Vivo</i> PK/PD and Efficacy</h3><div class="NLM_p last">Rat studies were undertaken in accordance with the Novartis Institutes for Biomedical Research Animal Care and Use Committee protocols and regulations. Mice were housed in a temperature- and humidity-controlled animal facility with <i>ad libitum</i> access to food and water and acclimated for at least 3 days before experimental procedures.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> Crystallography Methods</h3><div class="NLM_p last">The crystallization and data collection of wild-type BRAF (residues 445–723) were performed as described previously.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(10)</a></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i39"><a href="/doi/suppl/10.1021/acs.jmedchem.9b00161" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06683" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06683" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.9b00161" class="ext-link">10.1021/acs.jmedchem.9b00161</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Synthetic scheme and experimental procedure of compound <b>10</b>, metabolite identification methods, biochemical and cellular assay conditions, X-ray data table for <b>10</b> and <b>15</b>, and unbound fraction of <b>15</b> in plasma (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00161/suppl_file/jm9b00161_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00161/suppl_file/jm9b00161_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00161/suppl_file/jm9b00161_si_001.pdf">jm9b00161_si_001.pdf (410.29 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00161/suppl_file/jm9b00161_si_002.csv">jm9b00161_si_002.csv (1.09 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.9b00161" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44000" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44000" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Savithri Ramurthy</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, Novartis Institutes
for BioMedical Research, 5300 Chiron Way, Emeryville, California 94608, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2444-5309" title="Orcid link">http://orcid.org/0000-0002-2444-5309</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#6e1d0f18071a061c07401c0f031b1c1a06172e09030f0702400d0103"><span class="__cf_email__" data-cfemail="deadbfa8b7aab6acb7f0acbfb3abacaab6a79eb9b3bfb7b2f0bdb1b3">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Benjamin R. Taft</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, Novartis Institutes
for BioMedical Research, 5300 Chiron Way, Emeryville, California 94608, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Robert J. Aversa</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, Novartis Institutes
for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9873-4381" title="Orcid link">http://orcid.org/0000-0002-9873-4381</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul A. Barsanti</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, Novartis Institutes
for BioMedical Research, 5300 Chiron Way, Emeryville, California 94608, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matthew T. Burger</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, Novartis Institutes
for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yan Lou</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, Novartis Institutes
for BioMedical Research, 5300 Chiron Way, Emeryville, California 94608, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gisele A. Nishiguchi</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, Novartis Institutes
for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alice Rico</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, Novartis Institutes
for BioMedical Research, 5300 Chiron Way, Emeryville, California 94608, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lina Setti</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, Novartis Institutes
for BioMedical Research, 5300 Chiron Way, Emeryville, California 94608, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Aaron Smith</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, Novartis Institutes
for BioMedical Research, 5300 Chiron Way, Emeryville, California 94608, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sharadha Subramanian</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, Novartis Institutes
for BioMedical Research, 5300 Chiron Way, Emeryville, California 94608, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Victoriano Tamez</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, Novartis Institutes
for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Huw Tanner</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, Novartis Institutes
for BioMedical Research, 5300 Chiron Way, Emeryville, California 94608, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lifeng Wan</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, Novartis Institutes
for BioMedical Research, 5300 Chiron Way, Emeryville, California 94608, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Cheng Hu</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, Novartis Institutes
for BioMedical Research, 5300 Chiron Way, Emeryville, California 94608, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brent A. Appleton</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, Novartis Institutes
for BioMedical Research, 5300 Chiron Way, Emeryville, California 94608, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mulugeta Mamo</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, Novartis Institutes
for BioMedical Research, 5300 Chiron Way, Emeryville, California 94608, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Laura Tandeske</span> - <span class="hlFld-Affiliation affiliation">Oncology, Novartis Institutes for BioMedical Research, 5300 Chiron Way, Emeryville, California 94608, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John E. Tellew</span> - <span class="hlFld-Affiliation affiliation">Genomics
Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shenlin Huang</span> - <span class="hlFld-Affiliation affiliation">Genomics
Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qin Yue</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, Novartis Institutes
for BioMedical Research, 5300 Chiron Way, Emeryville, California 94608, United States</span></div></li><li><div class="authorItemInformation"><sup>¶</sup><span class="hlFld-ContribAuthor strong">Apurva Chaudhary</span> - <span class="hlFld-Affiliation affiliation">Process
Research and Development, Chemical and Analytical Development, Novartis Institute for Biomedical Research, One Health Plaza, East Hanover, New Jersey 07936, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hung Tian</span> - <span class="hlFld-Affiliation affiliation">Technical
Research & Development, Global Drug Development, Novartis Pharmaceuticals Corp., One Health Plaza, East Hanover, New Jersey 07936, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Raman Iyer</span> - <span class="hlFld-Affiliation affiliation">Technical
Research & Development, Global Drug Development, Novartis Pharmaceuticals Corp., One Health Plaza, East Hanover, New Jersey 07936, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">A. Quamrul Hassan</span> - <span class="hlFld-Affiliation affiliation">Oncology, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lesley A. Mathews Griner</span> - <span class="hlFld-Affiliation affiliation">Oncology, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Laura R. La Bonte</span> - <span class="hlFld-Affiliation affiliation">Oncology, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Vesselina G. Cooke</span> - <span class="hlFld-Affiliation affiliation">Oncology, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anne Van Abbema</span> - <span class="hlFld-Affiliation affiliation">Oncology, Novartis Institutes for BioMedical Research, 5300 Chiron Way, Emeryville, California 94608, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hanne Merritt</span> - <span class="hlFld-Affiliation affiliation">Oncology, Novartis Institutes for BioMedical Research, 5300 Chiron Way, Emeryville, California 94608, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kalyani Gampa</span> - <span class="hlFld-Affiliation affiliation">Oncology, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fei Feng</span> - <span class="hlFld-Affiliation affiliation">Oncology, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jing Yuan</span> - <span class="hlFld-Affiliation affiliation">Oncology, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yuji Mishina</span> - <span class="hlFld-Affiliation affiliation">Oncology, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yingyun Wang</span> - <span class="hlFld-Affiliation affiliation">Oncology, Novartis Institutes for BioMedical Research, 5300 Chiron Way, Emeryville, California 94608, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jacob R. Haling</span> - <span class="hlFld-Affiliation affiliation">Genomics
Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sepideh Vaziri</span> - <span class="hlFld-Affiliation affiliation">Genomics
Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mohammad Hekmat-Nejad</span> - <span class="hlFld-Affiliation affiliation">Oncology, Novartis Institutes for BioMedical Research, 5300 Chiron Way, Emeryville, California 94608, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Valery Polyakov</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, Novartis Institutes
for BioMedical Research, 5300 Chiron Way, Emeryville, California 94608, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Richard Zang</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, Novartis Institutes
for BioMedical Research, 5300 Chiron Way, Emeryville, California 94608, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Vijay Sethuraman</span> - <span class="hlFld-Affiliation affiliation">Oncology, Novartis Institutes for BioMedical Research, 5300 Chiron Way, Emeryville, California 94608, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Payman Amiri</span> - <span class="hlFld-Affiliation affiliation">Oncology, Novartis Institutes for BioMedical Research, 5300 Chiron Way, Emeryville, California 94608, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mallika Singh</span> - <span class="hlFld-Affiliation affiliation">Oncology, Novartis Institutes for BioMedical Research, 5300 Chiron Way, Emeryville, California 94608, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">William R. Sellers</span> - <span class="hlFld-Affiliation affiliation">Oncology, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Emma Lees</span> - <span class="hlFld-Affiliation affiliation">Oncology, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wenlin Shao</span> - <span class="hlFld-Affiliation affiliation">Oncology, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael P. Dillon</span> - <span class="hlFld-Affiliation affiliation">Global
Discovery Chemistry, Novartis Institutes
for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Darrin D. Stuart</span> - <span class="hlFld-Affiliation affiliation">Oncology, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br><sup>¶</sup>Died October 2018.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e3499-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i41">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73614" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73614" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Dazhi Tang, Elaine Ginn, Colin Lorentzen, and Kent Wong for generating solubility and <i>in vitro</i> ADME data as well as Shengtian Yang for running NMR structural elucidation of <b>15</b>.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">Sol</td><td class="NLM_def"><p class="first last">solubility</p></td></tr><tr><td class="NLM_term">CP</td><td class="NLM_def"><p class="first last">cell proliferation</p></td></tr><tr><td class="NLM_term">Cl</td><td class="NLM_def"><p class="first last">clearance</p></td></tr><tr><td class="NLM_term"><i>V</i><sub>ss</sub></td><td class="NLM_def"><p class="first last">volume of distribution</p></td></tr><tr><td class="NLM_term">DIEA</td><td class="NLM_def"><p class="first last">diisopropylethylamine</p></td></tr><tr><td class="NLM_term">EDC</td><td class="NLM_def"><p class="first last">1-ethyl-3-(3-(dimethylamino)propyl)carbodiimide</p></td></tr><tr><td class="NLM_term">HOAt</td><td class="NLM_def"><p class="first last">1-hydroxy-7-azabenzotriazole</p></td></tr><tr><td class="NLM_term">S<sub>N</sub>Ar</td><td class="NLM_def"><p class="first last">nucleophilic aromatic substitution</p></td></tr><tr><td class="NLM_term"><i>t</i><sub>R</sub></td><td class="NLM_def"><p class="first last">retention time</p></td></tr><tr><td class="NLM_term">RT</td><td class="NLM_def"><p class="first last">room temperature</p></td></tr><tr><td class="NLM_term">TCEP</td><td class="NLM_def"><p class="first last">(tris(2-carboxyethyl) phosphine)</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i43">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40731" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40731" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 22 other publications.
        </p><ol id="references" class="useLabel"><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ostrem, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sos, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span> <span> </span><span class="NLM_article-title">K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>503</i></span> (<span class="NLM_issue">7477</span>),  <span class="NLM_fpage">548</span>– <span class="NLM_lpage">551</span>, <span class="refDoi"> DOI: 10.1038/nature12796</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=10.1038%2Fnature12796" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=24256730" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVGqs7jO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=503&publication_year=2013&pages=548-551&issue=7477&author=J.+M.+Ostremauthor=U.+Petersauthor=M.+L.+Sosauthor=J.+A.+Wellsauthor=K.+M.+Shokat&title=K-Ras%28G12C%29+inhibitors+allosterically+control+GTP+affinity+and+effector+interactions&doi=10.1038%2Fnature12796"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions</span></div><div class="casAuthors">Ostrem, Jonathan M.; Peters, Ulf; Sos, Martin L.; Wells, James A.; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">503</span>
        (<span class="NLM_cas:issue">7477</span>),
    <span class="NLM_cas:pages">548-551</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Somatic mutations in the small GTPase K-Ras are the most common activating lesions found in human cancer, and are generally assocd. with poor response to std. therapies.  Efforts to target this oncogene directly have faced difficulties owing to its picomolar affinity for GTP/GDP and the absence of known allosteric regulatory sites.  Oncogenic mutations result in functional activation of Ras family proteins by impairing GTP hydrolysis.  With diminished regulation by GTPase activity, the nucleotide state of Ras becomes more dependent on relative nucleotide affinity and concn.  This gives GTP an advantage over GDP and increases the proportion of active GTP-bound Ras.  Here we report the development of small mols. that irreversibly bind to a common oncogenic mutant, K-Ras(G12C).  These compds. rely on the mutant cysteine for binding and therefore do not affect the wild-type protein.  Crystallog. studies reveal the formation of a new pocket that is not apparent in previous structures of Ras, beneath the effector binding switch-II region.  Binding of these inhibitors to K-Ras(G12C) disrupts both switch-I and switch-II, subverting the native nucleotide preference to favor GDP over GTP and impairing binding to Raf.  Our data provide structure-based validation of a new allosteric regulatory site on Ras that is targetable in a mutant-specific manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokkgcVXuBn_rVg90H21EOLACvtfcHk0lipjLCKsu4XoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVGqs7jO&md5=27c1e7d8ef6b7e4b2919e9f00a073923</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnature12796&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature12796%26sid%3Dliteratum%253Aachs%26aulast%3DOstrem%26aufirst%3DJ.%2BM.%26aulast%3DPeters%26aufirst%3DU.%26aulast%3DSos%26aufirst%3DM.%2BL.%26aulast%3DWells%26aufirst%3DJ.%2BA.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DK-Ras%2528G12C%2529%2520inhibitors%2520allosterically%2520control%2520GTP%2520affinity%2520and%2520effector%2520interactions%26jtitle%3DNature%26date%3D2013%26volume%3D503%26issue%3D7477%26spage%3D548%26epage%3D551%26doi%3D10.1038%2Fnature12796" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lito, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, N.</span></span> <span> </span><span class="NLM_article-title">Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>351</i></span> (<span class="NLM_issue">6273</span>),  <span class="NLM_fpage">604</span>– <span class="NLM_lpage">608</span>, <span class="refDoi"> DOI: 10.1126/science.aad6204</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=10.1126%2Fscience.aad6204" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=26841430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhsl2jt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=351&publication_year=2016&pages=604-608&issue=6273&author=P.+Litoauthor=M.+Solomonauthor=L.+S.+Liauthor=R.+Hansenauthor=N.+Rosen&title=Allele-specific+inhibitors+inactivate+mutant+KRAS+G12C+by+a+trapping+mechanism&doi=10.1126%2Fscience.aad6204"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism</span></div><div class="casAuthors">Lito, Piro; Solomon, Martha; Li, Lian-Sheng; Hansen, Rasmus; Rosen, Neal</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">351</span>
        (<span class="NLM_cas:issue">6273</span>),
    <span class="NLM_cas:pages">604-608</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">It is thought that KRAS oncoproteins are constitutively active because their guanosine triphosphatase (GTPase) activity is disabled.  Consequently, drugs targeting the inactive or GDP-bound conformation are not expected to be effective.  We describe a mechanism that enables such drugs to inhibit KRASG12C signaling and cancer cell growth.  Inhibition requires intact GTPase activity and occurs because drug-bound KRASG12C is insusceptible to nucleotide exchange factors and thus trapped in its inactive state.  Indeed, mutants completely lacking GTPase activity and those promoting exchange reduced the potency of the drug.  Suppressing nucleotide exchange activity downstream of various tyrosine kinases enhanced KRASG12C inhibition, whereas its potentiation had the opposite effect.  These findings reveal that KRASG12C undergoes nucleotide cycling in cancer cells and provide a basis for developing effective therapies to treat KRASG12C-driven cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqK3AbqEZO6k7Vg90H21EOLACvtfcHk0lipjLCKsu4XoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhsl2jt78%253D&md5=22a47908ac0146822ecf19f5d0c952de</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1126%2Fscience.aad6204&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aad6204%26sid%3Dliteratum%253Aachs%26aulast%3DLito%26aufirst%3DP.%26aulast%3DSolomon%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DL.%2BS.%26aulast%3DHansen%26aufirst%3DR.%26aulast%3DRosen%26aufirst%3DN.%26atitle%3DAllele-specific%2520inhibitors%2520inactivate%2520mutant%2520KRAS%2520G12C%2520by%2520a%2520trapping%2520mechanism%26jtitle%3DScience%26date%3D2016%26volume%3D351%26issue%3D6273%26spage%3D604%26epage%3D608%26doi%3D10.1126%2Fscience.aad6204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patricelli, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janes, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kessler, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kucharski, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ely, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firdaus, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babbar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span> <span> </span><span class="NLM_article-title">Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">316</span>– <span class="NLM_lpage">329</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-15-1105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=10.1158%2F2159-8290.CD-15-1105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=26739882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=1%3ACAS%3A528%3ADC%252BC28XktVyru7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=316-329&issue=3&author=M.+P.+Patricelliauthor=M.+R.+Janesauthor=L.+S.+Liauthor=R.+Hansenauthor=U.+Petersauthor=L.+V.+Kesslerauthor=Y.+Chenauthor=J.+M.+Kucharskiauthor=J.+Fengauthor=T.+Elyauthor=J.+H.+Chenauthor=S.+J.+Firdausauthor=A.+Babbarauthor=P.+Renauthor=Y.+Liu&title=Selective+inhibition+of+oncogenic+KRAS+output+with+small+molecules+targeting+the+inactive+state&doi=10.1158%2F2159-8290.CD-15-1105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State</span></div><div class="casAuthors">Patricelli, Matthew P.; Janes, Matthew R.; Li, Lian-Sheng; Hansen, Rasmus; Peters, Ulf; Kessler, Linda V.; Chen, Yuching; Kucharski, Jeff M.; Feng, Jun; Ely, Tess; Chen, Jeffrey H.; Firdaus, Sarah J.; Babbar, Anjali; Ren, Pingda; Liu, Yi</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">316-329</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">KRAS gain-of-function mutations occur in approx. 30% of all human cancers.  Despite more than 30 years of KRAS-focused research and development efforts, no targeted therapy has been discovered for cancers with KRAS mutations.  Here, we describe ARS-853, a selective, covalent inhibitor of KRASG12C that inhibits mutant KRAS-driven signaling by binding to the GDP-bound oncoprotein and preventing activation.  Based on the rates of engagement and inhibition obsd. for ARS-853, along with a mutant-specific mass spectrometry-based assay for assessing KRAS activation status, we show that the nucleotide state of KRASG12C is in a state of dynamic flux that can be modulated by upstream signaling factors.  These studies provide convincing evidence that the KRASG12C mutation generates a "hyperexcitable" rather than a "statically active" state and that targeting the inactive, GDP-bound form is a promising approach for generating novel anti-RAS therapeutics.  Significance: A cell-active, mutant-specific, covalent inhibitor of KRASG12C is described that targets the GDP-bound, inactive state and prevents subsequent activation.  Using this novel compd., we demonstrate that KRASG12C oncoprotein rapidly cycles bound nucleotide and responds to upstream signaling inputs to maintain a highly active state.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJJA-9IIHeN7Vg90H21EOLACvtfcHk0ljNnIl_bcNFLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktVyru7s%253D&md5=41db2f02006e8f0be7a9bb47354addcd</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-15-1105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-15-1105%26sid%3Dliteratum%253Aachs%26aulast%3DPatricelli%26aufirst%3DM.%2BP.%26aulast%3DJanes%26aufirst%3DM.%2BR.%26aulast%3DLi%26aufirst%3DL.%2BS.%26aulast%3DHansen%26aufirst%3DR.%26aulast%3DPeters%26aufirst%3DU.%26aulast%3DKessler%26aufirst%3DL.%2BV.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DKucharski%26aufirst%3DJ.%2BM.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DEly%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DJ.%2BH.%26aulast%3DFirdaus%26aufirst%3DS.%2BJ.%26aulast%3DBabbar%26aufirst%3DA.%26aulast%3DRen%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DY.%26atitle%3DSelective%2520inhibition%2520of%2520oncogenic%2520KRAS%2520output%2520with%2520small%2520molecules%2520targeting%2520the%2520inactive%2520state%26jtitle%3DCancer%2520Discovery%26date%3D2016%26volume%3D6%26issue%3D3%26spage%3D316%26epage%3D329%26doi%3D10.1158%2F2159-8290.CD-15-1105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hatzivassiliou, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandhuber, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarado, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludlam, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stokoe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gloor, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vigers, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aliagas, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sideris, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoeflich, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaiswal, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seshagiri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koeppen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belvin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malek, S.</span></span> <span> </span><span class="NLM_article-title">RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>464</i></span> (<span class="NLM_issue">7287</span>),  <span class="NLM_fpage">431</span>– <span class="NLM_lpage">435</span>, <span class="refDoi"> DOI: 10.1038/nature08833</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=10.1038%2Fnature08833" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=20130576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVygtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=464&publication_year=2010&pages=431-435&issue=7287&author=G.+Hatzivassiliouauthor=K.+Songauthor=I.+Yenauthor=B.+J.+Brandhuberauthor=D.+J.+Andersonauthor=R.+Alvaradoauthor=M.+J.+Ludlamauthor=D.+Stokoeauthor=S.+L.+Gloorauthor=G.+Vigersauthor=T.+Moralesauthor=I.+Aliagasauthor=B.+Liuauthor=S.+Siderisauthor=K.+P.+Hoeflichauthor=B.+S.+Jaiswalauthor=S.+Seshagiriauthor=H.+Koeppenauthor=M.+Belvinauthor=L.+S.+Friedmanauthor=S.+Malek&title=RAF+inhibitors+prime+wild-type+RAF+to+activate+the+MAPK+pathway+and+enhance+growth&doi=10.1038%2Fnature08833"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth</span></div><div class="casAuthors">Hatzivassiliou, Georgia; Song, Kyung; Yen, Ivana; Brandhuber, Barbara J.; Anderson, Daniel J.; Alvarado, Ryan; Ludlam, Mary J. C.; Stokoe, David; Gloor, Susan L.; Vigers, Guy; Morales, Tony; Aliagas, Ignacio; Liu, Bonnie; Sideris, Steve; Hoeflich, Klaus P.; Jaiswal, Bijay S.; Seshagiri, Somasekar; Koeppen, Hartmut; Belvin, Marcia; Friedman, Lori S.; Malek, Shiva</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">464</span>
        (<span class="NLM_cas:issue">7287</span>),
    <span class="NLM_cas:pages">431-435</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Activating mutations in KRAS and BRAF are found in more than 30% of all human tumors and 40% of melanoma, resp., thus targeting this pathway could have broad therapeutic effects.  Small mol. ATP-competitive RAF kinase inhibitors have potent antitumor effects on mutant BRAF(V600E) tumors but, in contrast to mitogen-activated protein kinase kinase (MEK) inhibitors, are not potent against RAS mutant tumor models, despite RAF functioning as a key effector downstream of RAS and upstream of MEK.  Here we show that ATP-competitive RAF inhibitors have two opposing mechanisms of action depending on the cellular context.  In BRAF(V600E) tumors, RAF inhibitors effectively block the mitogen-activated protein kinase (MAPK) signalling pathway and decrease tumor growth.  Notably, in KRAS mutant and RAS/RAF wild-type tumors, RAF inhibitors activate the RAF-MEK-ERK pathway in a RAS-dependent manner, thus enhancing tumor growth in some xenograft models.  Inhibitor binding activates wild-type RAF isoforms by inducing dimerization, membrane localization and interaction with RAS-GTP.  These events occur independently of kinase inhibition and are, instead, linked to direct conformational effects of inhibitors on the RAF kinase domain.  On the basis of these findings, we demonstrate that ATP-competitive kinase inhibitors can have opposing functions as inhibitors or activators of signalling pathways, depending on the cellular context.  Furthermore, this work provides new insights into the therapeutic use of ATP-competitive RAF inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGounpcMETzVoLVg90H21EOLACvtfcHk0ljNnIl_bcNFLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVygtb8%253D&md5=eb48bdf352ee9c9e182e63e38fd820a5</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnature08833&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08833%26sid%3Dliteratum%253Aachs%26aulast%3DHatzivassiliou%26aufirst%3DG.%26aulast%3DSong%26aufirst%3DK.%26aulast%3DYen%26aufirst%3DI.%26aulast%3DBrandhuber%26aufirst%3DB.%2BJ.%26aulast%3DAnderson%26aufirst%3DD.%2BJ.%26aulast%3DAlvarado%26aufirst%3DR.%26aulast%3DLudlam%26aufirst%3DM.%2BJ.%26aulast%3DStokoe%26aufirst%3DD.%26aulast%3DGloor%26aufirst%3DS.%2BL.%26aulast%3DVigers%26aufirst%3DG.%26aulast%3DMorales%26aufirst%3DT.%26aulast%3DAliagas%26aufirst%3DI.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DHoeflich%26aufirst%3DK.%2BP.%26aulast%3DJaiswal%26aufirst%3DB.%2BS.%26aulast%3DSeshagiri%26aufirst%3DS.%26aulast%3DKoeppen%26aufirst%3DH.%26aulast%3DBelvin%26aufirst%3DM.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DMalek%26aufirst%3DS.%26atitle%3DRAF%2520inhibitors%2520prime%2520wild-type%2520RAF%2520to%2520activate%2520the%2520MAPK%2520pathway%2520and%2520enhance%2520growth%26jtitle%3DNature%26date%3D2010%26volume%3D464%26issue%3D7287%26spage%3D431%26epage%3D435%26doi%3D10.1038%2Fnature08833" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heidorn, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milagre, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittaker, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nourry, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">NiculescuDuvas, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhomen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussain, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reis-Filho, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springer, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pritchard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marais, R.</span></span> <span> </span><span class="NLM_article-title">Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>140</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">209</span>– <span class="NLM_lpage">221</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2009.12.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=10.1016%2Fj.cell.2009.12.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=20141835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvVWitL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2010&pages=209-221&issue=2&author=S.+J.+Heidornauthor=C.+Milagreauthor=S.+Whittakerauthor=A.+Nourryauthor=I.+NiculescuDuvasauthor=N.+Dhomenauthor=J.+Hussainauthor=J.+S.+Reis-Filhoauthor=C.+J.+Springerauthor=C.+Pritchardauthor=R.+Marais&title=Kinase-dead+BRAF+and+oncogenic+RAS+cooperate+to+drive+tumor+progression+through+CRAF&doi=10.1016%2Fj.cell.2009.12.040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF</span></div><div class="casAuthors">Heidorn, Sonja J.; Milagre, Carla; Whittaker, Steven; Nourry, Arnaud; Niculescu-Duvas, Ion; Dhomen, Nathalie; Hussain, Jahan; Reis-Filho, Jorge S.; Springer, Caroline J.; Pritchard, Catrin; Marais, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">209-221</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">We describe a mechanism of tumorigenesis mediated by kinase-dead BRAF in the presence of oncogenic RAS.  We show that drugs that selectively inhibit BRAF drive RAS-dependent BRAF binding to CRAF, CRAF activation, and MEK-ERK signaling.  This does not occur when oncogenic BRAF is inhibited, demonstrating that BRAF inhibition per se does not drive pathway activation; it only occurs when BRAF is inhibited in the presence of oncogenic RAS.  Kinase-dead BRAF mimics the effects of the BRAF-selective drugs and kinase-dead Braf and oncogenic Ras cooperate to induce melanoma in mice.  Our data reveal another paradigm of BRAF-mediated signaling that promotes tumor progression.  They highlight the importance of understanding pathway signaling in clin. practice and of genotyping tumors prior to administering BRAF-selective drugs, to identify patients who are likely to respond and also to identify patients who may experience adverse effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMSb6ckHpR07Vg90H21EOLACvtfcHk0ljNnIl_bcNFLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvVWitL0%253D&md5=80af840cb978f5956b3d998b185115f4</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2009.12.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2009.12.040%26sid%3Dliteratum%253Aachs%26aulast%3DHeidorn%26aufirst%3DS.%2BJ.%26aulast%3DMilagre%26aufirst%3DC.%26aulast%3DWhittaker%26aufirst%3DS.%26aulast%3DNourry%26aufirst%3DA.%26aulast%3DNiculescuDuvas%26aufirst%3DI.%26aulast%3DDhomen%26aufirst%3DN.%26aulast%3DHussain%26aufirst%3DJ.%26aulast%3DReis-Filho%26aufirst%3DJ.%2BS.%26aulast%3DSpringer%26aufirst%3DC.%2BJ.%26aulast%3DPritchard%26aufirst%3DC.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DKinase-dead%2520BRAF%2520and%2520oncogenic%2520RAS%2520cooperate%2520to%2520drive%2520tumor%2520progression%2520through%2520CRAF%26jtitle%3DCell%26date%3D2010%26volume%3D140%26issue%3D2%26spage%3D209%26epage%3D221%26doi%3D10.1016%2Fj.cell.2009.12.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poulikakos, P. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen</span></span> <span> </span><span class="NLM_article-title">NRAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>464</i></span>,  <span class="NLM_fpage">427</span>– <span class="NLM_lpage">430</span>, <span class="refDoi"> DOI: 10.1038/nature08902</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=10.1038%2Fnature08902" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=20179705" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjsFWjsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=464&publication_year=2010&pages=427-430&author=P.+I.+Poulikakosauthor=C.+Zhangauthor=G.+Bollagauthor=K.+M.+Shokatauthor=+Rosen&title=NRAF+inhibitors+transactivate+RAF+dimers+and+ERK+signaling+in+cells+with+wild-type+BRAF&doi=10.1038%2Fnature08902"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF</span></div><div class="casAuthors">Poulikakos, Poulikos I.; Zhang, Chao; Bollag, Gideon; Shokat, Kevan M.; Rosen, Neal</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">464</span>
        (<span class="NLM_cas:issue">7287</span>),
    <span class="NLM_cas:pages">427-430</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Tumors with mutant BRAF are dependent on the RAF-MEK-ERK signaling pathway for their growth.  We found that ATP-competitive RAF inhibitors inhibit ERK signaling in cells with mutant BRAF, but unexpectedly enhance signaling in cells with wild-type BRAF.  Here we demonstrate the mechanistic basis for these findings.  We used chem. genetic methods to show that drug-mediated transactivation of RAF dimers is responsible for paradoxical activation of the enzyme by inhibitors.  Induction of ERK signaling requires direct binding of the drug to the ATP-binding site of one kinase of the dimer and is dependent on RAS activity.  Drug binding to one member of RAF homodimers (CRAF-CRAF) or heterodimers (CRAF-BRAF) inhibits one protomer, but results in transactivation of the drug-free protomer.  In BRAF(V600E) tumors, RAS is not activated, thus transactivation is minimal and ERK signaling is inhibited in cells exposed to RAF inhibitors.  These results indicate that RAF inhibitors will be effective in tumors in which BRAF is mutated.  Furthermore, because RAF inhibitors do not inhibit ERK signaling in other cells, the model predicts that they would have a higher therapeutic index and greater antitumor activity than mitogen-activated protein kinase (MEK) inhibitors, but could also cause toxicity due to MEK/ERK activation.  These predictions have been borne out in a recent clin. trial of the RAF inhibitor PLX4032 (refs 4, 5).  The model indicates that promotion of RAF dimerization by elevation of wild-type RAF expression or RAS activity could lead to drug resistance in mutant BRAF tumors.  In agreement with this prediction, RAF inhibitors do not inhibit ERK signaling in cells that coexpress BRAF(V600E) and mutant RAS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMlm9feupyNrVg90H21EOLACvtfcHk0ljoEtdf99aheg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjsFWjsrs%253D&md5=8323a558886ccbb8f7d85b22b9bfbc15</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnature08902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08902%26sid%3Dliteratum%253Aachs%26aulast%3DPoulikakos%26aufirst%3DP.%2BI.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DRosen%26atitle%3DNRAF%2520inhibitors%2520transactivate%2520RAF%2520dimers%2520and%2520ERK%2520signaling%2520in%2520cells%2520with%2520wild-type%2520BRAF%26jtitle%3DNature%26date%3D2010%26volume%3D464%26spage%3D427%26epage%3D430%26doi%3D10.1038%2Fnature08902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hauschild, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grob, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demidov, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jouary, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutzmer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millward, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutkowski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blank, C. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, W. H.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaempgen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martín-Algarra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karaszewska, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mauch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiarion-Sileni, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haney, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirakhur, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guckert, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodman, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, P. B.</span></span> <span> </span><span class="NLM_article-title">Dabrafenib in BRAF-mutated metastatic melanoma:a multicentre, open-label, phase 3 randomised controlled trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>380</i></span>,  <span class="NLM_fpage">358</span>– <span class="NLM_lpage">365</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(12)60868-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=10.1016%2FS0140-6736%2812%2960868-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=22735384" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=1%3ACAS%3A528%3ADC%252BC38Xpt1SgtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=380&publication_year=2012&pages=358-365&author=A.+Hauschildauthor=J.+Grobauthor=L.+V.+Demidovauthor=T.+Jouaryauthor=R.+Gutzmerauthor=M.+Millwardauthor=P.+Rutkowskiauthor=C.+U.+Blankauthor=W.+H.+Millerauthor=E.+Kaempgenauthor=S.+Mart%C3%ADn-Algarraauthor=B.+Karaszewskaauthor=C.+Mauchauthor=V.+Chiarion-Sileniauthor=A.+Martinauthor=S.+Swannauthor=P.+Haneyauthor=B.+Mirakhurauthor=M.+E.+Guckertauthor=V.+Goodmanauthor=P.+B.+Chapman&title=Dabrafenib+in+BRAF-mutated+metastatic+melanoma%3Aa+multicentre%2C+open-label%2C+phase+3+randomised+controlled+trial&doi=10.1016%2FS0140-6736%2812%2960868-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial</span></div><div class="casAuthors">Hauschild, Axel; Grob, Jean-Jacques; Demidov, Lev V.; Jouary, Thomas; Gutzmer, Ralf; Millward, Michael; Rutkowski, Piotr; Blank, Christian U.; Miller, Wilson H.; Kaempgen, Eckhart; Martin-Algarra, Salvador; Karaszewska, Boguslawa; Mauch, Cornelia; Chiarion-Sileni, Vanna; Martin, Anne-Marie; Swann, Suzanne; Haney, Patricia; Mirakhur, Beloo; Guckert, Mary E.; Goodman, Vicki; Chapman, Paul B.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">380</span>
        (<span class="NLM_cas:issue">9839</span>),
    <span class="NLM_cas:pages">358-365</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Dabrafenib, an inhibitor of mutated BRAF, has clin. activity with a manageable safety profile in studies of phase 1 and 2 in patients with BRAFV600-mutated metastatic melanoma.  We studied the efficacy of dabrafenib in patients with BRAFV600E-mutated metastatic melanoma.We enrolled patients in this open-label phase 3 trial between Dec 23, 2010, and Sept 1, 2011.  This report is based on a data cutoff date of Dec 19, 2011.  Patients aged 18 years or older with previously untreated, stage IV or unresectable stage III BRAFV600E mutation-pos. melanoma were randomly assigned (3:1) to receive dabrafenib (150 mg twice daily, orally) or dacarbazine (1000 mg/m2 i.v. every 3 wk).  Patients were stratified according to American Joint Committee on Cancer stage (unresectable III+IVM1a+IVM1b vs IVM1c).  The primary endpoint was investigator-assessed progression-free survival and was analyzed by intention to treat; safety was assessed per protocol.  This study is registered with ClinicalTrials.gov, no. NCT01227889.Of the 733 patients screened, 250 were randomly assigned to receive either dabrafenib (187 patients) or dacarbazine (63 patients).  Median progression-free survival was 5·1 mo for dabrafenib and 2·7 mo for dacarbazine, with a hazard ratio (HR) of 0·30 (95% CI 0·18-0·51; p<0·0001).  At data cutoff, 107 (57%) patients in the dabrafenib group and 14 (22%) in the dacarbazine group remained on randomized treatment.  Treatment-related adverse events (grade 2 or higher) occurred in 100 (53%) of the 187 patients who received dabrafenib and in 26 (44%) of the 59 patients who received dacarbazine.  The most common adverse events with dabrafenib were skin-related toxic effects, fever, fatigue, arthralgia, and headache.  The most common adverse events with dacarbazine were nausea, vomiting, neutropenia, fatigue, and asthenia.  Grade 3-4 adverse events were uncommon in both groups.Dabrafenib significantly improved progression-free survival compared with dacarbazine.GlaxoSmithKline.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEDYPJULE5c7Vg90H21EOLACvtfcHk0ljoEtdf99aheg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xpt1SgtLg%253D&md5=5e8699780f47bd37e075d39636e0d809</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2812%2960868-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252812%252960868-X%26sid%3Dliteratum%253Aachs%26aulast%3DHauschild%26aufirst%3DA.%26aulast%3DGrob%26aufirst%3DJ.%26aulast%3DDemidov%26aufirst%3DL.%2BV.%26aulast%3DJouary%26aufirst%3DT.%26aulast%3DGutzmer%26aufirst%3DR.%26aulast%3DMillward%26aufirst%3DM.%26aulast%3DRutkowski%26aufirst%3DP.%26aulast%3DBlank%26aufirst%3DC.%2BU.%26aulast%3DMiller%26aufirst%3DW.%2BH.%26aulast%3DKaempgen%26aufirst%3DE.%26aulast%3DMart%25C3%25ADn-Algarra%26aufirst%3DS.%26aulast%3DKaraszewska%26aufirst%3DB.%26aulast%3DMauch%26aufirst%3DC.%26aulast%3DChiarion-Sileni%26aufirst%3DV.%26aulast%3DMartin%26aufirst%3DA.%26aulast%3DSwann%26aufirst%3DS.%26aulast%3DHaney%26aufirst%3DP.%26aulast%3DMirakhur%26aufirst%3DB.%26aulast%3DGuckert%26aufirst%3DM.%2BE.%26aulast%3DGoodman%26aufirst%3DV.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26atitle%3DDabrafenib%2520in%2520BRAF-mutated%2520metastatic%2520melanoma%253Aa%2520multicentre%252C%2520open-label%252C%2520phase%25203%2520randomised%2520controlled%2520trial%26jtitle%3DLancet%26date%3D2012%26volume%3D380%26spage%3D358%26epage%3D365%26doi%3D10.1016%2FS0140-6736%2812%2960868-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karoulia, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amaia Lujambio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavathiotis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulikakos, P. I.</span></span> <span> </span><span class="NLM_article-title">An Integrated model of RAF Inhibitor action predicts inhibitor activity against oncogenic BRAF signaling</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">485</span>– <span class="NLM_lpage">498</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2016.06.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=10.1016%2Fj.ccell.2016.06.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=27523909" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtleis77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=485-498&author=Z.+Karouliaauthor=Y.+Yang+Wuauthor=T.+A.+Ahmedauthor=A.+Amaia+Lujambioauthor=E.+Gavathiotisauthor=P.+I.+Poulikakos&title=An+Integrated+model+of+RAF+Inhibitor+action+predicts+inhibitor+activity+against+oncogenic+BRAF+signaling&doi=10.1016%2Fj.ccell.2016.06.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling</span></div><div class="casAuthors">Karoulia, Zoi; Wu, Yang; Ahmed, Tamer A.; Xin, Qisheng; Bollard, Julien; Krepler, Clemens; Wu, Xuewei; Zhang, Chao; Bollag, Gideon; Herlyn, Meenhard; Fagin, James A.; Lujambio, Amaia; Gavathiotis, Evripidis; Poulikakos, Poulikos I.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">485-498</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The complex biochem. effects of RAF inhibitors account for both the effectiveness and mechanisms of resistance to these drugs, but a unified mechanistic model has been lacking.  Here we show that RAF inhibitors exert their effects via two distinct allosteric mechanisms.  Drug resistance due to dimerization is detd. by the position of the αC helix stabilized by inhibitor, whereas inhibitor-induced RAF priming and dimerization are the result of inhibitor-induced formation of the RAF/RAS-GTP complex.  The biochem. effect of RAF inhibitor in cells is the combined outcome of the two mechanisms.  Therapeutic strategies including αC-helix-IN inhibitors are more effective in multiple mutant BRAF-driven tumor models, including colorectal and thyroid BRAFV600E cancers, in which first-generation RAF inhibitors have been ineffective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9VLWvQ7ojJrVg90H21EOLACvtfcHk0ljoEtdf99aheg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtleis77I&md5=197711577048b889ea1dac8c87049a01</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2016.06.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2016.06.024%26sid%3Dliteratum%253Aachs%26aulast%3DKaroulia%26aufirst%3DZ.%26aulast%3DYang%2BWu%26aufirst%3DY.%26aulast%3DAhmed%26aufirst%3DT.%2BA.%26aulast%3DAmaia%2BLujambio%26aufirst%3DA.%26aulast%3DGavathiotis%26aufirst%3DE.%26aulast%3DPoulikakos%26aufirst%3DP.%2BI.%26atitle%3DAn%2520Integrated%2520model%2520of%2520RAF%2520Inhibitor%2520action%2520predicts%2520inhibitor%2520activity%2520against%2520oncogenic%2520BRAF%2520signaling%26jtitle%3DCancer%2520Cell%26date%3D2016%26volume%3D30%26spage%3D485%26epage%3D498%26doi%3D10.1016%2Fj.ccell.2016.06.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peng, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogeti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutkoski, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wise, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Horn, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yadav, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchanan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mochalkin, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kays, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donoho, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walgren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conti, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plowman, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Starling, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flynn, D. L.</span></span> <span> </span><span class="NLM_article-title">Inhibition of RAF isoforms and active dimers by LY3009120 leads to anti-tumor activities in RAS or BRAF mutant cancers</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">384</span>– <span class="NLM_lpage">398</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2015.08.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=10.1016%2Fj.ccell.2015.08.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=26343583" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVKgsr7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2015&pages=384-398&issue=3&author=S.+B.+Pengauthor=J.+R.+Henryauthor=M.+D.+Kaufmanauthor=W.+P.+Luauthor=B.+D.+Smithauthor=S.+Vogetiauthor=T.+J.+Rutkoskiauthor=S.+Wiseauthor=L.+Chunauthor=+Zhangauthor=R.+D.+Van+Hornauthor=T.+Yinauthor=X.+Zhangauthor=V.+Yadavauthor=S.+H.+Chenauthor=X.+Gongauthor=X.+Maauthor=Y.+Websterauthor=S.+Buchananauthor=I.+Mochalkinauthor=L.+Huberauthor=L.+Kaysauthor=G.+P.+Donohoauthor=J.+Walgrenauthor=D.+McCannauthor=P.+Patelauthor=I.+Contiauthor=G.+D.+Plowmanauthor=J.+J.+Starlingauthor=D.+L.+Flynn&title=Inhibition+of+RAF+isoforms+and+active+dimers+by+LY3009120+leads+to+anti-tumor+activities+in+RAS+or+BRAF+mutant+cancers&doi=10.1016%2Fj.ccell.2015.08.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers</span></div><div class="casAuthors">Peng, Sheng-Bin; Henry, James R.; Kaufman, Michael D.; Lu, Wei-Ping; Smith, Bryan D.; Vogeti, Subha; Rutloski, Thomas J.; Wise, Scott; Chun, Lawrence; Zhang, Youyan; Van Horn, Robert D.; Yin, Tinggui; Zhang, Xiaoyi; Yadav, Vipin; Chen, Shih-Hsun; Gong, Xueqian; Ma, Xiwen; Webster, Yue; Buchanan, Sean; Mochalkin, Igor; Huber, Lysiane; Kays, Lisa; Donoho, Gregory P.; Walgren, Jennie; McCann, Denis; Patel, Phenil; Conti, Ilaria; Plowman, Gregory D.; Starling, James J.; Flynn, Daniel L.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">384-398</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">LY3009120 is a pan-RAF and RAF dimer inhibitor that inhibits all RAF isoforms and occupies both protomers in RAF dimers.  Biochem. and cellular analyses revealed that LY3009120 inhibits ARAF, BRAF, and CRAF isoforms with similar affinity, while vemurafenib or dabrafenib have little or modest CRAF activity compared to their BRAF activities.  LY3009120 induces BRAF-CRAF dimerization but inhibits the phosphorylation of downstream MEK and ERK, suggesting that it effectively inhibits the kinase activity of BRAF-CRAF heterodimers.  Further analyses demonstrated that LY3009120 also inhibits various forms of RAF dimers including BRAF or CRAF homodimers.  Due to these unique properties, LY3009120 demonstrates minimal paradoxical activation, inhibits MEK1/2 phosphorylation, and exhibits anti-tumor activities across multiple models carrying KRAS, NRAS, or BRAF mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJMiHK-Gub5bVg90H21EOLACvtfcHk0livcidUvTJdOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVKgsr7O&md5=c167caa6e5a9b47a6ec1ee2ab6d9e0d1</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2015.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2015.08.002%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DS.%2BB.%26aulast%3DHenry%26aufirst%3DJ.%2BR.%26aulast%3DKaufman%26aufirst%3DM.%2BD.%26aulast%3DLu%26aufirst%3DW.%2BP.%26aulast%3DSmith%26aufirst%3DB.%2BD.%26aulast%3DVogeti%26aufirst%3DS.%26aulast%3DRutkoski%26aufirst%3DT.%2BJ.%26aulast%3DWise%26aufirst%3DS.%26aulast%3DChun%26aufirst%3DL.%26aulast%3DZhang%26aulast%3DVan%2BHorn%26aufirst%3DR.%2BD.%26aulast%3DYin%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DYadav%26aufirst%3DV.%26aulast%3DChen%26aufirst%3DS.%2BH.%26aulast%3DGong%26aufirst%3DX.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DWebster%26aufirst%3DY.%26aulast%3DBuchanan%26aufirst%3DS.%26aulast%3DMochalkin%26aufirst%3DI.%26aulast%3DHuber%26aufirst%3DL.%26aulast%3DKays%26aufirst%3DL.%26aulast%3DDonoho%26aufirst%3DG.%2BP.%26aulast%3DWalgren%26aufirst%3DJ.%26aulast%3DMcCann%26aufirst%3DD.%26aulast%3DPatel%26aufirst%3DP.%26aulast%3DConti%26aufirst%3DI.%26aulast%3DPlowman%26aufirst%3DG.%2BD.%26aulast%3DStarling%26aufirst%3DJ.%2BJ.%26aulast%3DFlynn%26aufirst%3DD.%2BL.%26atitle%3DInhibition%2520of%2520RAF%2520isoforms%2520and%2520active%2520dimers%2520by%2520LY3009120%2520leads%2520to%2520anti-tumor%2520activities%2520in%2520RAS%2520or%2520BRAF%2520mutant%2520cancers%26jtitle%3DCancer%2520Cell%26date%3D2015%26volume%3D28%26issue%3D3%26spage%3D384%26epage%3D398%26doi%3D10.1016%2Fj.ccell.2015.08.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nishiguchi, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rico, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aversa, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taft, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barsanti, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appleton, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tandeske, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dix, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tellew, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathews Griner, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, V. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Abbema, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merritt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gampa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haling, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaziri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hekmat-Nejad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansen, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polyakov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sethuraman, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amiri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lees, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dillon, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramurthy, S.</span></span> <span> </span><span class="NLM_article-title">Design and discovery of <i>N</i>-(2- methyl-5′-morpholino-6′-((tetrahydro-2<i>H</i>-pyran-4-yl)oxy)-[3,3′-bipyridin]-5yl)-3-(trifluoromethyl) benzamide (RAF709): A potent, selective and efficacious RAF inhibitor targeting RAS mutant cancers</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">4869</span>– <span class="NLM_lpage">4881</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01862</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01862" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=1%3ACAS%3A528%3ADC%252BC2sXos1Sgt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=4869-4881&issue=12&author=G.+A.+Nishiguchiauthor=A.+Ricoauthor=H.+Tannerauthor=R.+J.+Aversaauthor=B.+R.+Taftauthor=S.+Subramanianauthor=L.+Settiauthor=M.+T.+Burgerauthor=L.+Wanauthor=V.+Tamezauthor=A.+Smithauthor=Y.+Louauthor=P.+A.+Barsantiauthor=B.+A.+Appletonauthor=M.+Mamoauthor=L.+Tandeskeauthor=I.+Dixauthor=J.+E.+Tellewauthor=S.+Huangauthor=L.+A.+Mathews+Grinerauthor=V.+G.+Cookeauthor=A.+Van+Abbemaauthor=H.+Merrittauthor=S.+Maauthor=K.+Gampaauthor=F.+Fengauthor=J.+Yuanauthor=Y.+Wangauthor=J.+R.+Halingauthor=S.+Vaziriauthor=M.+Hekmat-Nejadauthor=J.+M.+Jansenauthor=V.+Polyakovauthor=R.+Zangauthor=V.+Sethuramanauthor=P.+Amiriauthor=M.+Singhauthor=E.+Leesauthor=W.+Shaoauthor=D.+D.+Stuartauthor=M.+P.+Dillonauthor=S.+Ramurthy&title=Design+and+discovery+of+N-%282-+methyl-5%E2%80%B2-morpholino-6%E2%80%B2-%28%28tetrahydro-2H-pyran-4-yl%29oxy%29-%5B3%2C3%E2%80%B2-bipyridin%5D-5yl%29-3-%28trifluoromethyl%29+benzamide+%28RAF709%29%3A+A+potent%2C+selective+and+efficacious+RAF+inhibitor+targeting+RAS+mutant+cancers&doi=10.1021%2Facs.jmedchem.6b01862"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Discovery of N-(2-Methyl-5'-morpholino-6'-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3'-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant Cancers</span></div><div class="casAuthors">Nishiguchi, Gisele A.; Rico, Alice; Tanner, Huw; Aversa, Robert J.; Taft, Benjamin R.; Subramanian, Sharadha; Setti, Lina; Burger, Matthew T.; Wan, Lifeng; Tamez, Victoriano; Smith, Aaron; Lou, Yan; Barsanti, Paul A.; Appleton, Brent A.; Mamo, Mulugeta; Tandeske, Laura; Dix, Ina; Tellew, John E.; Huang, Shenlin; Mathews Griner, Lesley A.; Cooke, Vesselina G.; Van Abbema, Anne; Merritt, Hanne; Ma, Sylvia; Gampa, Kalyani; Feng, Fei; Yuan, Jing; Wang, Yingyun; Haling, Jacob R.; Vaziri, Sepideh; Hekmat-Nejad, Mohammad; Jansen, Johanna M.; Polyakov, Valery; Zang, Richard; Sethuraman, Vijay; Amiri, Payman; Singh, Mallika; Lees, Emma; Shao, Wenlin; Stuart, Darrin D.; Dillon, Michael P.; Ramurthy, Savithri</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4869-4881</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">RAS oncogenes have been implicated in >30% of human cancers, all representing high unmet medical need.  The exquisite dependency on CRAF kinase in KRAS mutant tumors has been established in genetically engineered mouse models and human tumor cells.  To date, many small mol. approaches are under investigation to target CRAF, yet kinase-selective and cellular potent inhibitors remain challenging to identify.  Herein, we describe 14 (RAF709) [Aversa, Biaryl amide compds. as kinase inhibitors and their prepn. WO 2014151616, 2014], a selective B/C RAF inhibitor, which was developed through a hypothesis-driven approach focusing on drug-like properties.  A key challenge encountered in the medicinal chem. campaign was maintaining a balance between good soly. and potent cellular activity (suppression of pMEK and proliferation) in KRAS mutant tumor cell lines.  We investigated the small mol. crystal structure of lead mol. 7 and hypothesized that disruption of the crystal packing would improve soly., which led to a change from N-methylpyridone to a tetrahydropyranyl oxy-pyridine deriv. 14 proved to be sol., kinase selective, and efficacious in a KRAS mutant xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmcZ2Rl42uP7Vg90H21EOLACvtfcHk0livcidUvTJdOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXos1Sgt7s%253D&md5=ed35a93d83b721a8e639a992bee43f04</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01862%26sid%3Dliteratum%253Aachs%26aulast%3DNishiguchi%26aufirst%3DG.%2BA.%26aulast%3DRico%26aufirst%3DA.%26aulast%3DTanner%26aufirst%3DH.%26aulast%3DAversa%26aufirst%3DR.%2BJ.%26aulast%3DTaft%26aufirst%3DB.%2BR.%26aulast%3DSubramanian%26aufirst%3DS.%26aulast%3DSetti%26aufirst%3DL.%26aulast%3DBurger%26aufirst%3DM.%2BT.%26aulast%3DWan%26aufirst%3DL.%26aulast%3DTamez%26aufirst%3DV.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DLou%26aufirst%3DY.%26aulast%3DBarsanti%26aufirst%3DP.%2BA.%26aulast%3DAppleton%26aufirst%3DB.%2BA.%26aulast%3DMamo%26aufirst%3DM.%26aulast%3DTandeske%26aufirst%3DL.%26aulast%3DDix%26aufirst%3DI.%26aulast%3DTellew%26aufirst%3DJ.%2BE.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DMathews%2BGriner%26aufirst%3DL.%2BA.%26aulast%3DCooke%26aufirst%3DV.%2BG.%26aulast%3DVan%2BAbbema%26aufirst%3DA.%26aulast%3DMerritt%26aufirst%3DH.%26aulast%3DMa%26aufirst%3DS.%26aulast%3DGampa%26aufirst%3DK.%26aulast%3DFeng%26aufirst%3DF.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DHaling%26aufirst%3DJ.%2BR.%26aulast%3DVaziri%26aufirst%3DS.%26aulast%3DHekmat-Nejad%26aufirst%3DM.%26aulast%3DJansen%26aufirst%3DJ.%2BM.%26aulast%3DPolyakov%26aufirst%3DV.%26aulast%3DZang%26aufirst%3DR.%26aulast%3DSethuraman%26aufirst%3DV.%26aulast%3DAmiri%26aufirst%3DP.%26aulast%3DSingh%26aufirst%3DM.%26aulast%3DLees%26aufirst%3DE.%26aulast%3DShao%26aufirst%3DW.%26aulast%3DStuart%26aufirst%3DD.%2BD.%26aulast%3DDillon%26aufirst%3DM.%2BP.%26aulast%3DRamurthy%26aufirst%3DS.%26atitle%3DDesign%2520and%2520discovery%2520of%2520N-%25282-%2520methyl-5%25E2%2580%25B2-morpholino-6%25E2%2580%25B2-%2528%2528tetrahydro-2H-pyran-4-yl%2529oxy%2529-%255B3%252C3%25E2%2580%25B2-bipyridin%255D-5yl%2529-3-%2528trifluoromethyl%2529%2520benzamide%2520%2528RAF709%2529%253A%2520A%2520potent%252C%2520selective%2520and%2520efficacious%2520RAF%2520inhibitor%2520targeting%2520RAS%2520mutant%2520cancers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D12%26spage%3D4869%26epage%3D4881%26doi%3D10.1021%2Facs.jmedchem.6b01862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="note"><p class="first last">Molecular structure and synthesis of compound <b>10</b>, X-ray co-crystal structure data table of <b>10</b> and <b>15</b>, and kinase profile of <b>15</b> are given in the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aversa, R. J.</span>; <span class="NLM_string-name">Barsanti, P. A.</span>; <span class="NLM_string-name">Burger, M.</span>; <span class="NLM_string-name">Dillon, M. P.</span>; <span class="NLM_string-name">Dipsea, A.</span>; <span class="NLM_string-name">Hu, C.</span>; <span class="NLM_string-name">Lou, Y.</span>; <span class="NLM_string-name">Nishiguchi, G.</span>; <span class="NLM_string-name">Pan, Y.</span>; <span class="NLM_string-name">Polyakov, V.</span>; <span class="NLM_string-name">Ramurthy, S.</span>; <span class="NLM_string-name">Rico, A.</span>; <span class="NLM_string-name">Setti, L.</span>; <span class="NLM_string-name">Smith, A.</span>; <span class="NLM_string-name">Subramanian, S.</span>; <span class="NLM_string-name">Taft, B.</span>; <span class="NLM_string-name">Tanner, H.</span>; <span class="NLM_string-name">Wan, L.</span>; <span class="NLM_string-name">Yusuff, N.</span></span> <span> </span><span class="NLM_article-title">Biaryl Amide Compounds as Kinase Inhibitors and Their Preparation</span>. <span class="NLM_patent">WO 2014151616</span>, Sep 25, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=R.+J.+Aversa&author=P.+A.+Barsanti&author=M.+Burger&author=M.+P.+Dillon&author=A.+Dipsea&author=C.+Hu&author=Y.+Lou&author=G.+Nishiguchi&author=Y.+Pan&author=V.+Polyakov&author=S.+Ramurthy&author=A.+Rico&author=L.+Setti&author=A.+Smith&author=S.+Subramanian&author=B.+Taft&author=H.+Tanner&author=L.+Wan&author=N.+Yusuff&title=Biaryl+Amide+Compounds+as+Kinase+Inhibitors+and+Their+Preparation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAversa%26aufirst%3DR.%2BJ.%26atitle%3DBiaryl%2520Amide%2520Compounds%2520as%2520Kinase%2520Inhibitors%2520and%2520Their%2520Preparation%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerlin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trunzer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faller, B.</span></span> <span> </span><span class="NLM_article-title">CYP3A time-dependent inhibition risk assessment validated with 400 reference drugs</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>39</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1039</span>– <span class="NLM_lpage">1046</span>, <span class="refDoi"> DOI: 10.1124/dmd.110.037911</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=10.1124%2Fdmd.110.037911" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=21383203" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmvFGns7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=1039-1046&issue=6&author=A.+Zimmerlinauthor=M.+Trunzerauthor=B.+Faller&title=CYP3A+time-dependent+inhibition+risk+assessment+validated+with+400+reference+drugs&doi=10.1124%2Fdmd.110.037911"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">CYP3A time-dependent inhibition risk assessment validated with 400 reference drugs</span></div><div class="casAuthors">Zimmerlin, Alfred; Trunzer, Markus; Faller, Bernard</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1039-1046</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Although reversible CYP3A inhibition testing is well established for predicting the drug-drug interaction potential of clin. candidates, time-dependent inhibition (TDI) has become the focus of drug designers only recently.  Failure of several late-stage clin. candidates has been attributed to TDI, and this mechanism is also suspected to play a role in liver toxicities often obsd. in preclin. species.  Measurement of enzyme inactivation rates (kinact and KI) is tech. challenging, and a great deal of variability can be found in the literature.  In this article, we have evaluated the TDI potential for 400 registered drugs using a high-throughput assay format based on detn. of the inactivation rate (kobs) at a single concn. of test compd. (10 μM).  The advantages of this new assay format are highlighted by comparison with data generated using the IC50 shift assay, a current std. approach for preliminary assessment of TDI.  With use of an empirically defined pos./neg. kobs bin of 0.02 min-1, only 4% of registered drugs were found to be pos.  This proportion increased to more than 20% when inhouse lead optimization mols. were considered, emphasizing the importance of identifying this property in selection of promising drug candidates.  Finally, it is suggested that the data and technol. described here may be a good basis for building structure-activity relationships and in silico modeling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobYvW4ft03jbVg90H21EOLACvtfcHk0li1GFq_aaZxig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmvFGns7w%253D&md5=d21b39e85ab9410b7addfc820c1a4e18</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1124%2Fdmd.110.037911&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.110.037911%26sid%3Dliteratum%253Aachs%26aulast%3DZimmerlin%26aufirst%3DA.%26aulast%3DTrunzer%26aufirst%3DM.%26aulast%3DFaller%26aufirst%3DB.%26atitle%3DCYP3A%2520time-dependent%2520inhibition%2520risk%2520assessment%2520validated%2520with%2520400%2520reference%2520drugs%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26issue%3D6%26spage%3D1039%26epage%3D1046%26doi%3D10.1124%2Fdmd.110.037911" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vijayan, R. S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duong-Ly, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunbrack, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, R. M.</span></span> <span> </span><span class="NLM_article-title">Conformational analysis of the DFG-out kinase motif and biochemical profiling of structurally validated Type II inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">466</span>– <span class="NLM_lpage">479</span>, <span class="refDoi"> DOI: 10.1021/jm501603h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501603h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVCku7rP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=466-479&author=R.+S.+K.+Vijayanauthor=P.+Heauthor=V.+Modiauthor=K.+C.+Duong-Lyauthor=H.+Maauthor=J.+R.+Petersonauthor=R.+L.+Dunbrackauthor=R.+M.+Levy&title=Conformational+analysis+of+the+DFG-out+kinase+motif+and+biochemical+profiling+of+structurally+validated+Type+II+inhibitors&doi=10.1021%2Fjm501603h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Conformational Analysis of the DFG-Out Kinase Motif and Biochemical Profiling of Structurally Validated Type II Inhibitors</span></div><div class="casAuthors">Vijayan, R. S. K.; He, Peng; Modi, Vivek; Duong-Ly, Krisna C.; Ma, Haiching; Peterson, Jeffrey R.; Dunbrack, Roland L.; Levy, Ronald M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">466-479</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structural coverage of the human kinome has been steadily increasing over time.  The structures provide valuable insights into the mol. basis of kinase function and also provide a foundation for understanding the mechanisms of kinase inhibitors.  There are a large no. of kinase structures in the PDB for which the Asp and Phe of the DFG motif on the activation loop swap positions, resulting in the formation of a new allosteric pocket.  The authors refer to these structures as "classical DFG-out" conformations in order to distinguish them from conformations that have also been referred to as DFG-out in the literature but that do not have a fully formed allosteric pocket.  The authors have completed a structural anal. of almost 200 small mol. inhibitors bound to classical DFG-out conformations; the authors find that they are recognized by both type I and type II inhibitors.  In contrast, the authors find that nonclassical DFG-out conformations strongly select against type II inhibitors because these structures have not formed a large enough allosteric pocket to accommodate this type of binding mode.  In the course of this study the authors discovered that the no. of structurally validated type II inhibitors that can be found in the PDB and that are also represented in publicly available biochem. profiling studies of kinase inhibitors is very small.  The authors have obtained new profiling results for several addnl. structurally validated type II inhibitors identified through the conformational anal.  Although the available profiling data for type II inhibitors is still much smaller than for type I inhibitors, a comparison of the two data sets supports the conclusion that type II inhibitors are more selective than type I.  The authors comment on the possible contribution of the DFG-in to DFG-out conformational reorganization to the selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqb9E5JKOmDZ7Vg90H21EOLACvtfcHk0li1GFq_aaZxig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVCku7rP&md5=6d729997f242d582a4adff9463fd585c</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fjm501603h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501603h%26sid%3Dliteratum%253Aachs%26aulast%3DVijayan%26aufirst%3DR.%2BS.%2BK.%26aulast%3DHe%26aufirst%3DP.%26aulast%3DModi%26aufirst%3DV.%26aulast%3DDuong-Ly%26aufirst%3DK.%2BC.%26aulast%3DMa%26aufirst%3DH.%26aulast%3DPeterson%26aufirst%3DJ.%2BR.%26aulast%3DDunbrack%26aufirst%3DR.%2BL.%26aulast%3DLevy%26aufirst%3DR.%2BM.%26atitle%3DConformational%2520analysis%2520of%2520the%2520DFG-out%2520kinase%2520motif%2520and%2520biochemical%2520profiling%2520of%2520structurally%2520validated%2520Type%2520II%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D466%26epage%3D479%26doi%3D10.1021%2Fjm501603h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shao, W.</span>; <span class="NLM_string-name">Mishina, Y. M.</span>; <span class="NLM_string-name">Feng, Y.</span>; <span class="NLM_string-name">Caponigro, G.</span>; <span class="NLM_string-name">Cooke, V. G.</span>; <span class="NLM_string-name">Rivera, S.</span>; <span class="NLM_string-name">Wang, Y.</span>; <span class="NLM_string-name">Shen, F.</span>; <span class="NLM_string-name">Korn, J. M.</span>; <span class="NLM_string-name">Mathews Griner, L. A.</span>; <span class="NLM_string-name">Nishiguchi, G.</span>; <span class="NLM_string-name">Rico, A.</span>; <span class="NLM_string-name">Tellew, J.</span>; <span class="NLM_string-name">Haling, J. R.</span>; <span class="NLM_string-name">Aversa, R.</span>; <span class="NLM_string-name">Polyakov, V.</span>; <span class="NLM_string-name">Zang, R.</span>; <span class="NLM_string-name">Hekmat-Nejad, M.</span>; <span class="NLM_string-name">Amiri, P.</span>; <span class="NLM_string-name">Singh, M.</span>; <span class="NLM_string-name">Keen, N.</span>; <span class="NLM_string-name">Dillon, M. P.</span>; <span class="NLM_string-name">Lees, E.</span>; <span class="NLM_string-name">Ramurthy, S.</span>; <span class="NLM_string-name">Sellers, W. R.</span>; <span class="NLM_string-name">Stuart, D.</span></span> Unpublished results.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Shao%2C+W.%3B+Mishina%2C+Y.+M.%3B+Feng%2C+Y.%3B+Caponigro%2C+G.%3B+Cooke%2C+V.+G.%3B+Rivera%2C+S.%3B+Wang%2C+Y.%3B+Shen%2C+F.%3B+Korn%2C+J.+M.%3B+Mathews+Griner%2C+L.+A.%3B+Nishiguchi%2C+G.%3B+Rico%2C+A.%3B+Tellew%2C+J.%3B+Haling%2C+J.+R.%3B+Aversa%2C+R.%3B+Polyakov%2C+V.%3B+Zang%2C+R.%3B+Hekmat-Nejad%2C+M.%3B+Amiri%2C+P.%3B+Singh%2C+M.%3B+Keen%2C+N.%3B+Dillon%2C+M.+P.%3B+Lees%2C+E.%3B+Ramurthy%2C+S.%3B+Sellers%2C+W.+R.%3B+Stuart%2C+D.+Unpublished+results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DShao%26aufirst%3DW." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishina, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caponigro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, V. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korn, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathews Griner, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishiguchi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rico, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tellew, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haling, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aversa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polyakov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hekmat-Nejad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amiri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dillon, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lees, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramurthy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, D. D.</span></span> <span> </span><span class="NLM_article-title">Antitumor properties of RAF709, a highly selective and potent inhibitor of RAF kinase dimers, in tumors driven by mutant RAS or BRAF</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1537</span>– <span class="NLM_lpage">1548</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-17-2033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=10.1158%2F0008-5472.CAN-17-2033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=29343524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=1%3ACAS%3A528%3ADC%252BC1cXks1yls74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=1537-1548&issue=6&author=W.+Shaoauthor=Y.+M.+Mishinaauthor=Y.+Fengauthor=G.+Caponigroauthor=V.+G.+Cookeauthor=S.+Riveraauthor=Y.+Wangauthor=F.+Shenauthor=J.+M.+Kornauthor=L.+A.+Mathews+Grinerauthor=G.+Nishiguchiauthor=A.+Ricoauthor=J.+Tellewauthor=J.+R.+Halingauthor=R.+Aversaauthor=V.+Polyakovauthor=R.+Zangauthor=M.+Hekmat-Nejadauthor=P.+Amiriauthor=M.+Singhauthor=N.+Keenauthor=M.+P.+Dillonauthor=E.+Leesauthor=S.+Ramurthyauthor=W.+R.+Sellersauthor=D.+D.+Stuart&title=Antitumor+properties+of+RAF709%2C+a+highly+selective+and+potent+inhibitor+of+RAF+kinase+dimers%2C+in+tumors+driven+by+mutant+RAS+or+BRAF&doi=10.1158%2F0008-5472.CAN-17-2033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF</span></div><div class="casAuthors">Shao, Wenlin; Mishina, Yuji M.; Feng, Yun; Caponigro, Giordano; Cooke, Vesselina G.; Rivera, Stacy; Wang, Yingyun; Shen, Fang; Korn, Joshua M.; Mathews Griner, Lesley A.; Nishiguchi, Gisele; Rico, Alice; Tellew, John; Haling, Jacob R.; Aversa, Robert; Polyakov, Valery; Zang, Richard; Hekmat-Nejad, Mohammad; Amiri, Payman; Singh, Mallika; Keen, Nicholas; Dillon, Michael P.; Lees, Emma; Ramurthy, Savithri; Sellers, William R.; Stuart, Darrin D.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1537-1548</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Resistance to the RAF inhibitor vemurafenib arises commonly in melanomas driven by the activated BRAF oncogene.  Here, we report antitumor properties of RAF709, a novel ATP-competitive kinase inhibitor with high potency and selectivity against RAF kinases.  RAF709 exhibited a mode of RAF inhibition distinct from RAF monomer inhibitors such as vemurafenib, showing equal activity against both RAF monomers and dimers.  As a result, RAF709 inhibited MAPK signaling activity in tumor models harboring either BRAFV600 alterations or mutant N- and KRAS-driven signaling, with minimal paradoxical activation of wild-type RAF.  In cell lines and murine xenograft models, RAF709 demonstrated selective antitumor activity in tumor cells harboring BRAF or RAS mutations compared with cells with wild-type BRAF and RAS genes.  RAF709 demonstrated a direct pharmacokinetic/pharmacodynamic relationship in in vivo tumor models harboring KRAS mutation.  Furthermore, RAF709 elicited regression of primary human tumor-derived xenograft models with BRAF, NRAS, or KRAS mutations with excellent tolerability.  Our results support further development of inhibitors like RAF709, which represents a next-generation RAF inhibitor with unique biochem. and cellular properties that enables antitumor activities in RAS-mutant tumors.  Significance: In an effort to develop RAF inhibitors with the appropriate pharmacol. properties to treat RAS mutant tumors, RAF709, a compd. with potency, selectivity, and in vivo properties, was developed that will allow preclin. therapeutic hypothesis testing, but also provide an excellent probe to further unravel the complexities of RAF kinase signaling.  Cancer Res; 78(6); 1537-48. ©2018 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGOvhVkNT32bVg90H21EOLACvtfcHk0lgdUeKDyBXaKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXks1yls74%253D&md5=607b45deb150d83b01394d43f776c097</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-17-2033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-17-2033%26sid%3Dliteratum%253Aachs%26aulast%3DShao%26aufirst%3DW.%26aulast%3DMishina%26aufirst%3DY.%2BM.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DCaponigro%26aufirst%3DG.%26aulast%3DCooke%26aufirst%3DV.%2BG.%26aulast%3DRivera%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DShen%26aufirst%3DF.%26aulast%3DKorn%26aufirst%3DJ.%2BM.%26aulast%3DMathews%2BGriner%26aufirst%3DL.%2BA.%26aulast%3DNishiguchi%26aufirst%3DG.%26aulast%3DRico%26aufirst%3DA.%26aulast%3DTellew%26aufirst%3DJ.%26aulast%3DHaling%26aufirst%3DJ.%2BR.%26aulast%3DAversa%26aufirst%3DR.%26aulast%3DPolyakov%26aufirst%3DV.%26aulast%3DZang%26aufirst%3DR.%26aulast%3DHekmat-Nejad%26aufirst%3DM.%26aulast%3DAmiri%26aufirst%3DP.%26aulast%3DSingh%26aufirst%3DM.%26aulast%3DKeen%26aufirst%3DN.%26aulast%3DDillon%26aufirst%3DM.%2BP.%26aulast%3DLees%26aufirst%3DE.%26aulast%3DRamurthy%26aufirst%3DS.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DStuart%26aufirst%3DD.%2BD.%26atitle%3DAntitumor%2520properties%2520of%2520RAF709%252C%2520a%2520highly%2520selective%2520and%2520potent%2520inhibitor%2520of%2520RAF%2520kinase%2520dimers%252C%2520in%2520tumors%2520driven%2520by%2520mutant%2520RAS%2520or%2520BRAF%26jtitle%3DCancer%2520Res.%26date%3D2018%26volume%3D78%26issue%3D6%26spage%3D1537%26epage%3D1548%26doi%3D10.1158%2F0008-5472.CAN-17-2033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fabian, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biggs, W. H.,  III</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atteridge, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azimioara, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benedetti, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edeen, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerlach, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grotzfeld, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrgard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Insko, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Insko, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lelias, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milanov, Z. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velasco, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodicka, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockhart, D. J.</span></span> <span> </span><span class="NLM_article-title">A small molecule-kinase interaction map for clinical kinase inhibitors</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">329</span>– <span class="NLM_lpage">336</span>, <span class="refDoi"> DOI: 10.1038/nbt1068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=10.1038%2Fnbt1068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=15711537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=329-336&author=M.+A.+Fabianauthor=W.+H.+Biggsauthor=D.+K.+Treiberauthor=C.+E.+Atteridgeauthor=M.+D.+Azimioaraauthor=M.+G.+Benedettiauthor=T.+A.+Carterauthor=P.+Ciceriauthor=P.+T.+Edeenauthor=M.+Floydauthor=J.+M.+Fordauthor=M.+Galvinauthor=J.+L.+Gerlachauthor=R.+M.+Grotzfeldauthor=S.+Herrgardauthor=D.+E.+Inskoauthor=M.+A.+Inskoauthor=A.+G.+Laiauthor=J.-M.+Leliasauthor=S.+A.+Mehtaauthor=Z.+V.+Milanovauthor=A.+M.+Velascoauthor=L.+M.+Wodickaauthor=H.+K.+Patelauthor=P.+P.+Zarrinkarauthor=D.+J.+Lockhart&title=A+small+molecule-kinase+interaction+map+for+clinical+kinase+inhibitors&doi=10.1038%2Fnbt1068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">A small molecule-kinase interaction map for clinical kinase inhibitors</span></div><div class="casAuthors">Fabian, Miles A.; Biggs, William H.; Treiber, Daniel K.; Atteridge, Corey E.; Azimioara, Mihai D.; Benedetti, Michael G.; Carter, Todd A.; Ciceri, Pietro; Edeen, Philip T.; Floyd, Mark; Ford, Julia M.; Galvin, Margaret; Gerlach, Jay L.; Grotzfeld, Robert M.; Herrgard, Sanna; Insko, Darren E.; Insko, Michael A.; Lai, Andiliy G.; Lelias, Jean-Michel; Mehta, Shamal A.; Milanov, Zdravko V.; Velasco, Anne Marie; Wodicka, Lisa M.; Patel, Hitesh K.; Zarrinkar, Patrick P.; Lockhart, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">329-336</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors show great promise as a new class of therapeutics.  Here the authors describe an efficient way to det. kinase inhibitor specificity by measuring binding of small mols. to the ATP site of kinases.  The authors have profiled 20 kinase inhibitors, including 16 that are approved drugs or in clin. development, against a panel of 119 protein kinases.  The authors find that specificity varies widely and is not strongly correlated with chem. structure or the identity of the intended target.  Many novel interactions were identified, including tight binding of the p38 inhibitor BIRB-796 to an imatinib-resistant variant of the ABL kinase, and binding of imatinib to the SRC-family kinase LCK.  The authors also show that mutations in the epidermal growth factor receptor (EGFR) found in gefitinib-responsive patients do not affect the binding affinity of gefitinib or erlotinib.  Our results represent a systematic small mol.-protein interaction map for clin. compds. across a large no. of related proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA0vNmMOXrnrVg90H21EOLACvtfcHk0lgdUeKDyBXaKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D&md5=6aedd5ceb8f77cd26ee50425dcec7bdf</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fnbt1068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1068%26sid%3Dliteratum%253Aachs%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DAzimioara%26aufirst%3DM.%2BD.%26aulast%3DBenedetti%26aufirst%3DM.%2BG.%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DGalvin%26aufirst%3DM.%26aulast%3DGerlach%26aufirst%3DJ.%2BL.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DInsko%26aufirst%3DM.%2BA.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DLelias%26aufirst%3DJ.-M.%26aulast%3DMehta%26aufirst%3DS.%2BA.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26atitle%3DA%2520small%2520molecule-kinase%2520interaction%2520map%2520for%2520clinical%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Biotechnol.%26date%3D2005%26volume%3D23%26spage%3D329%26epage%3D336%26doi%3D10.1038%2Fnbt1068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karaman, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrgard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallant, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atteridge, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edeen, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faraoni, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockhart, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milanov, Z. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallares, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pritchard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodicka, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span> <span> </span><span class="NLM_article-title">A quantitative analysis of kinase inhibitor selectivity</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1038/nbt1358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=10.1038%2Fnbt1358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=18183025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=127-132&author=M.+W.+Karamanauthor=S.+Herrgardauthor=D.+K.+Treiberauthor=P.+Gallantauthor=C.+E.+Atteridgeauthor=B.+T.+Campbellauthor=K.+W.+Chanauthor=P.+Ciceriauthor=M.+I.+Davisauthor=P.+T.+Edeenauthor=R.+Faraoniauthor=M.+Floydauthor=J.+P.+Huntauthor=D.+J.+Lockhartauthor=Z.+V.+Milanovauthor=M.+J.+Morrisonauthor=G.+Pallaresauthor=H.+K.+Patelauthor=S.+Pritchardauthor=L.+M.+Wodickaauthor=P.+P.+Zarrinkar&title=A+quantitative+analysis+of+kinase+inhibitor+selectivity&doi=10.1038%2Fnbt1358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">A quantitative analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Karaman, Mazen W.; Herrgard, Sanna; Treiber, Daniel K.; Gallant, Paul; Atteridge, Corey E.; Campbell, Brian T.; Chan, Katrina W.; Ciceri, Pietro; Davis, Mindy I.; Edeen, Philip T.; Faraoni, Raffaella; Floyd, Mark; Hunt, Jeremy P.; Lockhart, Daniel J.; Milanov, Zdravko V.; Morrison, Michael J.; Pallares, Gabriel; Patel, Hitesh K.; Pritchard, Stephanie; Wodicka, Lisa M.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-132</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets.  The biol. consequences of multikinase activity are poorly defined, and an important step toward understanding the relationship between selectivity, efficacy and safety is the exploration of how inhibitors interact with the human kinome.  The authors present interaction maps for 38 kinase inhibitors across a panel of 317 kinases representing >50% of the predicted human protein kinome.  The data constitute the most comprehensive study of kinase inhibitor selectivity to date and reveal a wide diversity of interaction patterns.  To enable a global anal. of the results, the authors introduce the concept of a selectivity score as a general tool to quantify and differentiate the obsd. interaction patterns.  The authors further investigate the impact of panel size and find that small assay panels do not provide a robust measure of selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiArJSq2_lPrVg90H21EOLACvtfcHk0ljROtsZxou-DA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D&md5=346265d412853ced636ad4128ed8a76f</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnbt1358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1358%26sid%3Dliteratum%253Aachs%26aulast%3DKaraman%26aufirst%3DM.%2BW.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DGallant%26aufirst%3DP.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DCampbell%26aufirst%3DB.%2BT.%26aulast%3DChan%26aufirst%3DK.%2BW.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFaraoni%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DMorrison%26aufirst%3DM.%2BJ.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DPritchard%26aufirst%3DS.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DA%2520quantitative%2520analysis%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2008%26volume%3D26%26spage%3D127%26epage%3D132%26doi%3D10.1038%2Fnbt1358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Infante, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daud, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kefford, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamid, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuchter, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cebon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kudchadkar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burris, H. A.,  III</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falchook, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Algazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puzanov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebowitz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Little, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allred, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouellet, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, J.</span></span> <span> </span><span class="NLM_article-title">Combined BRAF and MEK inhibition in melanoma with BRAF V600 Mutations</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>367</i></span>,  <span class="NLM_fpage">1694</span>– <span class="NLM_lpage">1703</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1210093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=10.1056%2FNEJMoa1210093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=23020132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1eksLrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=1694-1703&author=K.+T.+Flahertyauthor=J.+R.+Infanteauthor=A.+Daudauthor=R.+Gonzalezauthor=R.+F.+Keffordauthor=J.+Sosmanauthor=O.+Hamidauthor=L.+Schuchterauthor=J.+Cebonauthor=N.+Ibrahimauthor=R.+Kudchadkarauthor=H.+A.+Burrisauthor=G.+Falchookauthor=A.+Algaziauthor=K.+Lewisauthor=G.+V.+Longauthor=I.+Puzanovauthor=P.+Lebowitzauthor=A.+Singhauthor=S.+Littleauthor=P.+Sunauthor=A.+Allredauthor=D.+Ouelletauthor=K.+B.+Kimauthor=K.+Patelauthor=J.+Weber&title=Combined+BRAF+and+MEK+inhibition+in+melanoma+with+BRAF+V600+Mutations&doi=10.1056%2FNEJMoa1210093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations</span></div><div class="casAuthors">Flaherty, Keith T.; Infante, Jeffery R.; Daud, Adil; Gonzalez, Rene; Kefford, Richard F.; Sosman, Jeffrey; Hamid, Omid; Schuchter, Lynn; Cebon, Jonathan; Ibrahim, Nageatte; Kudchadkar, Ragini; Burris, Howard A., III; Falchook, Gerald; Algazi, Alain; Lewis, Karl; Long, Georgina V.; Puzanov, Igor; Lebowitz, Peter; Singh, Ajay; Little, Shonda; Sun, Peng; Allred, Alicia; Ouellet, Daniele; Kim, Kevin B.; Patel, Kiran; Weber, Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1694-1703</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Resistance to therapy with BRAF kinase inhibitors is assocd. with reactivation of the mitogen-activated protein kinase (MAPK) pathway.  To address this problem, we conducted a phase 1 and 2 trial of combined treatment with dabrafenib, a selective BRAF inhibitor, and trametinib, a selective MAPK kinase (MEK) inhibitor.  METHODS In this open-label study involving 247 patients with metastatic melanoma and BRAF V600 mutations, we evaluated the pharmacokinetic activity and safety of oral dabrafenib (75 or 150 mg twice daily) and trametinib (1, 1.5, or 2 mg daily) in 85 patients and then randomly assigned 162 patients to receive combination therapy with dabrafenib (150 mg) plus trametinib (1 or 2 mg) or dabrafenib monotherapy.  The primary end points were the incidence of cutaneous squamous-cell carcinoma, survival free of melanoma progression, and response.  Secondary end points were overall survival and pharmacokinetic activity.  RESULTS Dose-limiting toxic effects were infrequently obsd. in patients receiving combination therapy with 150 mg of dabrafenib and 2 mg of trametinib (combination 150/2).  Cutaneous squamous-cell carcinoma was seen in 7% of patients receiving combination 150/2 and in 19% receiving monotherapy (P = 0.09), whereas pyrexia was more common in the combination 150/2 group than in the monotherapy group (71% vs. 26%).  Median progression-free survival in the combination 150/2 group was 9.4 mo, as compared with 5.8 mo in the monotherapy group (hazard ratio for progression or death, 0.39; 95% confidence interval, 0.25 to 0.62; P<0.001).  The rate of complete or partial response with combination 150/2 therapy was 76%, as compared with 54% with monotherapy (P = 0.03).  CONCLUSIONS Dabrafenib and trametinib were safely combined at full monotherapy doses.  The rate of pyrexia was increased with combination therapy, whereas the rate of proliferative skin lesions was nonsignificantly reduced.  Progression-free survival was significantly improved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhk7I8zrGTVbVg90H21EOLACvtfcHk0ljROtsZxou-DA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1eksLrJ&md5=199ae281d44c3b41309b934d88674cd3</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1210093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1210093%26sid%3Dliteratum%253Aachs%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DInfante%26aufirst%3DJ.%2BR.%26aulast%3DDaud%26aufirst%3DA.%26aulast%3DGonzalez%26aufirst%3DR.%26aulast%3DKefford%26aufirst%3DR.%2BF.%26aulast%3DSosman%26aufirst%3DJ.%26aulast%3DHamid%26aufirst%3DO.%26aulast%3DSchuchter%26aufirst%3DL.%26aulast%3DCebon%26aufirst%3DJ.%26aulast%3DIbrahim%26aufirst%3DN.%26aulast%3DKudchadkar%26aufirst%3DR.%26aulast%3DBurris%26aufirst%3DH.%2BA.%26aulast%3DFalchook%26aufirst%3DG.%26aulast%3DAlgazi%26aufirst%3DA.%26aulast%3DLewis%26aufirst%3DK.%26aulast%3DLong%26aufirst%3DG.%2BV.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DLebowitz%26aufirst%3DP.%26aulast%3DSingh%26aufirst%3DA.%26aulast%3DLittle%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DP.%26aulast%3DAllred%26aufirst%3DA.%26aulast%3DOuellet%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DPatel%26aufirst%3DK.%26aulast%3DWeber%26aufirst%3DJ.%26atitle%3DCombined%2520BRAF%2520and%2520MEK%2520inhibition%2520in%2520melanoma%2520with%2520BRAF%2520V600%2520Mutations%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D367%26spage%3D1694%26epage%3D1703%26doi%3D10.1056%2FNEJMoa1210093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hersey, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milhem, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demidov, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassel, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutkowski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohr, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dummer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trefzer, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larkin, J. M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Utikal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dreno, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nyakas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middleton, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casey, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherman, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouellet, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schadendorf, D.</span></span> <span> </span><span class="NLM_article-title">Improved survival with MEK inhibition in BRAF-mutated melanoma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>367</i></span>,  <span class="NLM_fpage">107</span>– <span class="NLM_lpage">114</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1203421</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=10.1056%2FNEJMoa1203421" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=22663011" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFKjs7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=107-114&author=K.+T.+Flahertyauthor=C.+Robertauthor=P.+Herseyauthor=P.+Nathanauthor=C.+Garbeauthor=M.+Milhemauthor=L.+V.+Demidovauthor=J.+C.+Hasselauthor=P.+Rutkowskiauthor=P.+Mohrauthor=R.+Dummerauthor=U.+Trefzerauthor=J.+M.+G.+Larkinauthor=J.+Utikalauthor=B.+Drenoauthor=M.+Nyakasauthor=M.+R.+Middletonauthor=J.+C.+Beckerauthor=M.+Caseyauthor=L.+J.+Shermanauthor=F.+S.+Wuauthor=D.+Ouelletauthor=A.+M.+Martinauthor=K.+Patelauthor=D.+Schadendorf&title=Improved+survival+with+MEK+inhibition+in+BRAF-mutated+melanoma&doi=10.1056%2FNEJMoa1203421"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Improved survival with MEK inhibition in BRAF-mutated melanoma</span></div><div class="casAuthors">Flaherty, Keith T.; Robert, Caroline; Hersey, Peter; Nathan, Paul; Garbe, Claus; Milhem, Mohammed; Demidov, Lev V.; Hassel, Jessica C.; Rutkowski, Piotr; Mohr, Peter; Dummer, Reinhard; Trefzer, Uwe; Larkin, James M. G.; Utikal, Jochen; Dreno, Brigitte; Nyakas, Marta; Middleton, Mark R.; Becker, Jurgen C.; Casey, Michelle; Sherman, Laurie J.; Wu, Frank S.; Ouellet, Daniele; Martin, Anne-Marie; Schadendorf, Dirk</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">107-114</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Activating mutations in serine-threonine protein kinase B-RAF (BRAF) are found in 50% of patients with advanced melanoma.  Selective BRAF-inhibitor therapy improves survival, as compared with chemotherapy, but responses are often short-lived.  In previous trials, MEK inhibition appeared to be promising in this population.  In this phase 3 open-label trial, we randomly assigned 322 patients who had metastatic melanoma with a V600E or V600K BRAF mutation to receive either trametinib, an oral selective MEK inhibitor, or chemotherapy in a 2:1 ratio.  Patients received trametinib (2 mg orally) once daily or i.v. dacarbazine (1000 mg per square meter of body-surface area) or paclitaxel (175 mg per square meter) every 3 wk.  Patients in the chemotherapy group who had disease progression were permitted to cross over to receive trametinib.  Progression-free survival was the primary end point, and overall survival was a secondary end point.  Median progression-free survival was 4.8 mo in the trametinib group and 1.5 mo in the chemotherapy group (hazard ratio for disease progression or death in the trametinib group, 0.45; 95% confidence interval [CI], 0.33 to 0.63; P < 0.001).  At 6 mo, the rate of overall survival was 81% in the trametinib group and 67% in the chemotherapy group despite crossover (hazard ratio for death, 0.54; 95% CI, 0.32 to 0.92; P = 0.01).  Rash, diarrhea, and peripheral edema were the most common toxic effects in the trametinib group and were managed with dose interruption and dose redn.; asymptomatic and reversible redn. in the cardiac ejection fraction and ocular toxic effects occurred infrequently.  Secondary skin neo- plasms were not obsd.  Trametinib, as compared with chemotherapy, improved rates of progression-free and overall survival among patients who had metastatic melanoma with a BRAF V600E or V600K mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQ9lseRU60cLVg90H21EOLACvtfcHk0liYJH78ffLMjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFKjs7zN&md5=bf084fd4ac6599e1f023cb732f0678a7</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1203421&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1203421%26sid%3Dliteratum%253Aachs%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DHersey%26aufirst%3DP.%26aulast%3DNathan%26aufirst%3DP.%26aulast%3DGarbe%26aufirst%3DC.%26aulast%3DMilhem%26aufirst%3DM.%26aulast%3DDemidov%26aufirst%3DL.%2BV.%26aulast%3DHassel%26aufirst%3DJ.%2BC.%26aulast%3DRutkowski%26aufirst%3DP.%26aulast%3DMohr%26aufirst%3DP.%26aulast%3DDummer%26aufirst%3DR.%26aulast%3DTrefzer%26aufirst%3DU.%26aulast%3DLarkin%26aufirst%3DJ.%2BM.%2BG.%26aulast%3DUtikal%26aufirst%3DJ.%26aulast%3DDreno%26aufirst%3DB.%26aulast%3DNyakas%26aufirst%3DM.%26aulast%3DMiddleton%26aufirst%3DM.%2BR.%26aulast%3DBecker%26aufirst%3DJ.%2BC.%26aulast%3DCasey%26aufirst%3DM.%26aulast%3DSherman%26aufirst%3DL.%2BJ.%26aulast%3DWu%26aufirst%3DF.%2BS.%26aulast%3DOuellet%26aufirst%3DD.%26aulast%3DMartin%26aufirst%3DA.%2BM.%26aulast%3DPatel%26aufirst%3DK.%26aulast%3DSchadendorf%26aufirst%3DD.%26atitle%3DImproved%2520survival%2520with%2520MEK%2520inhibition%2520in%2520BRAF-mutated%2520melanoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D367%26spage%3D107%26epage%3D114%26doi%3D10.1056%2FNEJMoa1203421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauschild, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haanen, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ascierto, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larkin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dummer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Testori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorigan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebbe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jouary, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schadendorf, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Day, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkwood, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eggermont, A. M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dreno, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolop, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McArthur, G. A.</span></span> <span> </span><span class="NLM_article-title">Improved survival with Vemurafenib in melanoma with BRAF V600E mutation</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>364</i></span>,  <span class="NLM_fpage">2507</span>– <span class="NLM_lpage">2516</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1103782</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=10.1056%2FNEJMoa1103782" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=21639808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosVeitbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2011&pages=2507-2516&author=P.+B.+Chapmanauthor=A.+Hauschildauthor=C.+Robertauthor=J.+B.+Haanenauthor=P.+Asciertoauthor=J.+Larkinauthor=R.+Dummerauthor=C.+Garbeauthor=A.+Testoriauthor=M.+Maioauthor=D.+Hoggauthor=P.+Loriganauthor=C.+Lebbeauthor=T.+Jouaryauthor=D.+Schadendorfauthor=A.+Ribasauthor=S.+J.+O%E2%80%99Dayauthor=J.+A.+Sosmanauthor=J.+M.+Kirkwoodauthor=A.+M.+M.+Eggermontauthor=B.+Drenoauthor=K.+Nolopauthor=J.+Liauthor=B.+Nelsonauthor=J.+Houauthor=R.+J.+Leeauthor=K.+T.+Flahertyauthor=G.+A.+McArthur&title=Improved+survival+with+Vemurafenib+in+melanoma+with+BRAF+V600E+mutation&doi=10.1056%2FNEJMoa1103782"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Improved survival with vemurafenib in melanoma with BRAF V600E mutation</span></div><div class="casAuthors">Chapman, Paul B.; Hauschild, Axel; Robert, Caroline; Haanen, John B.; Ascierto, Paolo; Larkin, James; Dummer, Reinhard; Garbe, Claus; Testori, Alessandro; Maio, Michele; Hogg, David; Lorigan, Paul; Lebbe, Celeste; Jouary, Thomas; Schadendorf, Dirk; Ribas, Antoni; O'Day, Steven J.; Sosman, Jeffrey A.; Kirkwood, John M.; Eggermont, Alexander M. M.; Dreno, Brigitte; Nolop, Keith; Li, Jiang; Nelson, Betty; Hou, Jeannie; Lee, Richard J.; Flaherty, Keith T.; McArthur, Grant A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">2507-2516</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Phase 1 and 2 clin. trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF V600E mutation.  METHODS: We conducted a phase 3 randomized clin. trial comparing vemurafenib with dacarbazine in 675 patients with previously untreated, metastatic melanoma with the BRAF V600E mutation.  Patients were randomly assigned to receive either vemurafenib (960 mg orally twice daily) or dacarbazine (1000 mg per square meter of body-surface area i.v. every 3 wk).  Coprimary end points were rates of overall and progression-free survival.  Secondary end points included the response rate, response duration, and safety.  A final anal. was planned after 196 deaths and an interim anal. after 98 deaths.  RESULTS: At 6 mo, overall survival was 840/ (95% confidence interval [CI], 78 to 89) in the vemurafenib group and 64% (95% CI, 56 to 73) in the dacarbazine group.  In the interim anal. for overall survival and final anal. for progression-free survival, vemurafenib was assocd. with a relative redn. of 63% in the risk of death and of 74% in the risk of either death or disease progression, as compared with dacarbazine (P < 0.001 for both comparisons).  After review of the interim anal. by an independent data and safety monitoring board, crossover from dacarbazine to vemurafenib was recommended.  Response rates were 48% for vemurafenib and 5% for dacarbazine.  Common adverse events assocd. with vemurafenib were arthralgia, rash, fatigue, alopecia, keratoacanthoma or squamous-cell carcinoma, photosensitivity, nausea, and diarrhea; 38% of patients required dose modification because of toxic effects.  CONCLUSIONS: Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4NFxmTaDz97Vg90H21EOLACvtfcHk0liYJH78ffLMjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosVeitbs%253D&md5=1a4b4f963221888dc63f620e87408070</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1103782&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1103782%26sid%3Dliteratum%253Aachs%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DHauschild%26aufirst%3DA.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DHaanen%26aufirst%3DJ.%2BB.%26aulast%3DAscierto%26aufirst%3DP.%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DDummer%26aufirst%3DR.%26aulast%3DGarbe%26aufirst%3DC.%26aulast%3DTestori%26aufirst%3DA.%26aulast%3DMaio%26aufirst%3DM.%26aulast%3DHogg%26aufirst%3DD.%26aulast%3DLorigan%26aufirst%3DP.%26aulast%3DLebbe%26aufirst%3DC.%26aulast%3DJouary%26aufirst%3DT.%26aulast%3DSchadendorf%26aufirst%3DD.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Day%26aufirst%3DS.%2BJ.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DKirkwood%26aufirst%3DJ.%2BM.%26aulast%3DEggermont%26aufirst%3DA.%2BM.%2BM.%26aulast%3DDreno%26aufirst%3DB.%26aulast%3DNolop%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DNelson%26aufirst%3DB.%26aulast%3DHou%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26atitle%3DImproved%2520survival%2520with%2520Vemurafenib%2520in%2520melanoma%2520with%2520BRAF%2520V600E%2520mutation%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D364%26spage%3D2507%26epage%3D2516%26doi%3D10.1056%2FNEJMoa1103782" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span> <span> </span><span class="NLM_article-title">25 years of small molecular weight kinase inhibitors: potentials and limitations</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>87</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">766</span>– <span class="NLM_lpage">775</span>, <span class="refDoi"> DOI: 10.1124/mol.114.095489</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=10.1124%2Fmol.114.095489" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=25549667" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlvVKltLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2015&pages=766-775&issue=5&author=D.+Fabbro&title=25+years+of+small+molecular+weight+kinase+inhibitors%3A+potentials+and+limitations&doi=10.1124%2Fmol.114.095489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">25 years of small molecular weight kinase inhibitors: potentials and limitations</span></div><div class="casAuthors">Fabbro, Doriano</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">766-775</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  Deregulation of protein and lipid kinase activities leads to a variety of pathologies, ranging from cancer inflammatory diseases, diabetes, infectious diseases, and cardiovascular disorders.  Protein kinases and lipid kinases represent, therefore, an important target for the pharmaceutical industry.  In fact, approx. one-third of all protein targets under investigation in the pharmaceutical industry are protein or lipid kinases.  To date, 30 kinase inhibitors have been approved, which, with few exceptions, are mainly for oncol. indications and directed against only a handful of protein and lipid kinases, leaving 70% of the kinome untapped.  Despite these successes in kinase drug discovery, the development of kinase inhibitors with outstanding selectivity, identification and validation of driver kinase(s) in diseases, and the emerging problem of resistance to the inhibition of key target kinases remain major challenges.  This mini review provides an insight into protein and lipid kinase drug discovery with respect to achievements, binding modes of inhibitors, and novel avenues for the generation of second-generation kinase inhibitors to treat cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZhF-9NQJx7bVg90H21EOLACvtfcHk0liYJH78ffLMjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlvVKltLk%253D&md5=6422b036e4e447379ac6c608662954c2</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1124%2Fmol.114.095489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.114.095489%26sid%3Dliteratum%253Aachs%26aulast%3DFabbro%26aufirst%3DD.%26atitle%3D25%2520years%2520of%2520small%2520molecular%2520weight%2520kinase%2520inhibitors%253A%2520potentials%2520and%2520limitations%26jtitle%3DMol.%2520Pharmacol.%26date%3D2015%26volume%3D87%26issue%3D5%26spage%3D766%26epage%3D775%26doi%3D10.1124%2Fmol.114.095489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref2':['cit2'],'ref12':[],'ref1':['cit1'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 10 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Malcolm P. Huestis, Darlene Dela Cruz, Antonio G. DiPasquale, Matthew R. Durk, Charles Eigenbrot, Paul Gibbons, Alberto Gobbi, Thomas L. Hunsaker, Hank La, Dennis H. Leung, Wendy Liu, Shiva Malek, Mark Merchant, John G. Moffat, Christine S. Muli, Christine J. Orr, Brendan T. Parr, Frances Shanahan, Christopher J. Sneeringer, Weiru Wang, Ivana Yen, Jianping Yin, Michael Siu, <span class="NLM_string-name hlFld-ContribAuthor">Joachim Rudolph</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a 5-Fluoro-4-(3H)-quinazolinone Aryl Urea pan-RAF Kinase Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (7)
                                     , 3940-3955. <a href="https://doi.org/10.1021/acs.jmedchem.0c02085" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c02085</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c02085%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTargeting%252BKRAS%252BMutant%252BCancers%252Bvia%252BCombination%252BTreatment%25253A%252BDiscovery%252Bof%252Ba%252B5-Fluoro-4-%2525283H%252529-quinazolinone%252BAryl%252BUrea%252Bpan-RAF%252BKinase%252BInhibitor%26aulast%3DHuestis%26aufirst%3DMalcolm%2BP.%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D01122020%26date%3D29032021%26volume%3D64%26issue%3D7%26spage%3D3940%26epage%3D3955" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ivana  Yen</span>, <span class="hlFld-ContribAuthor ">Frances  Shanahan</span>, <span class="hlFld-ContribAuthor ">Jeeyun  Lee</span>, <span class="hlFld-ContribAuthor ">Yong Sang  Hong</span>, <span class="hlFld-ContribAuthor ">Sang Joon  Shin</span>, <span class="hlFld-ContribAuthor ">Amanda R.  Moore</span>, <span class="hlFld-ContribAuthor ">Jawahar  Sudhamsu</span>, <span class="hlFld-ContribAuthor ">Matthew T.  Chang</span>, <span class="hlFld-ContribAuthor ">Inhwan  Bae</span>, <span class="hlFld-ContribAuthor ">Darlene  Dela Cruz</span>, <span class="hlFld-ContribAuthor ">Thomas  Hunsaker</span>, <span class="hlFld-ContribAuthor ">Christiaan  Klijn</span>, <span class="hlFld-ContribAuthor ">Nicholas P. D.  Liau</span>, <span class="hlFld-ContribAuthor ">Eva  Lin</span>, <span class="hlFld-ContribAuthor ">Scott E.  Martin</span>, <span class="hlFld-ContribAuthor ">Zora  Modrusan</span>, <span class="hlFld-ContribAuthor ">Robert  Piskol</span>, <span class="hlFld-ContribAuthor ">Ehud  Segal</span>, <span class="hlFld-ContribAuthor ">Avinashnarayan  Venkatanarayan</span>, <span class="hlFld-ContribAuthor ">Xin  Ye</span>, <span class="hlFld-ContribAuthor ">Jianping  Yin</span>, <span class="hlFld-ContribAuthor ">Liangxuan  Zhang</span>, <span class="hlFld-ContribAuthor ">Jin-Soo  Kim</span>, <span class="hlFld-ContribAuthor ">Hyeong-Seok  Lim</span>, <span class="hlFld-ContribAuthor ">Kyu-Pyo  Kim</span>, <span class="hlFld-ContribAuthor ">Yu Jung  Kim</span>, <span class="hlFld-ContribAuthor ">Hye Sook  Han</span>, <span class="hlFld-ContribAuthor ">Soo Jung  Lee</span>, <span class="hlFld-ContribAuthor ">Seung Tae  Kim</span>, <span class="hlFld-ContribAuthor ">Minkyu  Jung</span>, <span class="hlFld-ContribAuthor ">Yoon-hee  Hong</span>, <span class="hlFld-ContribAuthor ">Young Su  Noh</span>, <span class="hlFld-ContribAuthor ">Munjeong  Choi</span>, <span class="hlFld-ContribAuthor ">Oakpil  Han</span>, <span class="hlFld-ContribAuthor ">Malgorzata  Nowicka</span>, <span class="hlFld-ContribAuthor ">Shrividhya  Srinivasan</span>, <span class="hlFld-ContribAuthor ">Yibing  Yan</span>, <span class="hlFld-ContribAuthor ">Tae Won  Kim</span>, <span class="hlFld-ContribAuthor ">Shiva  Malek</span>. </span><span class="cited-content_cbyCitation_article-title">ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma. </span><span class="cited-content_cbyCitation_journal-name">Nature</span><span> <strong>2021,</strong> <em>594 </em>
                                    (7863)
                                     , 418-423. <a href="https://doi.org/10.1038/s41586-021-03515-1" title="DOI URL">https://doi.org/10.1038/s41586-021-03515-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41586-021-03515-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41586-021-03515-1%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%26atitle%3DARAF%252Bmutations%252Bconfer%252Bresistance%252Bto%252Bthe%252BRAF%252Binhibitor%252Bbelvarafenib%252Bin%252Bmelanoma%26aulast%3DYen%26aufirst%3DIvana%26date%3D2021%26date%3D2021%26volume%3D594%26issue%3D7863%26spage%3D418%26epage%3D423" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kelli-Ann  Monaco</span>, <span class="hlFld-ContribAuthor ">Scott  Delach</span>, <span class="hlFld-ContribAuthor ">Jing  Yuan</span>, <span class="hlFld-ContribAuthor ">Yuji  Mishina</span>, <span class="hlFld-ContribAuthor ">Paul  Fordjour</span>, <span class="hlFld-ContribAuthor ">Emma  Labrot</span>, <span class="hlFld-ContribAuthor ">Daniel  McKay</span>, <span class="hlFld-ContribAuthor ">Ribo  Guo</span>, <span class="hlFld-ContribAuthor ">Stacy  Higgins</span>, <span class="hlFld-ContribAuthor ">Hui Qin  Wang</span>, <span class="hlFld-ContribAuthor ">Jinsheng  Liang</span>, <span class="hlFld-ContribAuthor ">Karen  Bui</span>, <span class="hlFld-ContribAuthor ">John  Green</span>, <span class="hlFld-ContribAuthor ">Peter  Aspesi</span>, <span class="hlFld-ContribAuthor ">Jessi  Ambrose</span>, <span class="hlFld-ContribAuthor ">Felipa  Mapa</span>, <span class="hlFld-ContribAuthor ">Lesley  Griner</span>, <span class="hlFld-ContribAuthor ">Mariela  Jaskelioff</span>, <span class="hlFld-ContribAuthor ">John  Fuller</span>, <span class="hlFld-ContribAuthor ">Kenneth  Crawford</span>, <span class="hlFld-ContribAuthor ">Gwynn  Pardee</span>, <span class="hlFld-ContribAuthor ">Stephania  Widger</span>, <span class="hlFld-ContribAuthor ">Peter S.  Hammerman</span>, <span class="hlFld-ContribAuthor ">Jeffrey A.  Engelman</span>, <span class="hlFld-ContribAuthor ">Darrin D.  Stuart</span>, <span class="hlFld-ContribAuthor ">Vesselina G.  Cooke</span>, <span class="hlFld-ContribAuthor ">Giordano  Caponigro</span>. </span><span class="cited-content_cbyCitation_article-title">LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors. </span><span class="cited-content_cbyCitation_journal-name">Clinical Cancer Research</span><span> <strong>2021,</strong> <em>27 </em>
                                    (7)
                                     , 2061-2073. <a href="https://doi.org/10.1158/1078-0432.CCR-20-2563" title="DOI URL">https://doi.org/10.1158/1078-0432.CCR-20-2563</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1078-0432.CCR-20-2563&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1078-0432.CCR-20-2563%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Cancer%2520Research%26atitle%3DLXH254%25252C%252Ba%252BPotent%252Band%252BSelective%252BARAF-Sparing%252BInhibitor%252Bof%252BBRAF%252Band%252BCRAF%252Bfor%252Bthe%252BTreatment%252Bof%252BMAPK-Driven%252BTumors%26aulast%3DMonaco%26aufirst%3DKelli-Ann%26date%3D2021%26date%3D2020%26volume%3D27%26issue%3D7%26spage%3D2061%26epage%3D2073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hon Yan Kelvin  Yip</span>, <span class="hlFld-ContribAuthor ">Antonella  Papa</span>. </span><span class="cited-content_cbyCitation_article-title">Signaling Pathways in Cancer: Therapeutic Targets, Combinatorial Treatments, and New Developments. </span><span class="cited-content_cbyCitation_journal-name">Cells</span><span> <strong>2021,</strong> <em>10 </em>
                                    (3)
                                     , 659. <a href="https://doi.org/10.3390/cells10030659" title="DOI URL">https://doi.org/10.3390/cells10030659</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cells10030659&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcells10030659%26sid%3Dliteratum%253Aachs%26jtitle%3DCells%26atitle%3DSignaling%252BPathways%252Bin%252BCancer%25253A%252BTherapeutic%252BTargets%25252C%252BCombinatorial%252BTreatments%25252C%252Band%252BNew%252BDevelopments%26aulast%3DYip%26aufirst%3DHon%2BYan%2BKelvin%26date%3D2021%26date%3D2021%26volume%3D10%26issue%3D3%26spage%3D659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aayoung  Hong</span>, <span class="hlFld-ContribAuthor ">Marco  Piva</span>, <span class="hlFld-ContribAuthor ">Sixue  Liu</span>, <span class="hlFld-ContribAuthor ">Willy  Hugo</span>, <span class="hlFld-ContribAuthor ">Shirley H.  Lomeli</span>, <span class="hlFld-ContribAuthor ">Vincent  Zoete</span>, <span class="hlFld-ContribAuthor ">Christopher E.  Randolph</span>, <span class="hlFld-ContribAuthor ">Zhentao  Yang</span>, <span class="hlFld-ContribAuthor ">Yan  Wang</span>, <span class="hlFld-ContribAuthor ">Jordan J.  Lee</span>, <span class="hlFld-ContribAuthor ">Skylar J.  Lo</span>, <span class="hlFld-ContribAuthor ">Lu  Sun</span>, <span class="hlFld-ContribAuthor ">Agustin  Vega-Crespo</span>, <span class="hlFld-ContribAuthor ">Alejandro J.  Garcia</span>, <span class="hlFld-ContribAuthor ">David B.  Shackelford</span>, <span class="hlFld-ContribAuthor ">Steven M.  Dubinett</span>, <span class="hlFld-ContribAuthor ">Philip O.  Scumpia</span>, <span class="hlFld-ContribAuthor ">Stephanie D.  Byrum</span>, <span class="hlFld-ContribAuthor ">Alan J.  Tackett</span>, <span class="hlFld-ContribAuthor ">Timothy R.  Donahue</span>, <span class="hlFld-ContribAuthor ">Olivier  Michielin</span>, <span class="hlFld-ContribAuthor ">Sheri L.  Holmen</span>, <span class="hlFld-ContribAuthor ">Antoni  Ribas</span>, <span class="hlFld-ContribAuthor ">Gatien  Moriceau</span>, <span class="hlFld-ContribAuthor ">Roger S.  Lo</span>. </span><span class="cited-content_cbyCitation_article-title">Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity. </span><span class="cited-content_cbyCitation_journal-name">Cancer Discovery</span><span> <strong>2021,</strong> <em>11 </em>
                                    (3)
                                     , 714-735. <a href="https://doi.org/10.1158/2159-8290.CD-20-0873" title="DOI URL">https://doi.org/10.1158/2159-8290.CD-20-0873</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/2159-8290.CD-20-0873&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F2159-8290.CD-20-0873%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Discovery%26atitle%3DDurable%252BSuppression%252Bof%252BAcquired%252BMEK%252BInhibitor%252BResistance%252Bin%252BCancer%252Bby%252BSequestering%252BMEK%252Bfrom%252BERK%252Band%252BPromoting%252BAntitumor%252BT-cell%252BImmunity%26aulast%3DHong%26aufirst%3DAayoung%26date%3D2021%26date%3D2020%26volume%3D11%26issue%3D3%26spage%3D714%26epage%3D735" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nicolas  Dumaz</span>, <span class="hlFld-ContribAuthor ">Céleste  Lebbé</span>. </span><span class="cited-content_cbyCitation_article-title">New perspectives on targeting RAF, MEK and ERK in melanoma. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Oncology</span><span> <strong>2021,</strong> <em>33 </em>
                                    (2)
                                     , 120-126. <a href="https://doi.org/10.1097/CCO.0000000000000708" title="DOI URL">https://doi.org/10.1097/CCO.0000000000000708</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1097/CCO.0000000000000708&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1097%2FCCO.0000000000000708%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Oncology%26atitle%3DNew%252Bperspectives%252Bon%252Btargeting%252BRAF%25252C%252BMEK%252Band%252BERK%252Bin%252Bmelanoma%26aulast%3DDumaz%26aufirst%3DNicolas%26date%3D2021%26date%3D2020%26volume%3D33%26issue%3D2%26spage%3D120%26epage%3D126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christos  Adamopoulos</span>, <span class="hlFld-ContribAuthor ">Tamer A.  Ahmed</span>, <span class="hlFld-ContribAuthor ">Maxwell R.  Tucker</span>, <span class="hlFld-ContribAuthor ">Peter M.U.  Ung</span>, <span class="hlFld-ContribAuthor ">Min  Xiao</span>, <span class="hlFld-ContribAuthor ">Zoi  Karoulia</span>, <span class="hlFld-ContribAuthor ">Angelo  Amabile</span>, <span class="hlFld-ContribAuthor ">Xuewei  Wu</span>, <span class="hlFld-ContribAuthor ">Stuart A.  Aaronson</span>, <span class="hlFld-ContribAuthor ">Celina  Ang</span>, <span class="hlFld-ContribAuthor ">Vito W.  Rebecca</span>, <span class="hlFld-ContribAuthor ">Brian D.  Brown</span>, <span class="hlFld-ContribAuthor ">Avner  Schlessinger</span>, <span class="hlFld-ContribAuthor ">Meenhard  Herlyn</span>, <span class="hlFld-ContribAuthor ">Qi  Wang</span>, <span class="hlFld-ContribAuthor ">David E.  Shaw</span>, <span class="hlFld-ContribAuthor ">Poulikos I.  Poulikakos</span>. </span><span class="cited-content_cbyCitation_article-title">Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling. </span><span class="cited-content_cbyCitation_journal-name">Cancer Discovery</span><span> <strong>2021,</strong> <em> </em><a href="https://doi.org/10.1158/2159-8290.CD-20-1351" title="DOI URL">https://doi.org/10.1158/2159-8290.CD-20-1351</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/2159-8290.CD-20-1351&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F2159-8290.CD-20-1351%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Discovery%26atitle%3DExploiting%252BAllosteric%252BProperties%252Bof%252BRAF%252Band%252BMEK%252BInhibitors%252Bto%252BTarget%252BTherapy-Resistant%252BTumors%252BDriven%252Bby%252BOncogenic%252BBRAF%252BSignaling%26aulast%3DAdamopoulos%26aufirst%3DChristos%26date%3D2021%26date%3D2021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rong  Li</span>, <span class="hlFld-ContribAuthor ">Meiping  Ren</span>, <span class="hlFld-ContribAuthor ">Wei  Lu</span>, <span class="hlFld-ContribAuthor ">Yunhua  Yuan</span>, <span class="hlFld-ContribAuthor ">Jian  Li</span>, <span class="hlFld-ContribAuthor ">Wu  Zhong</span>. </span><span class="cited-content_cbyCitation_article-title">A validated LC–MS/MS method for the determination of RAF inhibitor LXH254: Application to pharmacokinetic study in rat. </span><span class="cited-content_cbyCitation_journal-name">Biomedical Chromatography</span><span> <strong>2021,</strong> <em>35 </em>
                                    (2)
                                     <a href="https://doi.org/10.1002/bmc.4968" title="DOI URL">https://doi.org/10.1002/bmc.4968</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/bmc.4968&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fbmc.4968%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomedical%2520Chromatography%26atitle%3DA%252Bvalidated%252BLC%2525E2%252580%252593MS%25252FMS%252Bmethod%252Bfor%252Bthe%252Bdetermination%252Bof%252BRAF%252Binhibitor%252BLXH254%25253A%252BApplication%252Bto%252Bpharmacokinetic%252Bstudy%252Bin%252Brat%26aulast%3DLi%26aufirst%3DRong%26date%3D2021%26date%3D2020%26volume%3D35%26issue%3D2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Diren  Usta</span>, <span class="hlFld-ContribAuthor ">Romain  Sigaud</span>, <span class="hlFld-ContribAuthor ">Juliane L.  Buhl</span>, <span class="hlFld-ContribAuthor ">Florian  Selt</span>, <span class="hlFld-ContribAuthor ">Viktoria  Marquardt</span>, <span class="hlFld-ContribAuthor ">David  Pauck</span>, <span class="hlFld-ContribAuthor ">Jennifer  Jansen</span>, <span class="hlFld-ContribAuthor ">Stefan  Pusch</span>, <span class="hlFld-ContribAuthor ">Jonas  Ecker</span>, <span class="hlFld-ContribAuthor ">Thomas  Hielscher</span>, <span class="hlFld-ContribAuthor ">Johanna  Vollmer</span>, <span class="hlFld-ContribAuthor ">Alexander C.  Sommerkamp</span>, <span class="hlFld-ContribAuthor ">Tobias  Rubner</span>, <span class="hlFld-ContribAuthor ">Darren  Hargrave</span>, <span class="hlFld-ContribAuthor ">Cornelis M.  van Tilburg</span>, <span class="hlFld-ContribAuthor ">Stefan M.  Pfister</span>, <span class="hlFld-ContribAuthor ">David T.W.  Jones</span>, <span class="hlFld-ContribAuthor ">Marc  Remke</span>, <span class="hlFld-ContribAuthor ">Tilman  Brummer</span>, <span class="hlFld-ContribAuthor ">Olaf  Witt</span>, <span class="hlFld-ContribAuthor ">Till  Milde</span>. </span><span class="cited-content_cbyCitation_article-title">A Cell-Based MAPK Reporter Assay Reveals Synergistic MAPK Pathway Activity Suppression by MAPK Inhibitor Combination in
              BRAF
              -Driven Pediatric Low-Grade Glioma Cells. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2020,</strong> <em>19 </em>
                                    (8)
                                     , 1736-1750. <a href="https://doi.org/10.1158/1535-7163.MCT-19-1021" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-19-1021</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-19-1021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-19-1021%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DA%252BCell-Based%252BMAPK%252BReporter%252BAssay%252BReveals%252BSynergistic%252BMAPK%252BPathway%252BActivity%252BSuppression%252Bby%252BMAPK%252BInhibitor%252BCombination%252Bin%252BBRAF%252B-Driven%252BPediatric%252BLow-Grade%252BGlioma%252BCells%26aulast%3DUsta%26aufirst%3DDiren%26date%3D2020%26date%3D2020%26volume%3D19%26issue%3D8%26spage%3D1736%26epage%3D1750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ufuk  Degirmenci</span>, <span class="hlFld-ContribAuthor ">Mei  Wang</span>, <span class="hlFld-ContribAuthor ">Jiancheng  Hu</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">Cells</span><span> <strong>2020,</strong> <em>9 </em>
                                    (1)
                                     , 198. <a href="https://doi.org/10.3390/cells9010198" title="DOI URL">https://doi.org/10.3390/cells9010198</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cells9010198&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcells9010198%26sid%3Dliteratum%253Aachs%26jtitle%3DCells%26atitle%3DTargeting%252BAberrant%252BRAS%25252FRAF%25252FMEK%25252FERK%252BSignaling%252Bfor%252BCancer%252BTherapy%26aulast%3DDegirmenci%26aufirst%3DUfuk%26date%3D2020%26date%3D2020%26volume%3D9%26issue%3D1%26spage%3D198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/medium/jm-2019-00161v_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/large/jm-2019-00161v_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00161&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Chart 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/medium/jm-2019-00161v_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/large/jm-2019-00161v_0001.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/large/jm-2019-00161v_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00161&amp;id=cht1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/medium/jm-2019-00161v_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/large/jm-2019-00161v_0002.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of metabolites of <b>3</b> in rat (R), dog (D), and human (H) hepatocyte (quantification based on UV response).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/large/jm-2019-00161v_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00161&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/medium/jm-2019-00161v_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/large/jm-2019-00161v_0003.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) X-ray structure of <b>10</b> in BRAF (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6N0Q">6N0Q</a>)<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(11)</a> (B) Docking models of <b>11</b> and <b>12</b> showing H-bond interaction with F595.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/large/jm-2019-00161v_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00161&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/medium/jm-2019-00161v_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/large/jm-2019-00161v_0004.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. X-ray structure of <b>15</b> in BRAF (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6N0P">6N0P</a>).<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(11)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/large/jm-2019-00161v_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00161&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/medium/jm-2019-00161v_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/large/jm-2019-00161v_0005.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. pMEK activity in Calu-6 cells of <b>15</b> vs <b>1</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/large/jm-2019-00161v_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00161&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/medium/jm-2019-00161v_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/large/jm-2019-00161v_0006.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Effect of <b>1</b> and <b>15</b> on the RAF dimerization in HCT116 cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/large/jm-2019-00161v_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00161&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/medium/jm-2019-00161v_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/large/jm-2019-00161v_0007.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. KINOME<i>scan</i> profile of <b>15</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/large/jm-2019-00161v_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00161&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/medium/jm-2019-00161v_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/large/jm-2019-00161v_0008.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. PK/PD analysis of <b>15</b> in the human Calu-6 NSCLC xenograft in rats. Percent pMEK levels (left axis) and free exposure (right axis) following a single dose of <b>15</b>, at time points indicated, in Calu-6 tumor-bearing rats.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/large/jm-2019-00161v_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00161&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/medium/jm-2019-00161v_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/large/jm-2019-00161v_0009.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Efficacy of <b>15</b> in Calu-6 xenograft in rats. Tumor volumes (A) or percent body weight change from initial (B) treatment groups vs vehicle control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/large/jm-2019-00161v_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00161&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/medium/jm-2019-00161v_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/large/jm-2019-00161v_0010.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Analogues <b>3</b>–<b>9</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/large/jm-2019-00161v_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00161&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) O(CH<sub>2</sub>CH<sub>2</sub>Br)<sub>2</sub>, NaH, DMF, 0 °C to RT; (b) morpholine, EtOH, RT; (c) <i>N</i>-(6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-3-(trifluoromethyl)benzamide, PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub>, DME, 2 M Na<sub>2</sub>CO<sub>3</sub>, 120 °C; (d) R-OH, NaH, dioxane or DMF, 90 °C; (e) NaNO<sub>2</sub>, H<sub>2</sub>SO<sub>4</sub>, acetic acid, 0–25 °C, then water, 25 °C; (f) Cs<sub>2</sub>CO<sub>3</sub>, MeI, DMF; (g) morpholine, DMF, DIEA, 120 °C; (h) 4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline, PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub>, DME, 2 M Na<sub>2</sub>CO<sub>3</sub>, 120 °C; (i) aryl-CO<sub>2</sub>H, HATU, DIEA, DMF.</p></p></figure><figure data-id="sch2" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/medium/jm-2019-00161v_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/large/jm-2019-00161v_0011.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Analogues <b>12</b>–<b>15</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/large/jm-2019-00161v_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00161&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) morpholine, DIPEA, EtOH, RT or 55 °C; (b) <i>N</i>-(4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3-(trifluoromethyl)benzamide, PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub>, DME, 2 M Na<sub>2</sub>CO<sub>3</sub>, 120 °C; (c) mCPBA, DCM, RT; (d) R-OH, NaH, dioxane, NMP, 150 °C or R-NH<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, DMSO, 55 °C; (e) (2,6-difluoropyridin-4-yl)boronic acid, PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub>, DME, 2 M Na<sub>2</sub>CO<sub>3</sub>, 60 °C; (f) H<sub>2</sub>, 10% Pd/C, EtOH; (g) aryl-CO<sub>2</sub>H, HATU, DIPEA, DMF.</p></p></figure><figure data-id="sch3" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/medium/jm-2019-00161v_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/large/jm-2019-00161v_0012.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Optimized Synthesis of <b>15</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b00161/20200306/images/large/jm-2019-00161v_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00161&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (2,6-difluoropyridin-4-yl)boronic acid, Pd-XPhos precatalyst, 0.5 M K<sub>3</sub>PO<sub>4</sub>, THF, 35–60 °C, 64% yield; (b) morpholine, K<sub>2</sub>CO<sub>3</sub>, DMSO, 40 °C, quantitative yield; (c) 2-((tetrahydro-2<i>H</i>-pyran-2-yl)oxy)ethanol, NaH, dioxane, 60–70 °C, 72% yield; (d) 2-(trifluoromethyl)-isonicotinic acid, EDC·HCl, HOAT, DIPEA, DMF, RT, then 2 M aqueous HCl, RT, 94% yield.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i43">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71077" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71077" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 22 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ostrem, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sos, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span> <span> </span><span class="NLM_article-title">K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>503</i></span> (<span class="NLM_issue">7477</span>),  <span class="NLM_fpage">548</span>– <span class="NLM_lpage">551</span>, <span class="refDoi"> DOI: 10.1038/nature12796</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=10.1038%2Fnature12796" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=24256730" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVGqs7jO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=503&publication_year=2013&pages=548-551&issue=7477&author=J.+M.+Ostremauthor=U.+Petersauthor=M.+L.+Sosauthor=J.+A.+Wellsauthor=K.+M.+Shokat&title=K-Ras%28G12C%29+inhibitors+allosterically+control+GTP+affinity+and+effector+interactions&doi=10.1038%2Fnature12796"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions</span></div><div class="casAuthors">Ostrem, Jonathan M.; Peters, Ulf; Sos, Martin L.; Wells, James A.; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">503</span>
        (<span class="NLM_cas:issue">7477</span>),
    <span class="NLM_cas:pages">548-551</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Somatic mutations in the small GTPase K-Ras are the most common activating lesions found in human cancer, and are generally assocd. with poor response to std. therapies.  Efforts to target this oncogene directly have faced difficulties owing to its picomolar affinity for GTP/GDP and the absence of known allosteric regulatory sites.  Oncogenic mutations result in functional activation of Ras family proteins by impairing GTP hydrolysis.  With diminished regulation by GTPase activity, the nucleotide state of Ras becomes more dependent on relative nucleotide affinity and concn.  This gives GTP an advantage over GDP and increases the proportion of active GTP-bound Ras.  Here we report the development of small mols. that irreversibly bind to a common oncogenic mutant, K-Ras(G12C).  These compds. rely on the mutant cysteine for binding and therefore do not affect the wild-type protein.  Crystallog. studies reveal the formation of a new pocket that is not apparent in previous structures of Ras, beneath the effector binding switch-II region.  Binding of these inhibitors to K-Ras(G12C) disrupts both switch-I and switch-II, subverting the native nucleotide preference to favor GDP over GTP and impairing binding to Raf.  Our data provide structure-based validation of a new allosteric regulatory site on Ras that is targetable in a mutant-specific manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokkgcVXuBn_rVg90H21EOLACvtfcHk0lhHMQPgM3u7ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVGqs7jO&md5=27c1e7d8ef6b7e4b2919e9f00a073923</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnature12796&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature12796%26sid%3Dliteratum%253Aachs%26aulast%3DOstrem%26aufirst%3DJ.%2BM.%26aulast%3DPeters%26aufirst%3DU.%26aulast%3DSos%26aufirst%3DM.%2BL.%26aulast%3DWells%26aufirst%3DJ.%2BA.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DK-Ras%2528G12C%2529%2520inhibitors%2520allosterically%2520control%2520GTP%2520affinity%2520and%2520effector%2520interactions%26jtitle%3DNature%26date%3D2013%26volume%3D503%26issue%3D7477%26spage%3D548%26epage%3D551%26doi%3D10.1038%2Fnature12796" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lito, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, N.</span></span> <span> </span><span class="NLM_article-title">Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>351</i></span> (<span class="NLM_issue">6273</span>),  <span class="NLM_fpage">604</span>– <span class="NLM_lpage">608</span>, <span class="refDoi"> DOI: 10.1126/science.aad6204</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=10.1126%2Fscience.aad6204" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=26841430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhsl2jt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=351&publication_year=2016&pages=604-608&issue=6273&author=P.+Litoauthor=M.+Solomonauthor=L.+S.+Liauthor=R.+Hansenauthor=N.+Rosen&title=Allele-specific+inhibitors+inactivate+mutant+KRAS+G12C+by+a+trapping+mechanism&doi=10.1126%2Fscience.aad6204"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism</span></div><div class="casAuthors">Lito, Piro; Solomon, Martha; Li, Lian-Sheng; Hansen, Rasmus; Rosen, Neal</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">351</span>
        (<span class="NLM_cas:issue">6273</span>),
    <span class="NLM_cas:pages">604-608</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">It is thought that KRAS oncoproteins are constitutively active because their guanosine triphosphatase (GTPase) activity is disabled.  Consequently, drugs targeting the inactive or GDP-bound conformation are not expected to be effective.  We describe a mechanism that enables such drugs to inhibit KRASG12C signaling and cancer cell growth.  Inhibition requires intact GTPase activity and occurs because drug-bound KRASG12C is insusceptible to nucleotide exchange factors and thus trapped in its inactive state.  Indeed, mutants completely lacking GTPase activity and those promoting exchange reduced the potency of the drug.  Suppressing nucleotide exchange activity downstream of various tyrosine kinases enhanced KRASG12C inhibition, whereas its potentiation had the opposite effect.  These findings reveal that KRASG12C undergoes nucleotide cycling in cancer cells and provide a basis for developing effective therapies to treat KRASG12C-driven cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqK3AbqEZO6k7Vg90H21EOLACvtfcHk0lhdDH61HMiyjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhsl2jt78%253D&md5=22a47908ac0146822ecf19f5d0c952de</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1126%2Fscience.aad6204&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aad6204%26sid%3Dliteratum%253Aachs%26aulast%3DLito%26aufirst%3DP.%26aulast%3DSolomon%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DL.%2BS.%26aulast%3DHansen%26aufirst%3DR.%26aulast%3DRosen%26aufirst%3DN.%26atitle%3DAllele-specific%2520inhibitors%2520inactivate%2520mutant%2520KRAS%2520G12C%2520by%2520a%2520trapping%2520mechanism%26jtitle%3DScience%26date%3D2016%26volume%3D351%26issue%3D6273%26spage%3D604%26epage%3D608%26doi%3D10.1126%2Fscience.aad6204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patricelli, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janes, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kessler, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kucharski, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ely, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Firdaus, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babbar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span> <span> </span><span class="NLM_article-title">Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">316</span>– <span class="NLM_lpage">329</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-15-1105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=10.1158%2F2159-8290.CD-15-1105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=26739882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=1%3ACAS%3A528%3ADC%252BC28XktVyru7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=316-329&issue=3&author=M.+P.+Patricelliauthor=M.+R.+Janesauthor=L.+S.+Liauthor=R.+Hansenauthor=U.+Petersauthor=L.+V.+Kesslerauthor=Y.+Chenauthor=J.+M.+Kucharskiauthor=J.+Fengauthor=T.+Elyauthor=J.+H.+Chenauthor=S.+J.+Firdausauthor=A.+Babbarauthor=P.+Renauthor=Y.+Liu&title=Selective+inhibition+of+oncogenic+KRAS+output+with+small+molecules+targeting+the+inactive+state&doi=10.1158%2F2159-8290.CD-15-1105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State</span></div><div class="casAuthors">Patricelli, Matthew P.; Janes, Matthew R.; Li, Lian-Sheng; Hansen, Rasmus; Peters, Ulf; Kessler, Linda V.; Chen, Yuching; Kucharski, Jeff M.; Feng, Jun; Ely, Tess; Chen, Jeffrey H.; Firdaus, Sarah J.; Babbar, Anjali; Ren, Pingda; Liu, Yi</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">316-329</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">KRAS gain-of-function mutations occur in approx. 30% of all human cancers.  Despite more than 30 years of KRAS-focused research and development efforts, no targeted therapy has been discovered for cancers with KRAS mutations.  Here, we describe ARS-853, a selective, covalent inhibitor of KRASG12C that inhibits mutant KRAS-driven signaling by binding to the GDP-bound oncoprotein and preventing activation.  Based on the rates of engagement and inhibition obsd. for ARS-853, along with a mutant-specific mass spectrometry-based assay for assessing KRAS activation status, we show that the nucleotide state of KRASG12C is in a state of dynamic flux that can be modulated by upstream signaling factors.  These studies provide convincing evidence that the KRASG12C mutation generates a "hyperexcitable" rather than a "statically active" state and that targeting the inactive, GDP-bound form is a promising approach for generating novel anti-RAS therapeutics.  Significance: A cell-active, mutant-specific, covalent inhibitor of KRASG12C is described that targets the GDP-bound, inactive state and prevents subsequent activation.  Using this novel compd., we demonstrate that KRASG12C oncoprotein rapidly cycles bound nucleotide and responds to upstream signaling inputs to maintain a highly active state.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJJA-9IIHeN7Vg90H21EOLACvtfcHk0lhdDH61HMiyjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktVyru7s%253D&md5=41db2f02006e8f0be7a9bb47354addcd</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-15-1105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-15-1105%26sid%3Dliteratum%253Aachs%26aulast%3DPatricelli%26aufirst%3DM.%2BP.%26aulast%3DJanes%26aufirst%3DM.%2BR.%26aulast%3DLi%26aufirst%3DL.%2BS.%26aulast%3DHansen%26aufirst%3DR.%26aulast%3DPeters%26aufirst%3DU.%26aulast%3DKessler%26aufirst%3DL.%2BV.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DKucharski%26aufirst%3DJ.%2BM.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DEly%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DJ.%2BH.%26aulast%3DFirdaus%26aufirst%3DS.%2BJ.%26aulast%3DBabbar%26aufirst%3DA.%26aulast%3DRen%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DY.%26atitle%3DSelective%2520inhibition%2520of%2520oncogenic%2520KRAS%2520output%2520with%2520small%2520molecules%2520targeting%2520the%2520inactive%2520state%26jtitle%3DCancer%2520Discovery%26date%3D2016%26volume%3D6%26issue%3D3%26spage%3D316%26epage%3D329%26doi%3D10.1158%2F2159-8290.CD-15-1105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hatzivassiliou, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandhuber, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarado, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludlam, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stokoe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gloor, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vigers, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aliagas, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sideris, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoeflich, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaiswal, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seshagiri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koeppen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belvin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malek, S.</span></span> <span> </span><span class="NLM_article-title">RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>464</i></span> (<span class="NLM_issue">7287</span>),  <span class="NLM_fpage">431</span>– <span class="NLM_lpage">435</span>, <span class="refDoi"> DOI: 10.1038/nature08833</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=10.1038%2Fnature08833" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=20130576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVygtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=464&publication_year=2010&pages=431-435&issue=7287&author=G.+Hatzivassiliouauthor=K.+Songauthor=I.+Yenauthor=B.+J.+Brandhuberauthor=D.+J.+Andersonauthor=R.+Alvaradoauthor=M.+J.+Ludlamauthor=D.+Stokoeauthor=S.+L.+Gloorauthor=G.+Vigersauthor=T.+Moralesauthor=I.+Aliagasauthor=B.+Liuauthor=S.+Siderisauthor=K.+P.+Hoeflichauthor=B.+S.+Jaiswalauthor=S.+Seshagiriauthor=H.+Koeppenauthor=M.+Belvinauthor=L.+S.+Friedmanauthor=S.+Malek&title=RAF+inhibitors+prime+wild-type+RAF+to+activate+the+MAPK+pathway+and+enhance+growth&doi=10.1038%2Fnature08833"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth</span></div><div class="casAuthors">Hatzivassiliou, Georgia; Song, Kyung; Yen, Ivana; Brandhuber, Barbara J.; Anderson, Daniel J.; Alvarado, Ryan; Ludlam, Mary J. C.; Stokoe, David; Gloor, Susan L.; Vigers, Guy; Morales, Tony; Aliagas, Ignacio; Liu, Bonnie; Sideris, Steve; Hoeflich, Klaus P.; Jaiswal, Bijay S.; Seshagiri, Somasekar; Koeppen, Hartmut; Belvin, Marcia; Friedman, Lori S.; Malek, Shiva</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">464</span>
        (<span class="NLM_cas:issue">7287</span>),
    <span class="NLM_cas:pages">431-435</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Activating mutations in KRAS and BRAF are found in more than 30% of all human tumors and 40% of melanoma, resp., thus targeting this pathway could have broad therapeutic effects.  Small mol. ATP-competitive RAF kinase inhibitors have potent antitumor effects on mutant BRAF(V600E) tumors but, in contrast to mitogen-activated protein kinase kinase (MEK) inhibitors, are not potent against RAS mutant tumor models, despite RAF functioning as a key effector downstream of RAS and upstream of MEK.  Here we show that ATP-competitive RAF inhibitors have two opposing mechanisms of action depending on the cellular context.  In BRAF(V600E) tumors, RAF inhibitors effectively block the mitogen-activated protein kinase (MAPK) signalling pathway and decrease tumor growth.  Notably, in KRAS mutant and RAS/RAF wild-type tumors, RAF inhibitors activate the RAF-MEK-ERK pathway in a RAS-dependent manner, thus enhancing tumor growth in some xenograft models.  Inhibitor binding activates wild-type RAF isoforms by inducing dimerization, membrane localization and interaction with RAS-GTP.  These events occur independently of kinase inhibition and are, instead, linked to direct conformational effects of inhibitors on the RAF kinase domain.  On the basis of these findings, we demonstrate that ATP-competitive kinase inhibitors can have opposing functions as inhibitors or activators of signalling pathways, depending on the cellular context.  Furthermore, this work provides new insights into the therapeutic use of ATP-competitive RAF inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGounpcMETzVoLVg90H21EOLACvtfcHk0lji2RoR3cSj2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVygtb8%253D&md5=eb48bdf352ee9c9e182e63e38fd820a5</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnature08833&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08833%26sid%3Dliteratum%253Aachs%26aulast%3DHatzivassiliou%26aufirst%3DG.%26aulast%3DSong%26aufirst%3DK.%26aulast%3DYen%26aufirst%3DI.%26aulast%3DBrandhuber%26aufirst%3DB.%2BJ.%26aulast%3DAnderson%26aufirst%3DD.%2BJ.%26aulast%3DAlvarado%26aufirst%3DR.%26aulast%3DLudlam%26aufirst%3DM.%2BJ.%26aulast%3DStokoe%26aufirst%3DD.%26aulast%3DGloor%26aufirst%3DS.%2BL.%26aulast%3DVigers%26aufirst%3DG.%26aulast%3DMorales%26aufirst%3DT.%26aulast%3DAliagas%26aufirst%3DI.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DHoeflich%26aufirst%3DK.%2BP.%26aulast%3DJaiswal%26aufirst%3DB.%2BS.%26aulast%3DSeshagiri%26aufirst%3DS.%26aulast%3DKoeppen%26aufirst%3DH.%26aulast%3DBelvin%26aufirst%3DM.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DMalek%26aufirst%3DS.%26atitle%3DRAF%2520inhibitors%2520prime%2520wild-type%2520RAF%2520to%2520activate%2520the%2520MAPK%2520pathway%2520and%2520enhance%2520growth%26jtitle%3DNature%26date%3D2010%26volume%3D464%26issue%3D7287%26spage%3D431%26epage%3D435%26doi%3D10.1038%2Fnature08833" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heidorn, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milagre, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittaker, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nourry, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">NiculescuDuvas, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhomen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussain, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reis-Filho, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springer, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pritchard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marais, R.</span></span> <span> </span><span class="NLM_article-title">Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>140</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">209</span>– <span class="NLM_lpage">221</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2009.12.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=10.1016%2Fj.cell.2009.12.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=20141835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvVWitL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2010&pages=209-221&issue=2&author=S.+J.+Heidornauthor=C.+Milagreauthor=S.+Whittakerauthor=A.+Nourryauthor=I.+NiculescuDuvasauthor=N.+Dhomenauthor=J.+Hussainauthor=J.+S.+Reis-Filhoauthor=C.+J.+Springerauthor=C.+Pritchardauthor=R.+Marais&title=Kinase-dead+BRAF+and+oncogenic+RAS+cooperate+to+drive+tumor+progression+through+CRAF&doi=10.1016%2Fj.cell.2009.12.040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF</span></div><div class="casAuthors">Heidorn, Sonja J.; Milagre, Carla; Whittaker, Steven; Nourry, Arnaud; Niculescu-Duvas, Ion; Dhomen, Nathalie; Hussain, Jahan; Reis-Filho, Jorge S.; Springer, Caroline J.; Pritchard, Catrin; Marais, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">209-221</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">We describe a mechanism of tumorigenesis mediated by kinase-dead BRAF in the presence of oncogenic RAS.  We show that drugs that selectively inhibit BRAF drive RAS-dependent BRAF binding to CRAF, CRAF activation, and MEK-ERK signaling.  This does not occur when oncogenic BRAF is inhibited, demonstrating that BRAF inhibition per se does not drive pathway activation; it only occurs when BRAF is inhibited in the presence of oncogenic RAS.  Kinase-dead BRAF mimics the effects of the BRAF-selective drugs and kinase-dead Braf and oncogenic Ras cooperate to induce melanoma in mice.  Our data reveal another paradigm of BRAF-mediated signaling that promotes tumor progression.  They highlight the importance of understanding pathway signaling in clin. practice and of genotyping tumors prior to administering BRAF-selective drugs, to identify patients who are likely to respond and also to identify patients who may experience adverse effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMSb6ckHpR07Vg90H21EOLACvtfcHk0lji2RoR3cSj2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvVWitL0%253D&md5=80af840cb978f5956b3d998b185115f4</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2009.12.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2009.12.040%26sid%3Dliteratum%253Aachs%26aulast%3DHeidorn%26aufirst%3DS.%2BJ.%26aulast%3DMilagre%26aufirst%3DC.%26aulast%3DWhittaker%26aufirst%3DS.%26aulast%3DNourry%26aufirst%3DA.%26aulast%3DNiculescuDuvas%26aufirst%3DI.%26aulast%3DDhomen%26aufirst%3DN.%26aulast%3DHussain%26aufirst%3DJ.%26aulast%3DReis-Filho%26aufirst%3DJ.%2BS.%26aulast%3DSpringer%26aufirst%3DC.%2BJ.%26aulast%3DPritchard%26aufirst%3DC.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DKinase-dead%2520BRAF%2520and%2520oncogenic%2520RAS%2520cooperate%2520to%2520drive%2520tumor%2520progression%2520through%2520CRAF%26jtitle%3DCell%26date%3D2010%26volume%3D140%26issue%3D2%26spage%3D209%26epage%3D221%26doi%3D10.1016%2Fj.cell.2009.12.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poulikakos, P. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen</span></span> <span> </span><span class="NLM_article-title">NRAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>464</i></span>,  <span class="NLM_fpage">427</span>– <span class="NLM_lpage">430</span>, <span class="refDoi"> DOI: 10.1038/nature08902</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=10.1038%2Fnature08902" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=20179705" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjsFWjsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=464&publication_year=2010&pages=427-430&author=P.+I.+Poulikakosauthor=C.+Zhangauthor=G.+Bollagauthor=K.+M.+Shokatauthor=+Rosen&title=NRAF+inhibitors+transactivate+RAF+dimers+and+ERK+signaling+in+cells+with+wild-type+BRAF&doi=10.1038%2Fnature08902"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF</span></div><div class="casAuthors">Poulikakos, Poulikos I.; Zhang, Chao; Bollag, Gideon; Shokat, Kevan M.; Rosen, Neal</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">464</span>
        (<span class="NLM_cas:issue">7287</span>),
    <span class="NLM_cas:pages">427-430</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Tumors with mutant BRAF are dependent on the RAF-MEK-ERK signaling pathway for their growth.  We found that ATP-competitive RAF inhibitors inhibit ERK signaling in cells with mutant BRAF, but unexpectedly enhance signaling in cells with wild-type BRAF.  Here we demonstrate the mechanistic basis for these findings.  We used chem. genetic methods to show that drug-mediated transactivation of RAF dimers is responsible for paradoxical activation of the enzyme by inhibitors.  Induction of ERK signaling requires direct binding of the drug to the ATP-binding site of one kinase of the dimer and is dependent on RAS activity.  Drug binding to one member of RAF homodimers (CRAF-CRAF) or heterodimers (CRAF-BRAF) inhibits one protomer, but results in transactivation of the drug-free protomer.  In BRAF(V600E) tumors, RAS is not activated, thus transactivation is minimal and ERK signaling is inhibited in cells exposed to RAF inhibitors.  These results indicate that RAF inhibitors will be effective in tumors in which BRAF is mutated.  Furthermore, because RAF inhibitors do not inhibit ERK signaling in other cells, the model predicts that they would have a higher therapeutic index and greater antitumor activity than mitogen-activated protein kinase (MEK) inhibitors, but could also cause toxicity due to MEK/ERK activation.  These predictions have been borne out in a recent clin. trial of the RAF inhibitor PLX4032 (refs 4, 5).  The model indicates that promotion of RAF dimerization by elevation of wild-type RAF expression or RAS activity could lead to drug resistance in mutant BRAF tumors.  In agreement with this prediction, RAF inhibitors do not inhibit ERK signaling in cells that coexpress BRAF(V600E) and mutant RAS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMlm9feupyNrVg90H21EOLACvtfcHk0lji2RoR3cSj2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjsFWjsrs%253D&md5=8323a558886ccbb8f7d85b22b9bfbc15</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnature08902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08902%26sid%3Dliteratum%253Aachs%26aulast%3DPoulikakos%26aufirst%3DP.%2BI.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DRosen%26atitle%3DNRAF%2520inhibitors%2520transactivate%2520RAF%2520dimers%2520and%2520ERK%2520signaling%2520in%2520cells%2520with%2520wild-type%2520BRAF%26jtitle%3DNature%26date%3D2010%26volume%3D464%26spage%3D427%26epage%3D430%26doi%3D10.1038%2Fnature08902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hauschild, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grob, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demidov, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jouary, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutzmer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millward, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutkowski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blank, C. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, W. H.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaempgen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martín-Algarra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karaszewska, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mauch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiarion-Sileni, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haney, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirakhur, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guckert, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodman, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, P. B.</span></span> <span> </span><span class="NLM_article-title">Dabrafenib in BRAF-mutated metastatic melanoma:a multicentre, open-label, phase 3 randomised controlled trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>380</i></span>,  <span class="NLM_fpage">358</span>– <span class="NLM_lpage">365</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(12)60868-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=10.1016%2FS0140-6736%2812%2960868-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=22735384" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=1%3ACAS%3A528%3ADC%252BC38Xpt1SgtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=380&publication_year=2012&pages=358-365&author=A.+Hauschildauthor=J.+Grobauthor=L.+V.+Demidovauthor=T.+Jouaryauthor=R.+Gutzmerauthor=M.+Millwardauthor=P.+Rutkowskiauthor=C.+U.+Blankauthor=W.+H.+Millerauthor=E.+Kaempgenauthor=S.+Mart%C3%ADn-Algarraauthor=B.+Karaszewskaauthor=C.+Mauchauthor=V.+Chiarion-Sileniauthor=A.+Martinauthor=S.+Swannauthor=P.+Haneyauthor=B.+Mirakhurauthor=M.+E.+Guckertauthor=V.+Goodmanauthor=P.+B.+Chapman&title=Dabrafenib+in+BRAF-mutated+metastatic+melanoma%3Aa+multicentre%2C+open-label%2C+phase+3+randomised+controlled+trial&doi=10.1016%2FS0140-6736%2812%2960868-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial</span></div><div class="casAuthors">Hauschild, Axel; Grob, Jean-Jacques; Demidov, Lev V.; Jouary, Thomas; Gutzmer, Ralf; Millward, Michael; Rutkowski, Piotr; Blank, Christian U.; Miller, Wilson H.; Kaempgen, Eckhart; Martin-Algarra, Salvador; Karaszewska, Boguslawa; Mauch, Cornelia; Chiarion-Sileni, Vanna; Martin, Anne-Marie; Swann, Suzanne; Haney, Patricia; Mirakhur, Beloo; Guckert, Mary E.; Goodman, Vicki; Chapman, Paul B.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">380</span>
        (<span class="NLM_cas:issue">9839</span>),
    <span class="NLM_cas:pages">358-365</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Dabrafenib, an inhibitor of mutated BRAF, has clin. activity with a manageable safety profile in studies of phase 1 and 2 in patients with BRAFV600-mutated metastatic melanoma.  We studied the efficacy of dabrafenib in patients with BRAFV600E-mutated metastatic melanoma.We enrolled patients in this open-label phase 3 trial between Dec 23, 2010, and Sept 1, 2011.  This report is based on a data cutoff date of Dec 19, 2011.  Patients aged 18 years or older with previously untreated, stage IV or unresectable stage III BRAFV600E mutation-pos. melanoma were randomly assigned (3:1) to receive dabrafenib (150 mg twice daily, orally) or dacarbazine (1000 mg/m2 i.v. every 3 wk).  Patients were stratified according to American Joint Committee on Cancer stage (unresectable III+IVM1a+IVM1b vs IVM1c).  The primary endpoint was investigator-assessed progression-free survival and was analyzed by intention to treat; safety was assessed per protocol.  This study is registered with ClinicalTrials.gov, no. NCT01227889.Of the 733 patients screened, 250 were randomly assigned to receive either dabrafenib (187 patients) or dacarbazine (63 patients).  Median progression-free survival was 5·1 mo for dabrafenib and 2·7 mo for dacarbazine, with a hazard ratio (HR) of 0·30 (95% CI 0·18-0·51; p<0·0001).  At data cutoff, 107 (57%) patients in the dabrafenib group and 14 (22%) in the dacarbazine group remained on randomized treatment.  Treatment-related adverse events (grade 2 or higher) occurred in 100 (53%) of the 187 patients who received dabrafenib and in 26 (44%) of the 59 patients who received dacarbazine.  The most common adverse events with dabrafenib were skin-related toxic effects, fever, fatigue, arthralgia, and headache.  The most common adverse events with dacarbazine were nausea, vomiting, neutropenia, fatigue, and asthenia.  Grade 3-4 adverse events were uncommon in both groups.Dabrafenib significantly improved progression-free survival compared with dacarbazine.GlaxoSmithKline.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEDYPJULE5c7Vg90H21EOLACvtfcHk0lgMq1_Gs0XqbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xpt1SgtLg%253D&md5=5e8699780f47bd37e075d39636e0d809</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2812%2960868-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252812%252960868-X%26sid%3Dliteratum%253Aachs%26aulast%3DHauschild%26aufirst%3DA.%26aulast%3DGrob%26aufirst%3DJ.%26aulast%3DDemidov%26aufirst%3DL.%2BV.%26aulast%3DJouary%26aufirst%3DT.%26aulast%3DGutzmer%26aufirst%3DR.%26aulast%3DMillward%26aufirst%3DM.%26aulast%3DRutkowski%26aufirst%3DP.%26aulast%3DBlank%26aufirst%3DC.%2BU.%26aulast%3DMiller%26aufirst%3DW.%2BH.%26aulast%3DKaempgen%26aufirst%3DE.%26aulast%3DMart%25C3%25ADn-Algarra%26aufirst%3DS.%26aulast%3DKaraszewska%26aufirst%3DB.%26aulast%3DMauch%26aufirst%3DC.%26aulast%3DChiarion-Sileni%26aufirst%3DV.%26aulast%3DMartin%26aufirst%3DA.%26aulast%3DSwann%26aufirst%3DS.%26aulast%3DHaney%26aufirst%3DP.%26aulast%3DMirakhur%26aufirst%3DB.%26aulast%3DGuckert%26aufirst%3DM.%2BE.%26aulast%3DGoodman%26aufirst%3DV.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26atitle%3DDabrafenib%2520in%2520BRAF-mutated%2520metastatic%2520melanoma%253Aa%2520multicentre%252C%2520open-label%252C%2520phase%25203%2520randomised%2520controlled%2520trial%26jtitle%3DLancet%26date%3D2012%26volume%3D380%26spage%3D358%26epage%3D365%26doi%3D10.1016%2FS0140-6736%2812%2960868-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karoulia, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amaia Lujambio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavathiotis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulikakos, P. I.</span></span> <span> </span><span class="NLM_article-title">An Integrated model of RAF Inhibitor action predicts inhibitor activity against oncogenic BRAF signaling</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">485</span>– <span class="NLM_lpage">498</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2016.06.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=10.1016%2Fj.ccell.2016.06.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=27523909" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtleis77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=485-498&author=Z.+Karouliaauthor=Y.+Yang+Wuauthor=T.+A.+Ahmedauthor=A.+Amaia+Lujambioauthor=E.+Gavathiotisauthor=P.+I.+Poulikakos&title=An+Integrated+model+of+RAF+Inhibitor+action+predicts+inhibitor+activity+against+oncogenic+BRAF+signaling&doi=10.1016%2Fj.ccell.2016.06.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling</span></div><div class="casAuthors">Karoulia, Zoi; Wu, Yang; Ahmed, Tamer A.; Xin, Qisheng; Bollard, Julien; Krepler, Clemens; Wu, Xuewei; Zhang, Chao; Bollag, Gideon; Herlyn, Meenhard; Fagin, James A.; Lujambio, Amaia; Gavathiotis, Evripidis; Poulikakos, Poulikos I.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">485-498</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The complex biochem. effects of RAF inhibitors account for both the effectiveness and mechanisms of resistance to these drugs, but a unified mechanistic model has been lacking.  Here we show that RAF inhibitors exert their effects via two distinct allosteric mechanisms.  Drug resistance due to dimerization is detd. by the position of the αC helix stabilized by inhibitor, whereas inhibitor-induced RAF priming and dimerization are the result of inhibitor-induced formation of the RAF/RAS-GTP complex.  The biochem. effect of RAF inhibitor in cells is the combined outcome of the two mechanisms.  Therapeutic strategies including αC-helix-IN inhibitors are more effective in multiple mutant BRAF-driven tumor models, including colorectal and thyroid BRAFV600E cancers, in which first-generation RAF inhibitors have been ineffective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9VLWvQ7ojJrVg90H21EOLACvtfcHk0lgMq1_Gs0XqbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtleis77I&md5=197711577048b889ea1dac8c87049a01</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2016.06.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2016.06.024%26sid%3Dliteratum%253Aachs%26aulast%3DKaroulia%26aufirst%3DZ.%26aulast%3DYang%2BWu%26aufirst%3DY.%26aulast%3DAhmed%26aufirst%3DT.%2BA.%26aulast%3DAmaia%2BLujambio%26aufirst%3DA.%26aulast%3DGavathiotis%26aufirst%3DE.%26aulast%3DPoulikakos%26aufirst%3DP.%2BI.%26atitle%3DAn%2520Integrated%2520model%2520of%2520RAF%2520Inhibitor%2520action%2520predicts%2520inhibitor%2520activity%2520against%2520oncogenic%2520BRAF%2520signaling%26jtitle%3DCancer%2520Cell%26date%3D2016%26volume%3D30%26spage%3D485%26epage%3D498%26doi%3D10.1016%2Fj.ccell.2016.06.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peng, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogeti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutkoski, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wise, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Horn, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yadav, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchanan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mochalkin, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kays, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donoho, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walgren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conti, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plowman, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Starling, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flynn, D. L.</span></span> <span> </span><span class="NLM_article-title">Inhibition of RAF isoforms and active dimers by LY3009120 leads to anti-tumor activities in RAS or BRAF mutant cancers</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">384</span>– <span class="NLM_lpage">398</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2015.08.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=10.1016%2Fj.ccell.2015.08.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=26343583" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVKgsr7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2015&pages=384-398&issue=3&author=S.+B.+Pengauthor=J.+R.+Henryauthor=M.+D.+Kaufmanauthor=W.+P.+Luauthor=B.+D.+Smithauthor=S.+Vogetiauthor=T.+J.+Rutkoskiauthor=S.+Wiseauthor=L.+Chunauthor=+Zhangauthor=R.+D.+Van+Hornauthor=T.+Yinauthor=X.+Zhangauthor=V.+Yadavauthor=S.+H.+Chenauthor=X.+Gongauthor=X.+Maauthor=Y.+Websterauthor=S.+Buchananauthor=I.+Mochalkinauthor=L.+Huberauthor=L.+Kaysauthor=G.+P.+Donohoauthor=J.+Walgrenauthor=D.+McCannauthor=P.+Patelauthor=I.+Contiauthor=G.+D.+Plowmanauthor=J.+J.+Starlingauthor=D.+L.+Flynn&title=Inhibition+of+RAF+isoforms+and+active+dimers+by+LY3009120+leads+to+anti-tumor+activities+in+RAS+or+BRAF+mutant+cancers&doi=10.1016%2Fj.ccell.2015.08.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers</span></div><div class="casAuthors">Peng, Sheng-Bin; Henry, James R.; Kaufman, Michael D.; Lu, Wei-Ping; Smith, Bryan D.; Vogeti, Subha; Rutloski, Thomas J.; Wise, Scott; Chun, Lawrence; Zhang, Youyan; Van Horn, Robert D.; Yin, Tinggui; Zhang, Xiaoyi; Yadav, Vipin; Chen, Shih-Hsun; Gong, Xueqian; Ma, Xiwen; Webster, Yue; Buchanan, Sean; Mochalkin, Igor; Huber, Lysiane; Kays, Lisa; Donoho, Gregory P.; Walgren, Jennie; McCann, Denis; Patel, Phenil; Conti, Ilaria; Plowman, Gregory D.; Starling, James J.; Flynn, Daniel L.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">384-398</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">LY3009120 is a pan-RAF and RAF dimer inhibitor that inhibits all RAF isoforms and occupies both protomers in RAF dimers.  Biochem. and cellular analyses revealed that LY3009120 inhibits ARAF, BRAF, and CRAF isoforms with similar affinity, while vemurafenib or dabrafenib have little or modest CRAF activity compared to their BRAF activities.  LY3009120 induces BRAF-CRAF dimerization but inhibits the phosphorylation of downstream MEK and ERK, suggesting that it effectively inhibits the kinase activity of BRAF-CRAF heterodimers.  Further analyses demonstrated that LY3009120 also inhibits various forms of RAF dimers including BRAF or CRAF homodimers.  Due to these unique properties, LY3009120 demonstrates minimal paradoxical activation, inhibits MEK1/2 phosphorylation, and exhibits anti-tumor activities across multiple models carrying KRAS, NRAS, or BRAF mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJMiHK-Gub5bVg90H21EOLACvtfcHk0lihQz5dbMI9qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVKgsr7O&md5=c167caa6e5a9b47a6ec1ee2ab6d9e0d1</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2015.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2015.08.002%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DS.%2BB.%26aulast%3DHenry%26aufirst%3DJ.%2BR.%26aulast%3DKaufman%26aufirst%3DM.%2BD.%26aulast%3DLu%26aufirst%3DW.%2BP.%26aulast%3DSmith%26aufirst%3DB.%2BD.%26aulast%3DVogeti%26aufirst%3DS.%26aulast%3DRutkoski%26aufirst%3DT.%2BJ.%26aulast%3DWise%26aufirst%3DS.%26aulast%3DChun%26aufirst%3DL.%26aulast%3DZhang%26aulast%3DVan%2BHorn%26aufirst%3DR.%2BD.%26aulast%3DYin%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DYadav%26aufirst%3DV.%26aulast%3DChen%26aufirst%3DS.%2BH.%26aulast%3DGong%26aufirst%3DX.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DWebster%26aufirst%3DY.%26aulast%3DBuchanan%26aufirst%3DS.%26aulast%3DMochalkin%26aufirst%3DI.%26aulast%3DHuber%26aufirst%3DL.%26aulast%3DKays%26aufirst%3DL.%26aulast%3DDonoho%26aufirst%3DG.%2BP.%26aulast%3DWalgren%26aufirst%3DJ.%26aulast%3DMcCann%26aufirst%3DD.%26aulast%3DPatel%26aufirst%3DP.%26aulast%3DConti%26aufirst%3DI.%26aulast%3DPlowman%26aufirst%3DG.%2BD.%26aulast%3DStarling%26aufirst%3DJ.%2BJ.%26aulast%3DFlynn%26aufirst%3DD.%2BL.%26atitle%3DInhibition%2520of%2520RAF%2520isoforms%2520and%2520active%2520dimers%2520by%2520LY3009120%2520leads%2520to%2520anti-tumor%2520activities%2520in%2520RAS%2520or%2520BRAF%2520mutant%2520cancers%26jtitle%3DCancer%2520Cell%26date%3D2015%26volume%3D28%26issue%3D3%26spage%3D384%26epage%3D398%26doi%3D10.1016%2Fj.ccell.2015.08.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nishiguchi, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rico, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aversa, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taft, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barsanti, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appleton, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tandeske, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dix, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tellew, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathews Griner, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, V. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Abbema, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merritt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gampa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haling, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaziri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hekmat-Nejad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansen, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polyakov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sethuraman, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amiri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lees, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dillon, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramurthy, S.</span></span> <span> </span><span class="NLM_article-title">Design and discovery of <i>N</i>-(2- methyl-5′-morpholino-6′-((tetrahydro-2<i>H</i>-pyran-4-yl)oxy)-[3,3′-bipyridin]-5yl)-3-(trifluoromethyl) benzamide (RAF709): A potent, selective and efficacious RAF inhibitor targeting RAS mutant cancers</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">4869</span>– <span class="NLM_lpage">4881</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01862</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01862" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=1%3ACAS%3A528%3ADC%252BC2sXos1Sgt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=4869-4881&issue=12&author=G.+A.+Nishiguchiauthor=A.+Ricoauthor=H.+Tannerauthor=R.+J.+Aversaauthor=B.+R.+Taftauthor=S.+Subramanianauthor=L.+Settiauthor=M.+T.+Burgerauthor=L.+Wanauthor=V.+Tamezauthor=A.+Smithauthor=Y.+Louauthor=P.+A.+Barsantiauthor=B.+A.+Appletonauthor=M.+Mamoauthor=L.+Tandeskeauthor=I.+Dixauthor=J.+E.+Tellewauthor=S.+Huangauthor=L.+A.+Mathews+Grinerauthor=V.+G.+Cookeauthor=A.+Van+Abbemaauthor=H.+Merrittauthor=S.+Maauthor=K.+Gampaauthor=F.+Fengauthor=J.+Yuanauthor=Y.+Wangauthor=J.+R.+Halingauthor=S.+Vaziriauthor=M.+Hekmat-Nejadauthor=J.+M.+Jansenauthor=V.+Polyakovauthor=R.+Zangauthor=V.+Sethuramanauthor=P.+Amiriauthor=M.+Singhauthor=E.+Leesauthor=W.+Shaoauthor=D.+D.+Stuartauthor=M.+P.+Dillonauthor=S.+Ramurthy&title=Design+and+discovery+of+N-%282-+methyl-5%E2%80%B2-morpholino-6%E2%80%B2-%28%28tetrahydro-2H-pyran-4-yl%29oxy%29-%5B3%2C3%E2%80%B2-bipyridin%5D-5yl%29-3-%28trifluoromethyl%29+benzamide+%28RAF709%29%3A+A+potent%2C+selective+and+efficacious+RAF+inhibitor+targeting+RAS+mutant+cancers&doi=10.1021%2Facs.jmedchem.6b01862"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Discovery of N-(2-Methyl-5'-morpholino-6'-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3'-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant Cancers</span></div><div class="casAuthors">Nishiguchi, Gisele A.; Rico, Alice; Tanner, Huw; Aversa, Robert J.; Taft, Benjamin R.; Subramanian, Sharadha; Setti, Lina; Burger, Matthew T.; Wan, Lifeng; Tamez, Victoriano; Smith, Aaron; Lou, Yan; Barsanti, Paul A.; Appleton, Brent A.; Mamo, Mulugeta; Tandeske, Laura; Dix, Ina; Tellew, John E.; Huang, Shenlin; Mathews Griner, Lesley A.; Cooke, Vesselina G.; Van Abbema, Anne; Merritt, Hanne; Ma, Sylvia; Gampa, Kalyani; Feng, Fei; Yuan, Jing; Wang, Yingyun; Haling, Jacob R.; Vaziri, Sepideh; Hekmat-Nejad, Mohammad; Jansen, Johanna M.; Polyakov, Valery; Zang, Richard; Sethuraman, Vijay; Amiri, Payman; Singh, Mallika; Lees, Emma; Shao, Wenlin; Stuart, Darrin D.; Dillon, Michael P.; Ramurthy, Savithri</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4869-4881</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">RAS oncogenes have been implicated in >30% of human cancers, all representing high unmet medical need.  The exquisite dependency on CRAF kinase in KRAS mutant tumors has been established in genetically engineered mouse models and human tumor cells.  To date, many small mol. approaches are under investigation to target CRAF, yet kinase-selective and cellular potent inhibitors remain challenging to identify.  Herein, we describe 14 (RAF709) [Aversa, Biaryl amide compds. as kinase inhibitors and their prepn. WO 2014151616, 2014], a selective B/C RAF inhibitor, which was developed through a hypothesis-driven approach focusing on drug-like properties.  A key challenge encountered in the medicinal chem. campaign was maintaining a balance between good soly. and potent cellular activity (suppression of pMEK and proliferation) in KRAS mutant tumor cell lines.  We investigated the small mol. crystal structure of lead mol. 7 and hypothesized that disruption of the crystal packing would improve soly., which led to a change from N-methylpyridone to a tetrahydropyranyl oxy-pyridine deriv. 14 proved to be sol., kinase selective, and efficacious in a KRAS mutant xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmcZ2Rl42uP7Vg90H21EOLACvtfcHk0lihQz5dbMI9qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXos1Sgt7s%253D&md5=ed35a93d83b721a8e639a992bee43f04</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01862%26sid%3Dliteratum%253Aachs%26aulast%3DNishiguchi%26aufirst%3DG.%2BA.%26aulast%3DRico%26aufirst%3DA.%26aulast%3DTanner%26aufirst%3DH.%26aulast%3DAversa%26aufirst%3DR.%2BJ.%26aulast%3DTaft%26aufirst%3DB.%2BR.%26aulast%3DSubramanian%26aufirst%3DS.%26aulast%3DSetti%26aufirst%3DL.%26aulast%3DBurger%26aufirst%3DM.%2BT.%26aulast%3DWan%26aufirst%3DL.%26aulast%3DTamez%26aufirst%3DV.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DLou%26aufirst%3DY.%26aulast%3DBarsanti%26aufirst%3DP.%2BA.%26aulast%3DAppleton%26aufirst%3DB.%2BA.%26aulast%3DMamo%26aufirst%3DM.%26aulast%3DTandeske%26aufirst%3DL.%26aulast%3DDix%26aufirst%3DI.%26aulast%3DTellew%26aufirst%3DJ.%2BE.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DMathews%2BGriner%26aufirst%3DL.%2BA.%26aulast%3DCooke%26aufirst%3DV.%2BG.%26aulast%3DVan%2BAbbema%26aufirst%3DA.%26aulast%3DMerritt%26aufirst%3DH.%26aulast%3DMa%26aufirst%3DS.%26aulast%3DGampa%26aufirst%3DK.%26aulast%3DFeng%26aufirst%3DF.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DHaling%26aufirst%3DJ.%2BR.%26aulast%3DVaziri%26aufirst%3DS.%26aulast%3DHekmat-Nejad%26aufirst%3DM.%26aulast%3DJansen%26aufirst%3DJ.%2BM.%26aulast%3DPolyakov%26aufirst%3DV.%26aulast%3DZang%26aufirst%3DR.%26aulast%3DSethuraman%26aufirst%3DV.%26aulast%3DAmiri%26aufirst%3DP.%26aulast%3DSingh%26aufirst%3DM.%26aulast%3DLees%26aufirst%3DE.%26aulast%3DShao%26aufirst%3DW.%26aulast%3DStuart%26aufirst%3DD.%2BD.%26aulast%3DDillon%26aufirst%3DM.%2BP.%26aulast%3DRamurthy%26aufirst%3DS.%26atitle%3DDesign%2520and%2520discovery%2520of%2520N-%25282-%2520methyl-5%25E2%2580%25B2-morpholino-6%25E2%2580%25B2-%2528%2528tetrahydro-2H-pyran-4-yl%2529oxy%2529-%255B3%252C3%25E2%2580%25B2-bipyridin%255D-5yl%2529-3-%2528trifluoromethyl%2529%2520benzamide%2520%2528RAF709%2529%253A%2520A%2520potent%252C%2520selective%2520and%2520efficacious%2520RAF%2520inhibitor%2520targeting%2520RAS%2520mutant%2520cancers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D12%26spage%3D4869%26epage%3D4881%26doi%3D10.1021%2Facs.jmedchem.6b01862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">11</a></strong><div class="note"><p class="first last">Molecular structure and synthesis of compound <b>10</b>, X-ray co-crystal structure data table of <b>10</b> and <b>15</b>, and kinase profile of <b>15</b> are given in the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aversa, R. J.</span>; <span class="NLM_string-name">Barsanti, P. A.</span>; <span class="NLM_string-name">Burger, M.</span>; <span class="NLM_string-name">Dillon, M. P.</span>; <span class="NLM_string-name">Dipsea, A.</span>; <span class="NLM_string-name">Hu, C.</span>; <span class="NLM_string-name">Lou, Y.</span>; <span class="NLM_string-name">Nishiguchi, G.</span>; <span class="NLM_string-name">Pan, Y.</span>; <span class="NLM_string-name">Polyakov, V.</span>; <span class="NLM_string-name">Ramurthy, S.</span>; <span class="NLM_string-name">Rico, A.</span>; <span class="NLM_string-name">Setti, L.</span>; <span class="NLM_string-name">Smith, A.</span>; <span class="NLM_string-name">Subramanian, S.</span>; <span class="NLM_string-name">Taft, B.</span>; <span class="NLM_string-name">Tanner, H.</span>; <span class="NLM_string-name">Wan, L.</span>; <span class="NLM_string-name">Yusuff, N.</span></span> <span> </span><span class="NLM_article-title">Biaryl Amide Compounds as Kinase Inhibitors and Their Preparation</span>. <span class="NLM_patent">WO 2014151616</span>, Sep 25, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=R.+J.+Aversa&author=P.+A.+Barsanti&author=M.+Burger&author=M.+P.+Dillon&author=A.+Dipsea&author=C.+Hu&author=Y.+Lou&author=G.+Nishiguchi&author=Y.+Pan&author=V.+Polyakov&author=S.+Ramurthy&author=A.+Rico&author=L.+Setti&author=A.+Smith&author=S.+Subramanian&author=B.+Taft&author=H.+Tanner&author=L.+Wan&author=N.+Yusuff&title=Biaryl+Amide+Compounds+as+Kinase+Inhibitors+and+Their+Preparation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAversa%26aufirst%3DR.%2BJ.%26atitle%3DBiaryl%2520Amide%2520Compounds%2520as%2520Kinase%2520Inhibitors%2520and%2520Their%2520Preparation%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerlin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trunzer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faller, B.</span></span> <span> </span><span class="NLM_article-title">CYP3A time-dependent inhibition risk assessment validated with 400 reference drugs</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>39</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1039</span>– <span class="NLM_lpage">1046</span>, <span class="refDoi"> DOI: 10.1124/dmd.110.037911</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=10.1124%2Fdmd.110.037911" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=21383203" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmvFGns7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=1039-1046&issue=6&author=A.+Zimmerlinauthor=M.+Trunzerauthor=B.+Faller&title=CYP3A+time-dependent+inhibition+risk+assessment+validated+with+400+reference+drugs&doi=10.1124%2Fdmd.110.037911"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">CYP3A time-dependent inhibition risk assessment validated with 400 reference drugs</span></div><div class="casAuthors">Zimmerlin, Alfred; Trunzer, Markus; Faller, Bernard</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1039-1046</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Although reversible CYP3A inhibition testing is well established for predicting the drug-drug interaction potential of clin. candidates, time-dependent inhibition (TDI) has become the focus of drug designers only recently.  Failure of several late-stage clin. candidates has been attributed to TDI, and this mechanism is also suspected to play a role in liver toxicities often obsd. in preclin. species.  Measurement of enzyme inactivation rates (kinact and KI) is tech. challenging, and a great deal of variability can be found in the literature.  In this article, we have evaluated the TDI potential for 400 registered drugs using a high-throughput assay format based on detn. of the inactivation rate (kobs) at a single concn. of test compd. (10 μM).  The advantages of this new assay format are highlighted by comparison with data generated using the IC50 shift assay, a current std. approach for preliminary assessment of TDI.  With use of an empirically defined pos./neg. kobs bin of 0.02 min-1, only 4% of registered drugs were found to be pos.  This proportion increased to more than 20% when inhouse lead optimization mols. were considered, emphasizing the importance of identifying this property in selection of promising drug candidates.  Finally, it is suggested that the data and technol. described here may be a good basis for building structure-activity relationships and in silico modeling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobYvW4ft03jbVg90H21EOLACvtfcHk0lhUrc99uwzsWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmvFGns7w%253D&md5=d21b39e85ab9410b7addfc820c1a4e18</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1124%2Fdmd.110.037911&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.110.037911%26sid%3Dliteratum%253Aachs%26aulast%3DZimmerlin%26aufirst%3DA.%26aulast%3DTrunzer%26aufirst%3DM.%26aulast%3DFaller%26aufirst%3DB.%26atitle%3DCYP3A%2520time-dependent%2520inhibition%2520risk%2520assessment%2520validated%2520with%2520400%2520reference%2520drugs%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26issue%3D6%26spage%3D1039%26epage%3D1046%26doi%3D10.1124%2Fdmd.110.037911" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vijayan, R. S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duong-Ly, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunbrack, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, R. M.</span></span> <span> </span><span class="NLM_article-title">Conformational analysis of the DFG-out kinase motif and biochemical profiling of structurally validated Type II inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">466</span>– <span class="NLM_lpage">479</span>, <span class="refDoi"> DOI: 10.1021/jm501603h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501603h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVCku7rP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=466-479&author=R.+S.+K.+Vijayanauthor=P.+Heauthor=V.+Modiauthor=K.+C.+Duong-Lyauthor=H.+Maauthor=J.+R.+Petersonauthor=R.+L.+Dunbrackauthor=R.+M.+Levy&title=Conformational+analysis+of+the+DFG-out+kinase+motif+and+biochemical+profiling+of+structurally+validated+Type+II+inhibitors&doi=10.1021%2Fjm501603h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Conformational Analysis of the DFG-Out Kinase Motif and Biochemical Profiling of Structurally Validated Type II Inhibitors</span></div><div class="casAuthors">Vijayan, R. S. K.; He, Peng; Modi, Vivek; Duong-Ly, Krisna C.; Ma, Haiching; Peterson, Jeffrey R.; Dunbrack, Roland L.; Levy, Ronald M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">466-479</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structural coverage of the human kinome has been steadily increasing over time.  The structures provide valuable insights into the mol. basis of kinase function and also provide a foundation for understanding the mechanisms of kinase inhibitors.  There are a large no. of kinase structures in the PDB for which the Asp and Phe of the DFG motif on the activation loop swap positions, resulting in the formation of a new allosteric pocket.  The authors refer to these structures as "classical DFG-out" conformations in order to distinguish them from conformations that have also been referred to as DFG-out in the literature but that do not have a fully formed allosteric pocket.  The authors have completed a structural anal. of almost 200 small mol. inhibitors bound to classical DFG-out conformations; the authors find that they are recognized by both type I and type II inhibitors.  In contrast, the authors find that nonclassical DFG-out conformations strongly select against type II inhibitors because these structures have not formed a large enough allosteric pocket to accommodate this type of binding mode.  In the course of this study the authors discovered that the no. of structurally validated type II inhibitors that can be found in the PDB and that are also represented in publicly available biochem. profiling studies of kinase inhibitors is very small.  The authors have obtained new profiling results for several addnl. structurally validated type II inhibitors identified through the conformational anal.  Although the available profiling data for type II inhibitors is still much smaller than for type I inhibitors, a comparison of the two data sets supports the conclusion that type II inhibitors are more selective than type I.  The authors comment on the possible contribution of the DFG-in to DFG-out conformational reorganization to the selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqb9E5JKOmDZ7Vg90H21EOLACvtfcHk0lhUrc99uwzsWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVCku7rP&md5=6d729997f242d582a4adff9463fd585c</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fjm501603h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501603h%26sid%3Dliteratum%253Aachs%26aulast%3DVijayan%26aufirst%3DR.%2BS.%2BK.%26aulast%3DHe%26aufirst%3DP.%26aulast%3DModi%26aufirst%3DV.%26aulast%3DDuong-Ly%26aufirst%3DK.%2BC.%26aulast%3DMa%26aufirst%3DH.%26aulast%3DPeterson%26aufirst%3DJ.%2BR.%26aulast%3DDunbrack%26aufirst%3DR.%2BL.%26aulast%3DLevy%26aufirst%3DR.%2BM.%26atitle%3DConformational%2520analysis%2520of%2520the%2520DFG-out%2520kinase%2520motif%2520and%2520biochemical%2520profiling%2520of%2520structurally%2520validated%2520Type%2520II%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D466%26epage%3D479%26doi%3D10.1021%2Fjm501603h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shao, W.</span>; <span class="NLM_string-name">Mishina, Y. M.</span>; <span class="NLM_string-name">Feng, Y.</span>; <span class="NLM_string-name">Caponigro, G.</span>; <span class="NLM_string-name">Cooke, V. G.</span>; <span class="NLM_string-name">Rivera, S.</span>; <span class="NLM_string-name">Wang, Y.</span>; <span class="NLM_string-name">Shen, F.</span>; <span class="NLM_string-name">Korn, J. M.</span>; <span class="NLM_string-name">Mathews Griner, L. A.</span>; <span class="NLM_string-name">Nishiguchi, G.</span>; <span class="NLM_string-name">Rico, A.</span>; <span class="NLM_string-name">Tellew, J.</span>; <span class="NLM_string-name">Haling, J. R.</span>; <span class="NLM_string-name">Aversa, R.</span>; <span class="NLM_string-name">Polyakov, V.</span>; <span class="NLM_string-name">Zang, R.</span>; <span class="NLM_string-name">Hekmat-Nejad, M.</span>; <span class="NLM_string-name">Amiri, P.</span>; <span class="NLM_string-name">Singh, M.</span>; <span class="NLM_string-name">Keen, N.</span>; <span class="NLM_string-name">Dillon, M. P.</span>; <span class="NLM_string-name">Lees, E.</span>; <span class="NLM_string-name">Ramurthy, S.</span>; <span class="NLM_string-name">Sellers, W. R.</span>; <span class="NLM_string-name">Stuart, D.</span></span> Unpublished results.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Shao%2C+W.%3B+Mishina%2C+Y.+M.%3B+Feng%2C+Y.%3B+Caponigro%2C+G.%3B+Cooke%2C+V.+G.%3B+Rivera%2C+S.%3B+Wang%2C+Y.%3B+Shen%2C+F.%3B+Korn%2C+J.+M.%3B+Mathews+Griner%2C+L.+A.%3B+Nishiguchi%2C+G.%3B+Rico%2C+A.%3B+Tellew%2C+J.%3B+Haling%2C+J.+R.%3B+Aversa%2C+R.%3B+Polyakov%2C+V.%3B+Zang%2C+R.%3B+Hekmat-Nejad%2C+M.%3B+Amiri%2C+P.%3B+Singh%2C+M.%3B+Keen%2C+N.%3B+Dillon%2C+M.+P.%3B+Lees%2C+E.%3B+Ramurthy%2C+S.%3B+Sellers%2C+W.+R.%3B+Stuart%2C+D.+Unpublished+results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DShao%26aufirst%3DW." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishina, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caponigro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, V. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korn, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathews Griner, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishiguchi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rico, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tellew, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haling, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aversa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polyakov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hekmat-Nejad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amiri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dillon, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lees, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramurthy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, D. D.</span></span> <span> </span><span class="NLM_article-title">Antitumor properties of RAF709, a highly selective and potent inhibitor of RAF kinase dimers, in tumors driven by mutant RAS or BRAF</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1537</span>– <span class="NLM_lpage">1548</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-17-2033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=10.1158%2F0008-5472.CAN-17-2033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=29343524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=1%3ACAS%3A528%3ADC%252BC1cXks1yls74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=1537-1548&issue=6&author=W.+Shaoauthor=Y.+M.+Mishinaauthor=Y.+Fengauthor=G.+Caponigroauthor=V.+G.+Cookeauthor=S.+Riveraauthor=Y.+Wangauthor=F.+Shenauthor=J.+M.+Kornauthor=L.+A.+Mathews+Grinerauthor=G.+Nishiguchiauthor=A.+Ricoauthor=J.+Tellewauthor=J.+R.+Halingauthor=R.+Aversaauthor=V.+Polyakovauthor=R.+Zangauthor=M.+Hekmat-Nejadauthor=P.+Amiriauthor=M.+Singhauthor=N.+Keenauthor=M.+P.+Dillonauthor=E.+Leesauthor=S.+Ramurthyauthor=W.+R.+Sellersauthor=D.+D.+Stuart&title=Antitumor+properties+of+RAF709%2C+a+highly+selective+and+potent+inhibitor+of+RAF+kinase+dimers%2C+in+tumors+driven+by+mutant+RAS+or+BRAF&doi=10.1158%2F0008-5472.CAN-17-2033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF</span></div><div class="casAuthors">Shao, Wenlin; Mishina, Yuji M.; Feng, Yun; Caponigro, Giordano; Cooke, Vesselina G.; Rivera, Stacy; Wang, Yingyun; Shen, Fang; Korn, Joshua M.; Mathews Griner, Lesley A.; Nishiguchi, Gisele; Rico, Alice; Tellew, John; Haling, Jacob R.; Aversa, Robert; Polyakov, Valery; Zang, Richard; Hekmat-Nejad, Mohammad; Amiri, Payman; Singh, Mallika; Keen, Nicholas; Dillon, Michael P.; Lees, Emma; Ramurthy, Savithri; Sellers, William R.; Stuart, Darrin D.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1537-1548</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Resistance to the RAF inhibitor vemurafenib arises commonly in melanomas driven by the activated BRAF oncogene.  Here, we report antitumor properties of RAF709, a novel ATP-competitive kinase inhibitor with high potency and selectivity against RAF kinases.  RAF709 exhibited a mode of RAF inhibition distinct from RAF monomer inhibitors such as vemurafenib, showing equal activity against both RAF monomers and dimers.  As a result, RAF709 inhibited MAPK signaling activity in tumor models harboring either BRAFV600 alterations or mutant N- and KRAS-driven signaling, with minimal paradoxical activation of wild-type RAF.  In cell lines and murine xenograft models, RAF709 demonstrated selective antitumor activity in tumor cells harboring BRAF or RAS mutations compared with cells with wild-type BRAF and RAS genes.  RAF709 demonstrated a direct pharmacokinetic/pharmacodynamic relationship in in vivo tumor models harboring KRAS mutation.  Furthermore, RAF709 elicited regression of primary human tumor-derived xenograft models with BRAF, NRAS, or KRAS mutations with excellent tolerability.  Our results support further development of inhibitors like RAF709, which represents a next-generation RAF inhibitor with unique biochem. and cellular properties that enables antitumor activities in RAS-mutant tumors.  Significance: In an effort to develop RAF inhibitors with the appropriate pharmacol. properties to treat RAS mutant tumors, RAF709, a compd. with potency, selectivity, and in vivo properties, was developed that will allow preclin. therapeutic hypothesis testing, but also provide an excellent probe to further unravel the complexities of RAF kinase signaling.  Cancer Res; 78(6); 1537-48. ©2018 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGOvhVkNT32bVg90H21EOLACvtfcHk0lgzEb_1sxmk0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXks1yls74%253D&md5=607b45deb150d83b01394d43f776c097</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-17-2033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-17-2033%26sid%3Dliteratum%253Aachs%26aulast%3DShao%26aufirst%3DW.%26aulast%3DMishina%26aufirst%3DY.%2BM.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DCaponigro%26aufirst%3DG.%26aulast%3DCooke%26aufirst%3DV.%2BG.%26aulast%3DRivera%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DShen%26aufirst%3DF.%26aulast%3DKorn%26aufirst%3DJ.%2BM.%26aulast%3DMathews%2BGriner%26aufirst%3DL.%2BA.%26aulast%3DNishiguchi%26aufirst%3DG.%26aulast%3DRico%26aufirst%3DA.%26aulast%3DTellew%26aufirst%3DJ.%26aulast%3DHaling%26aufirst%3DJ.%2BR.%26aulast%3DAversa%26aufirst%3DR.%26aulast%3DPolyakov%26aufirst%3DV.%26aulast%3DZang%26aufirst%3DR.%26aulast%3DHekmat-Nejad%26aufirst%3DM.%26aulast%3DAmiri%26aufirst%3DP.%26aulast%3DSingh%26aufirst%3DM.%26aulast%3DKeen%26aufirst%3DN.%26aulast%3DDillon%26aufirst%3DM.%2BP.%26aulast%3DLees%26aufirst%3DE.%26aulast%3DRamurthy%26aufirst%3DS.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DStuart%26aufirst%3DD.%2BD.%26atitle%3DAntitumor%2520properties%2520of%2520RAF709%252C%2520a%2520highly%2520selective%2520and%2520potent%2520inhibitor%2520of%2520RAF%2520kinase%2520dimers%252C%2520in%2520tumors%2520driven%2520by%2520mutant%2520RAS%2520or%2520BRAF%26jtitle%3DCancer%2520Res.%26date%3D2018%26volume%3D78%26issue%3D6%26spage%3D1537%26epage%3D1548%26doi%3D10.1158%2F0008-5472.CAN-17-2033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fabian, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biggs, W. H.,  III</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atteridge, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azimioara, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benedetti, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edeen, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerlach, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grotzfeld, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrgard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Insko, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Insko, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lelias, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milanov, Z. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velasco, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodicka, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockhart, D. J.</span></span> <span> </span><span class="NLM_article-title">A small molecule-kinase interaction map for clinical kinase inhibitors</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">329</span>– <span class="NLM_lpage">336</span>, <span class="refDoi"> DOI: 10.1038/nbt1068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=10.1038%2Fnbt1068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=15711537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=329-336&author=M.+A.+Fabianauthor=W.+H.+Biggsauthor=D.+K.+Treiberauthor=C.+E.+Atteridgeauthor=M.+D.+Azimioaraauthor=M.+G.+Benedettiauthor=T.+A.+Carterauthor=P.+Ciceriauthor=P.+T.+Edeenauthor=M.+Floydauthor=J.+M.+Fordauthor=M.+Galvinauthor=J.+L.+Gerlachauthor=R.+M.+Grotzfeldauthor=S.+Herrgardauthor=D.+E.+Inskoauthor=M.+A.+Inskoauthor=A.+G.+Laiauthor=J.-M.+Leliasauthor=S.+A.+Mehtaauthor=Z.+V.+Milanovauthor=A.+M.+Velascoauthor=L.+M.+Wodickaauthor=H.+K.+Patelauthor=P.+P.+Zarrinkarauthor=D.+J.+Lockhart&title=A+small+molecule-kinase+interaction+map+for+clinical+kinase+inhibitors&doi=10.1038%2Fnbt1068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">A small molecule-kinase interaction map for clinical kinase inhibitors</span></div><div class="casAuthors">Fabian, Miles A.; Biggs, William H.; Treiber, Daniel K.; Atteridge, Corey E.; Azimioara, Mihai D.; Benedetti, Michael G.; Carter, Todd A.; Ciceri, Pietro; Edeen, Philip T.; Floyd, Mark; Ford, Julia M.; Galvin, Margaret; Gerlach, Jay L.; Grotzfeld, Robert M.; Herrgard, Sanna; Insko, Darren E.; Insko, Michael A.; Lai, Andiliy G.; Lelias, Jean-Michel; Mehta, Shamal A.; Milanov, Zdravko V.; Velasco, Anne Marie; Wodicka, Lisa M.; Patel, Hitesh K.; Zarrinkar, Patrick P.; Lockhart, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">329-336</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors show great promise as a new class of therapeutics.  Here the authors describe an efficient way to det. kinase inhibitor specificity by measuring binding of small mols. to the ATP site of kinases.  The authors have profiled 20 kinase inhibitors, including 16 that are approved drugs or in clin. development, against a panel of 119 protein kinases.  The authors find that specificity varies widely and is not strongly correlated with chem. structure or the identity of the intended target.  Many novel interactions were identified, including tight binding of the p38 inhibitor BIRB-796 to an imatinib-resistant variant of the ABL kinase, and binding of imatinib to the SRC-family kinase LCK.  The authors also show that mutations in the epidermal growth factor receptor (EGFR) found in gefitinib-responsive patients do not affect the binding affinity of gefitinib or erlotinib.  Our results represent a systematic small mol.-protein interaction map for clin. compds. across a large no. of related proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA0vNmMOXrnrVg90H21EOLACvtfcHk0lgzEb_1sxmk0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D&md5=6aedd5ceb8f77cd26ee50425dcec7bdf</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fnbt1068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1068%26sid%3Dliteratum%253Aachs%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DAzimioara%26aufirst%3DM.%2BD.%26aulast%3DBenedetti%26aufirst%3DM.%2BG.%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DGalvin%26aufirst%3DM.%26aulast%3DGerlach%26aufirst%3DJ.%2BL.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DInsko%26aufirst%3DM.%2BA.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DLelias%26aufirst%3DJ.-M.%26aulast%3DMehta%26aufirst%3DS.%2BA.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26atitle%3DA%2520small%2520molecule-kinase%2520interaction%2520map%2520for%2520clinical%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Biotechnol.%26date%3D2005%26volume%3D23%26spage%3D329%26epage%3D336%26doi%3D10.1038%2Fnbt1068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karaman, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrgard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallant, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atteridge, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edeen, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faraoni, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockhart, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milanov, Z. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallares, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pritchard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodicka, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span> <span> </span><span class="NLM_article-title">A quantitative analysis of kinase inhibitor selectivity</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1038/nbt1358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=10.1038%2Fnbt1358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=18183025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=127-132&author=M.+W.+Karamanauthor=S.+Herrgardauthor=D.+K.+Treiberauthor=P.+Gallantauthor=C.+E.+Atteridgeauthor=B.+T.+Campbellauthor=K.+W.+Chanauthor=P.+Ciceriauthor=M.+I.+Davisauthor=P.+T.+Edeenauthor=R.+Faraoniauthor=M.+Floydauthor=J.+P.+Huntauthor=D.+J.+Lockhartauthor=Z.+V.+Milanovauthor=M.+J.+Morrisonauthor=G.+Pallaresauthor=H.+K.+Patelauthor=S.+Pritchardauthor=L.+M.+Wodickaauthor=P.+P.+Zarrinkar&title=A+quantitative+analysis+of+kinase+inhibitor+selectivity&doi=10.1038%2Fnbt1358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">A quantitative analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Karaman, Mazen W.; Herrgard, Sanna; Treiber, Daniel K.; Gallant, Paul; Atteridge, Corey E.; Campbell, Brian T.; Chan, Katrina W.; Ciceri, Pietro; Davis, Mindy I.; Edeen, Philip T.; Faraoni, Raffaella; Floyd, Mark; Hunt, Jeremy P.; Lockhart, Daniel J.; Milanov, Zdravko V.; Morrison, Michael J.; Pallares, Gabriel; Patel, Hitesh K.; Pritchard, Stephanie; Wodicka, Lisa M.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-132</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets.  The biol. consequences of multikinase activity are poorly defined, and an important step toward understanding the relationship between selectivity, efficacy and safety is the exploration of how inhibitors interact with the human kinome.  The authors present interaction maps for 38 kinase inhibitors across a panel of 317 kinases representing >50% of the predicted human protein kinome.  The data constitute the most comprehensive study of kinase inhibitor selectivity to date and reveal a wide diversity of interaction patterns.  To enable a global anal. of the results, the authors introduce the concept of a selectivity score as a general tool to quantify and differentiate the obsd. interaction patterns.  The authors further investigate the impact of panel size and find that small assay panels do not provide a robust measure of selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiArJSq2_lPrVg90H21EOLACvtfcHk0lgzEb_1sxmk0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D&md5=346265d412853ced636ad4128ed8a76f</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnbt1358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1358%26sid%3Dliteratum%253Aachs%26aulast%3DKaraman%26aufirst%3DM.%2BW.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DGallant%26aufirst%3DP.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DCampbell%26aufirst%3DB.%2BT.%26aulast%3DChan%26aufirst%3DK.%2BW.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFaraoni%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DMorrison%26aufirst%3DM.%2BJ.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DPritchard%26aufirst%3DS.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DA%2520quantitative%2520analysis%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2008%26volume%3D26%26spage%3D127%26epage%3D132%26doi%3D10.1038%2Fnbt1358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Infante, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daud, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kefford, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamid, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuchter, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cebon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kudchadkar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burris, H. A.,  III</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falchook, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Algazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puzanov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebowitz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Little, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allred, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouellet, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, J.</span></span> <span> </span><span class="NLM_article-title">Combined BRAF and MEK inhibition in melanoma with BRAF V600 Mutations</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>367</i></span>,  <span class="NLM_fpage">1694</span>– <span class="NLM_lpage">1703</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1210093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=10.1056%2FNEJMoa1210093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=23020132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1eksLrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=1694-1703&author=K.+T.+Flahertyauthor=J.+R.+Infanteauthor=A.+Daudauthor=R.+Gonzalezauthor=R.+F.+Keffordauthor=J.+Sosmanauthor=O.+Hamidauthor=L.+Schuchterauthor=J.+Cebonauthor=N.+Ibrahimauthor=R.+Kudchadkarauthor=H.+A.+Burrisauthor=G.+Falchookauthor=A.+Algaziauthor=K.+Lewisauthor=G.+V.+Longauthor=I.+Puzanovauthor=P.+Lebowitzauthor=A.+Singhauthor=S.+Littleauthor=P.+Sunauthor=A.+Allredauthor=D.+Ouelletauthor=K.+B.+Kimauthor=K.+Patelauthor=J.+Weber&title=Combined+BRAF+and+MEK+inhibition+in+melanoma+with+BRAF+V600+Mutations&doi=10.1056%2FNEJMoa1210093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations</span></div><div class="casAuthors">Flaherty, Keith T.; Infante, Jeffery R.; Daud, Adil; Gonzalez, Rene; Kefford, Richard F.; Sosman, Jeffrey; Hamid, Omid; Schuchter, Lynn; Cebon, Jonathan; Ibrahim, Nageatte; Kudchadkar, Ragini; Burris, Howard A., III; Falchook, Gerald; Algazi, Alain; Lewis, Karl; Long, Georgina V.; Puzanov, Igor; Lebowitz, Peter; Singh, Ajay; Little, Shonda; Sun, Peng; Allred, Alicia; Ouellet, Daniele; Kim, Kevin B.; Patel, Kiran; Weber, Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1694-1703</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Resistance to therapy with BRAF kinase inhibitors is assocd. with reactivation of the mitogen-activated protein kinase (MAPK) pathway.  To address this problem, we conducted a phase 1 and 2 trial of combined treatment with dabrafenib, a selective BRAF inhibitor, and trametinib, a selective MAPK kinase (MEK) inhibitor.  METHODS In this open-label study involving 247 patients with metastatic melanoma and BRAF V600 mutations, we evaluated the pharmacokinetic activity and safety of oral dabrafenib (75 or 150 mg twice daily) and trametinib (1, 1.5, or 2 mg daily) in 85 patients and then randomly assigned 162 patients to receive combination therapy with dabrafenib (150 mg) plus trametinib (1 or 2 mg) or dabrafenib monotherapy.  The primary end points were the incidence of cutaneous squamous-cell carcinoma, survival free of melanoma progression, and response.  Secondary end points were overall survival and pharmacokinetic activity.  RESULTS Dose-limiting toxic effects were infrequently obsd. in patients receiving combination therapy with 150 mg of dabrafenib and 2 mg of trametinib (combination 150/2).  Cutaneous squamous-cell carcinoma was seen in 7% of patients receiving combination 150/2 and in 19% receiving monotherapy (P = 0.09), whereas pyrexia was more common in the combination 150/2 group than in the monotherapy group (71% vs. 26%).  Median progression-free survival in the combination 150/2 group was 9.4 mo, as compared with 5.8 mo in the monotherapy group (hazard ratio for progression or death, 0.39; 95% confidence interval, 0.25 to 0.62; P<0.001).  The rate of complete or partial response with combination 150/2 therapy was 76%, as compared with 54% with monotherapy (P = 0.03).  CONCLUSIONS Dabrafenib and trametinib were safely combined at full monotherapy doses.  The rate of pyrexia was increased with combination therapy, whereas the rate of proliferative skin lesions was nonsignificantly reduced.  Progression-free survival was significantly improved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhk7I8zrGTVbVg90H21EOLACvtfcHk0ljetO2zVoSkkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1eksLrJ&md5=199ae281d44c3b41309b934d88674cd3</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1210093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1210093%26sid%3Dliteratum%253Aachs%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DInfante%26aufirst%3DJ.%2BR.%26aulast%3DDaud%26aufirst%3DA.%26aulast%3DGonzalez%26aufirst%3DR.%26aulast%3DKefford%26aufirst%3DR.%2BF.%26aulast%3DSosman%26aufirst%3DJ.%26aulast%3DHamid%26aufirst%3DO.%26aulast%3DSchuchter%26aufirst%3DL.%26aulast%3DCebon%26aufirst%3DJ.%26aulast%3DIbrahim%26aufirst%3DN.%26aulast%3DKudchadkar%26aufirst%3DR.%26aulast%3DBurris%26aufirst%3DH.%2BA.%26aulast%3DFalchook%26aufirst%3DG.%26aulast%3DAlgazi%26aufirst%3DA.%26aulast%3DLewis%26aufirst%3DK.%26aulast%3DLong%26aufirst%3DG.%2BV.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DLebowitz%26aufirst%3DP.%26aulast%3DSingh%26aufirst%3DA.%26aulast%3DLittle%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DP.%26aulast%3DAllred%26aufirst%3DA.%26aulast%3DOuellet%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DPatel%26aufirst%3DK.%26aulast%3DWeber%26aufirst%3DJ.%26atitle%3DCombined%2520BRAF%2520and%2520MEK%2520inhibition%2520in%2520melanoma%2520with%2520BRAF%2520V600%2520Mutations%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D367%26spage%3D1694%26epage%3D1703%26doi%3D10.1056%2FNEJMoa1210093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hersey, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milhem, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demidov, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassel, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutkowski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohr, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dummer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trefzer, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larkin, J. M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Utikal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dreno, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nyakas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middleton, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casey, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherman, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouellet, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schadendorf, D.</span></span> <span> </span><span class="NLM_article-title">Improved survival with MEK inhibition in BRAF-mutated melanoma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>367</i></span>,  <span class="NLM_fpage">107</span>– <span class="NLM_lpage">114</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1203421</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=10.1056%2FNEJMoa1203421" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=22663011" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFKjs7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=107-114&author=K.+T.+Flahertyauthor=C.+Robertauthor=P.+Herseyauthor=P.+Nathanauthor=C.+Garbeauthor=M.+Milhemauthor=L.+V.+Demidovauthor=J.+C.+Hasselauthor=P.+Rutkowskiauthor=P.+Mohrauthor=R.+Dummerauthor=U.+Trefzerauthor=J.+M.+G.+Larkinauthor=J.+Utikalauthor=B.+Drenoauthor=M.+Nyakasauthor=M.+R.+Middletonauthor=J.+C.+Beckerauthor=M.+Caseyauthor=L.+J.+Shermanauthor=F.+S.+Wuauthor=D.+Ouelletauthor=A.+M.+Martinauthor=K.+Patelauthor=D.+Schadendorf&title=Improved+survival+with+MEK+inhibition+in+BRAF-mutated+melanoma&doi=10.1056%2FNEJMoa1203421"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Improved survival with MEK inhibition in BRAF-mutated melanoma</span></div><div class="casAuthors">Flaherty, Keith T.; Robert, Caroline; Hersey, Peter; Nathan, Paul; Garbe, Claus; Milhem, Mohammed; Demidov, Lev V.; Hassel, Jessica C.; Rutkowski, Piotr; Mohr, Peter; Dummer, Reinhard; Trefzer, Uwe; Larkin, James M. G.; Utikal, Jochen; Dreno, Brigitte; Nyakas, Marta; Middleton, Mark R.; Becker, Jurgen C.; Casey, Michelle; Sherman, Laurie J.; Wu, Frank S.; Ouellet, Daniele; Martin, Anne-Marie; Schadendorf, Dirk</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">107-114</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Activating mutations in serine-threonine protein kinase B-RAF (BRAF) are found in 50% of patients with advanced melanoma.  Selective BRAF-inhibitor therapy improves survival, as compared with chemotherapy, but responses are often short-lived.  In previous trials, MEK inhibition appeared to be promising in this population.  In this phase 3 open-label trial, we randomly assigned 322 patients who had metastatic melanoma with a V600E or V600K BRAF mutation to receive either trametinib, an oral selective MEK inhibitor, or chemotherapy in a 2:1 ratio.  Patients received trametinib (2 mg orally) once daily or i.v. dacarbazine (1000 mg per square meter of body-surface area) or paclitaxel (175 mg per square meter) every 3 wk.  Patients in the chemotherapy group who had disease progression were permitted to cross over to receive trametinib.  Progression-free survival was the primary end point, and overall survival was a secondary end point.  Median progression-free survival was 4.8 mo in the trametinib group and 1.5 mo in the chemotherapy group (hazard ratio for disease progression or death in the trametinib group, 0.45; 95% confidence interval [CI], 0.33 to 0.63; P < 0.001).  At 6 mo, the rate of overall survival was 81% in the trametinib group and 67% in the chemotherapy group despite crossover (hazard ratio for death, 0.54; 95% CI, 0.32 to 0.92; P = 0.01).  Rash, diarrhea, and peripheral edema were the most common toxic effects in the trametinib group and were managed with dose interruption and dose redn.; asymptomatic and reversible redn. in the cardiac ejection fraction and ocular toxic effects occurred infrequently.  Secondary skin neo- plasms were not obsd.  Trametinib, as compared with chemotherapy, improved rates of progression-free and overall survival among patients who had metastatic melanoma with a BRAF V600E or V600K mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQ9lseRU60cLVg90H21EOLACvtfcHk0ljetO2zVoSkkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFKjs7zN&md5=bf084fd4ac6599e1f023cb732f0678a7</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1203421&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1203421%26sid%3Dliteratum%253Aachs%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DHersey%26aufirst%3DP.%26aulast%3DNathan%26aufirst%3DP.%26aulast%3DGarbe%26aufirst%3DC.%26aulast%3DMilhem%26aufirst%3DM.%26aulast%3DDemidov%26aufirst%3DL.%2BV.%26aulast%3DHassel%26aufirst%3DJ.%2BC.%26aulast%3DRutkowski%26aufirst%3DP.%26aulast%3DMohr%26aufirst%3DP.%26aulast%3DDummer%26aufirst%3DR.%26aulast%3DTrefzer%26aufirst%3DU.%26aulast%3DLarkin%26aufirst%3DJ.%2BM.%2BG.%26aulast%3DUtikal%26aufirst%3DJ.%26aulast%3DDreno%26aufirst%3DB.%26aulast%3DNyakas%26aufirst%3DM.%26aulast%3DMiddleton%26aufirst%3DM.%2BR.%26aulast%3DBecker%26aufirst%3DJ.%2BC.%26aulast%3DCasey%26aufirst%3DM.%26aulast%3DSherman%26aufirst%3DL.%2BJ.%26aulast%3DWu%26aufirst%3DF.%2BS.%26aulast%3DOuellet%26aufirst%3DD.%26aulast%3DMartin%26aufirst%3DA.%2BM.%26aulast%3DPatel%26aufirst%3DK.%26aulast%3DSchadendorf%26aufirst%3DD.%26atitle%3DImproved%2520survival%2520with%2520MEK%2520inhibition%2520in%2520BRAF-mutated%2520melanoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D367%26spage%3D107%26epage%3D114%26doi%3D10.1056%2FNEJMoa1203421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauschild, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haanen, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ascierto, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larkin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dummer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Testori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorigan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebbe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jouary, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schadendorf, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Day, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkwood, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eggermont, A. M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dreno, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolop, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McArthur, G. A.</span></span> <span> </span><span class="NLM_article-title">Improved survival with Vemurafenib in melanoma with BRAF V600E mutation</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>364</i></span>,  <span class="NLM_fpage">2507</span>– <span class="NLM_lpage">2516</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1103782</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=10.1056%2FNEJMoa1103782" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=21639808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosVeitbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2011&pages=2507-2516&author=P.+B.+Chapmanauthor=A.+Hauschildauthor=C.+Robertauthor=J.+B.+Haanenauthor=P.+Asciertoauthor=J.+Larkinauthor=R.+Dummerauthor=C.+Garbeauthor=A.+Testoriauthor=M.+Maioauthor=D.+Hoggauthor=P.+Loriganauthor=C.+Lebbeauthor=T.+Jouaryauthor=D.+Schadendorfauthor=A.+Ribasauthor=S.+J.+O%E2%80%99Dayauthor=J.+A.+Sosmanauthor=J.+M.+Kirkwoodauthor=A.+M.+M.+Eggermontauthor=B.+Drenoauthor=K.+Nolopauthor=J.+Liauthor=B.+Nelsonauthor=J.+Houauthor=R.+J.+Leeauthor=K.+T.+Flahertyauthor=G.+A.+McArthur&title=Improved+survival+with+Vemurafenib+in+melanoma+with+BRAF+V600E+mutation&doi=10.1056%2FNEJMoa1103782"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Improved survival with vemurafenib in melanoma with BRAF V600E mutation</span></div><div class="casAuthors">Chapman, Paul B.; Hauschild, Axel; Robert, Caroline; Haanen, John B.; Ascierto, Paolo; Larkin, James; Dummer, Reinhard; Garbe, Claus; Testori, Alessandro; Maio, Michele; Hogg, David; Lorigan, Paul; Lebbe, Celeste; Jouary, Thomas; Schadendorf, Dirk; Ribas, Antoni; O'Day, Steven J.; Sosman, Jeffrey A.; Kirkwood, John M.; Eggermont, Alexander M. M.; Dreno, Brigitte; Nolop, Keith; Li, Jiang; Nelson, Betty; Hou, Jeannie; Lee, Richard J.; Flaherty, Keith T.; McArthur, Grant A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">2507-2516</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Phase 1 and 2 clin. trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF V600E mutation.  METHODS: We conducted a phase 3 randomized clin. trial comparing vemurafenib with dacarbazine in 675 patients with previously untreated, metastatic melanoma with the BRAF V600E mutation.  Patients were randomly assigned to receive either vemurafenib (960 mg orally twice daily) or dacarbazine (1000 mg per square meter of body-surface area i.v. every 3 wk).  Coprimary end points were rates of overall and progression-free survival.  Secondary end points included the response rate, response duration, and safety.  A final anal. was planned after 196 deaths and an interim anal. after 98 deaths.  RESULTS: At 6 mo, overall survival was 840/ (95% confidence interval [CI], 78 to 89) in the vemurafenib group and 64% (95% CI, 56 to 73) in the dacarbazine group.  In the interim anal. for overall survival and final anal. for progression-free survival, vemurafenib was assocd. with a relative redn. of 63% in the risk of death and of 74% in the risk of either death or disease progression, as compared with dacarbazine (P < 0.001 for both comparisons).  After review of the interim anal. by an independent data and safety monitoring board, crossover from dacarbazine to vemurafenib was recommended.  Response rates were 48% for vemurafenib and 5% for dacarbazine.  Common adverse events assocd. with vemurafenib were arthralgia, rash, fatigue, alopecia, keratoacanthoma or squamous-cell carcinoma, photosensitivity, nausea, and diarrhea; 38% of patients required dose modification because of toxic effects.  CONCLUSIONS: Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4NFxmTaDz97Vg90H21EOLACvtfcHk0lg5MJHljXZmAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosVeitbs%253D&md5=1a4b4f963221888dc63f620e87408070</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1103782&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1103782%26sid%3Dliteratum%253Aachs%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DHauschild%26aufirst%3DA.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DHaanen%26aufirst%3DJ.%2BB.%26aulast%3DAscierto%26aufirst%3DP.%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DDummer%26aufirst%3DR.%26aulast%3DGarbe%26aufirst%3DC.%26aulast%3DTestori%26aufirst%3DA.%26aulast%3DMaio%26aufirst%3DM.%26aulast%3DHogg%26aufirst%3DD.%26aulast%3DLorigan%26aufirst%3DP.%26aulast%3DLebbe%26aufirst%3DC.%26aulast%3DJouary%26aufirst%3DT.%26aulast%3DSchadendorf%26aufirst%3DD.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Day%26aufirst%3DS.%2BJ.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DKirkwood%26aufirst%3DJ.%2BM.%26aulast%3DEggermont%26aufirst%3DA.%2BM.%2BM.%26aulast%3DDreno%26aufirst%3DB.%26aulast%3DNolop%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DNelson%26aufirst%3DB.%26aulast%3DHou%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26atitle%3DImproved%2520survival%2520with%2520Vemurafenib%2520in%2520melanoma%2520with%2520BRAF%2520V600E%2520mutation%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D364%26spage%3D2507%26epage%3D2516%26doi%3D10.1056%2FNEJMoa1103782" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span> <span> </span><span class="NLM_article-title">25 years of small molecular weight kinase inhibitors: potentials and limitations</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>87</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">766</span>– <span class="NLM_lpage">775</span>, <span class="refDoi"> DOI: 10.1124/mol.114.095489</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=10.1124%2Fmol.114.095489" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=25549667" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlvVKltLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2015&pages=766-775&issue=5&author=D.+Fabbro&title=25+years+of+small+molecular+weight+kinase+inhibitors%3A+potentials+and+limitations&doi=10.1124%2Fmol.114.095489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">25 years of small molecular weight kinase inhibitors: potentials and limitations</span></div><div class="casAuthors">Fabbro, Doriano</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">766-775</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  Deregulation of protein and lipid kinase activities leads to a variety of pathologies, ranging from cancer inflammatory diseases, diabetes, infectious diseases, and cardiovascular disorders.  Protein kinases and lipid kinases represent, therefore, an important target for the pharmaceutical industry.  In fact, approx. one-third of all protein targets under investigation in the pharmaceutical industry are protein or lipid kinases.  To date, 30 kinase inhibitors have been approved, which, with few exceptions, are mainly for oncol. indications and directed against only a handful of protein and lipid kinases, leaving 70% of the kinome untapped.  Despite these successes in kinase drug discovery, the development of kinase inhibitors with outstanding selectivity, identification and validation of driver kinase(s) in diseases, and the emerging problem of resistance to the inhibition of key target kinases remain major challenges.  This mini review provides an insight into protein and lipid kinase drug discovery with respect to achievements, binding modes of inhibitors, and novel avenues for the generation of second-generation kinase inhibitors to treat cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZhF-9NQJx7bVg90H21EOLACvtfcHk0lg5MJHljXZmAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlvVKltLk%253D&md5=6422b036e4e447379ac6c608662954c2</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1124%2Fmol.114.095489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.114.095489%26sid%3Dliteratum%253Aachs%26aulast%3DFabbro%26aufirst%3DD.%26atitle%3D25%2520years%2520of%2520small%2520molecular%2520weight%2520kinase%2520inhibitors%253A%2520potentials%2520and%2520limitations%26jtitle%3DMol.%2520Pharmacol.%26date%3D2015%26volume%3D87%26issue%3D5%26spage%3D766%26epage%3D775%26doi%3D10.1124%2Fmol.114.095489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6N0Q" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6N0Q','PDB','6N0Q'); return false;">PDB: 6N0Q</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6N0P" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6N0P','PDB','6N0P'); return false;">PDB: 6N0P</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i39"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00161">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_26802"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.9b00161">10.1021/acs.jmedchem.9b00161</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Synthetic scheme and experimental procedure of compound <b>10</b>, metabolite identification methods, biochemical and cellular assay conditions, X-ray data table for <b>10</b> and <b>15</b>, and unbound fraction of <b>15</b> in plasma (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00161/suppl_file/jm9b00161_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00161/suppl_file/jm9b00161_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00161/suppl_file/jm9b00161_si_001.pdf">jm9b00161_si_001.pdf (410.29 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00161/suppl_file/jm9b00161_si_002.csv">jm9b00161_si_002.csv (1.09 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b00161%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-5" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b00161" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                7MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677a89512de03d06","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
